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Introduction 
Gynaecological cancers account for approximately 10% of all cancer diagnosed in 
women in the United Kingdom. Of these, endometrial cancer and ovarian cancer 
(including fallopian tubes and primary peritoneal cancer) are the most prevalent with 
more than 15.500 new cases diagnosed in 2012 (1). While the incidence of other 
cancers have levelled or declined in the last decades, rates of endometrial cancer 
and ovarian cancer are increasing (2, 3). One of the main reasons for this is the 
obesity epidemic, which continues to escalate in developed countries and has 
resulted in 32% of women in the United Kingdom being overweight and 25% being 
obese (4, 5). 
Endometrial cancer
The majority of endometrial cancer patients are diagnosed with early stage disease 
(FIGO stage I/II, Table 1) due to early presentation of the disease in the form of 
postmenopausal bleeding or irregular pre- and peri-menopausal bleeding (6, 7). Two 
types of endometrial cancer are distinguished based on histopathology and clinical 
outcomes. Type I tumours comprise 80% of all endometrial cancers and are caused 
by an unopposed estrogen stimulation leading to endometrioid adenocarcinomas, 
and are often preceded by glandular hyperplasia of the endometrium. Type II tumours 
exhibit a non-endometrioid histology, are generally less well differentiated and have 
a relatively poorer prognosis compared to the endometrioid carcinoma (6). 
Table 1 Cancer of corpus uteri FIGO stages (2009)
FIGO stage
I
    IA
    IB
Tumour confined to corpus uteri
  No or less than half myometrial invasion
  Invasion equal to or more than half of the myometrium
II Tumour invades the cervical stroma, but does not extend beyond the uterus
III
    IIIA
    IIIB
    IIIC 
    IIIC1
    IIIC2
Local and/or regional spread of the tumour
  Tumour invades the serosa of the corpus uteri and/or adnexae
  Vaginal involvement and/or parametrial involvement
  Metastases to pelvic and/or para-aortic lymph nodes
  Metastases to pelvic nodes
  Metastases to para-aortic nodes
IV
    IVA
    IVB
Tumour invades bladder and/or bowel mucosa, and/or distant metastases
  Tumour invasion of bladder and/or bowel mucosa
  Distant metastasis, including intra-abdominal metastases and/or 
  inguinal nodes
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Endometrial cancer was the first cancer to be recognised as being related to obesity, 
with an estimated 34% being attributed to excess weight and obesity (8). The 
mechanisms through which obesity increases endometrial cancer risk involve both 
endocrine and metabolic pathways. Obese women have higher estrogen and androgen 
levels due to the conversion of androstenedione in peripheral adipose tissue. This 
leads to constant stimulation of the endometrium and the resulting transformation to 
hyperplasia and cancer. Other mechanisms include insulin resistance and elevated 
insulin and glucose levels, increased levels of the adipose-derived hormone leptin, 
and possibly inflammation (9, 10).
 The standard treatment of endometrial cancer consists of a primary hysterectomy 
and bilateral salpingo-oophorectomy, which can be performed through open surgery, 
minimal invasive approaches (laparoscopic or robotic) or vaginally. Lymphadenectomy 
is not part of routine practice with low grade tumours, but may be performed in 
high grade disease or non-endometrioid histology. Adjuvant treatment is tailored 
according to stage, grade and histology, with adjuvant radiotherapy (brachytherapy 
and/or external beam) used in patient with intermediate and high risk disease confined 
to the corpus uteri, or when the disease has extended beyond the corpus uteri 
(FIGO stage II-IV). Chemotherapy is considered in patients with stage II-IV disease, 
and may be an option for stage I, grade 3 disease with adverse risk factors (age, 
lymphovascular space invasion and high tumour volume) (6).
Ovarian cancer
Ovarian cancer usually presents as advanced stage disease (FIGO stage III/IV, Table 2) 
due to the late onset of symptoms (11, 12). Over 90% of ovarian tumours arise from 
epithelial cells, while a minority originate from non-epithelial cells and include germ 
cell tumours or sex-chord stromal tumours (12, 13). The exact cause of ovarian cancer 
remains unknown, although several risk factors and associated gene mutations have 
been identified (12).
 In ovarian cancer, only 4% of cases have been attributed to overweight and 
obesity (8). The exact obesity-mediated pathological pathways are less well understood 
compared to endometrial cancer, but it is believed to be mediated through increased 
estrogen levels, which stimulate the growth of ovarian cells. Furthermore, hyper-
insulinemia and higher levels of insulin-like growth factors, androgens and leptin, which 
are associated with obesity, have been proposed as additional mechanisms (14).
 The standard care for ovarian cancer usually consists of surgery and platinum- 
based cytotoxic chemotherapy. The aim for surgery in presumed stage I disease is 
to remove the tumour and perform an appropriate staging procedure. In advanced 
stage ovarian cancer (II-IV), the aim is to remove all visible disease, as this is an 
important prognostic factor for survival (12, 15). Chemotherapy is recommended for 
all patients with stage II-IV disease post-surgery, and may be considered for 
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intermediate and high-risk stage I disease. Neoadjuvant chemotherapy with interval 
surgery has been proposed as an alternative to primary surgery (16-18). Unlike 
endometrial cancer, radiotherapy does not play a role in the management of primary 
ovarian cancer (12).
Over the years there have been significant advances in treatment and consequently 
survival. However ovarian cancer survival remains poor with a 5-year survival of 46%, 
compared to a 5-year survival of 79% for endometrial cancer (19). 
Table 2  Ovarian cancer FIGO stages (2013)
FIGO stage
I
    IA
    IB
    IC
    IC1
    IC2
    IC3
Tumour confined to the ovaries or fallopian tube(s)
   Tumour limited to 1 ovary (capsule intact) or fallopian tube, no tumour on 
ovarian of fallopian tube surface; no malignant cells in the ascites or peritoneal 
washings
   Tumour limited to both ovaries (capsules intact) or fallopian tubes, no tumour 
on ovarian of fallopian tube surface; no malignant cells in the ascites or 
 peritoneal washings 
  Tumour limited to 1 or both ovaries or fallopian tubes with any of the following:
- Surgical spill intraoperatively 
- Capsule rupture before surgery or tumour on ovarian or fallopian tube surface
- Malignant cells in the ascites or peritoneal washings
II
    IIA
    IIB
Tumour invades 1 or both ovarian or fallopian tubes with pelvic extension  
(below pelvic brim) or primary peritoneal cancer
  Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
  Extension to other pelvic intraperitoneal tissues
III
    IIIA
    IIIB
    IIIC 
Tumour invades 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, 
with cytologically or histologically confirmed spread to the peritoneum outside 
the pelvis and/or metastasis to the retroperitoneal lymph nodes
  Positive retroperitoneal lymph nodes only
  Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in   
  greatest dimension (includes extension of tumour to capsule of liver  
  and spleen without parenchymal involvement of either organ)
  Macroscopic peritoneal metastasis beyond the pelvis more than 2 
  cm in greatest dimension (includes extension of tumour to capsule   
  of liver and spleen without parenchymal involvement of either organ)
IV
    IVA
    IVB
Distant metastasis excluding peritoneal metastases
  Pleural effusion with positive histology
  Parenchymal metastases and metastases to extra-abdominal organs  
   (including inguinal lymph nodes and lymph nodes outside of the abdominal 
cavity)
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 Patient reported outcomes have received increasing interest over the past years, 
causing current practise to evolve beyond clinical endpoints to include quality of life 
(QoL) as important outcomes for cancer patients (20). It is well established that 
cancer diagnosis and treatment have a significant impact on the QoL, and that these 
effects may persist well into the patients’ survivorship years (21). 
 In the United Kingdom, the majority of endometrial and ovarian cancer patients 
are overweight (body mass index (BMI) 25-29.9 kg/m²) or obese (BMI ≥ 30 kg/m²) 
(22, 23). There have been studies suggesting an adverse effect of obesity on cancer 
treatment and a negative impact on endometrial and ovarian cancer survivorship, but 
the magnitude of this effect remains unclear (22, 23). In addition, gynaecological 
oncologists are increasingly treating women within the obese, morbidly obese (BMI 
≥ 40 kg/m²) and even super obese classifications (BMI ≥ 50 kg/m²), but clear clinical 
guidance for this group of women remains unavailable. 
 This thesis will evaluate the effect of body mass index on treatment and quality of 
life outcomes of endometrial and ovarian cancer patients, and assess the effect of 
lifestyle interventions as a means to improve quality of life.
Outline of the thesis
Endometrial cancer is the most common gynaecological cancer and surgery is one 
of the cornerstones of curative treatment. Chapter 2 discusses the effect of BMI on the 
surgical outcomes of endometrial cancer patients. Radiotherapy plays an important 
role in adjuvant treatment of endometrial cancer and in Chapter 3 we assess the 
impact of BMI on radiotherapy toxicities and complications. 
 Quality of life has been recognised as an important outcome of cancer survivors. 
With the majority of endometrial cancer patients being obese, we assess the influence 
of BMI on the QoL of survivors in our institution and through a review of the literature 
in Chapter 4.
 Chronic inflammation is known to play a role in the process of carcinogenesis 
and has been linked to obesity. In Chapter 5 we have evaluated the association 
between inflammatory markers and obesity, and their prognostic value in endometrial 
cancer.
 Although the relationship between ovarian cancer and obesity is less pronounced 
compared to endometrial cancer, the reality is that the majority women in the United 
Kingdom are overweight or obese. For this reason, in Chapter 6 we describe the 
impact of BMI on surgical treatment and outcomes of ovarian cancer surgery. 
 In Chapter 7 and 8 we have described the effect of excess weight on the QoL 
outcomes of ovarian cancer survivors at our institution. As physical activity is closely 
correlated with weight, we have assessed the effect of physical activity in relation to 
BMI and the QoL of ovarian cancer survivors in a two-centre study (Chapter 8). 
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 In Chapter 9 we review the evidence for the effect of lifestyle interventions to 
improve the QoL of endometrial and ovarian cancer survivors. As a result, we have 
suggested guidance for future interventions, which has led us to the development of 
a feasibility intervention study at our institution, which is outlined in Chapter 10.
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CHAPTER 2
Abstract
Objectives
We aimed to evaluate the association between body mass index (BMI), perioperative 
complications and outcomes in endometrial cancer (EC) patients at our institution. In 
addition, we performed a systematic review to compare our results to the literature.
Methods
This was a retrospective study of surgically managed EC patients between January 
2006 and January 2015. Patient characteristics, surgical complications and intra- and 
postoperative outcomes were evaluated across BMI groups; BMI <30 kg/m², BMI 
≥30 kg/m² and BMI ≥40 kg/m². The systematic review was performed according to 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines. 
Results
In total, we identified 627 women of which 514 were included; 249 women had a BMI 
<30 kg/m², 195 women had a BMI 30-39.9 kg/m², and 70 women were morbidly 
obese (BMI ≥40 kg/m²). Obese women (BMI ≥30 kg/m²) had significantly more 
postoperative surgical complications, including wound complications and antibiotics 
use, which was confirmed by the systematic review. The increase in complications 
mainly occurred in open surgery and morbidly obese patients were at highest risk. 
Obesity did not impact other outcomes including 30-day mortality.  
Conclusion
Obesity is associated with an increased risk of surgical morbidity in EC patients, and 
is most profound in open surgery and among the morbidly obese. Laparoscopic 
surgery may well prevent the majority of postoperative complications in this group of 
patients, and should therefore be the favoured approach. 
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Background
Endometrial cancer (EC) is the most common gynaecological malignancy in the UK, 
with over 8000 women being diagnosed annually (1). The incidence has risen over 
the recent decades, most likely due to increasing obesity (2, 3), with studies reporting 
up to 81% of EC patients being obese, and 19% to 36% being morbidly obese (4, 5). 
Furthermore, the majority of these women are insufficiently active and have several 
medical obesity-related comorbidities (6, 7). This poses significant challenges for EC 
management and has been suggested to negatively influence long-term outcomes 
(8, 9).  
 Surgery is the cornerstone of EC treatment, and obesity may have an effect on 
morbidity and outcomes in EC surgery. A recent study identified EC patients with a 
body mass index (BMI) of ≥40 kg/m² being at increased risk of developing surgical 
complications compared to their non-obese counterparts (10). However, other studies 
have failed to show any association between BMI and surgical morbidity (11, 12). 
 As the global obesity epidemic continues to grow, it is important to improve our 
understanding of the impact of BMI on surgical complications and outcomes in EC 
(3). This may help identify patients at risk prior to surgery and develop guidelines for 
clinical care to minimise adverse outcomes. Therefore, we have evaluated the impact 
of BMI on perioperative complications and outcomes in EC patients at our institution, 
and performed a systematic review to compare our results to that in the literature.
Methods
Primary study
Design and setting
We performed a retrospective cohort study of surgically managed EC patients at the 
Royal Cornwall Hospital Trust (RCHT). The study population consisted of women who 
underwent surgery for EC between January 2006 and January 2015. During this 
period, surgical management shifted from open approach to laparoscopic approach. 
We excluded women with insufficient data on their perioperative course, or an 
unknown preoperative BMI. Ethical approval was obtained through the London – 
Fulham Ethical committee and the study had full hospital approval.
Data collection 
Patients were identified through the cancer registry of the South West Intelligence 
Service. Patients’ medical records were reviewed to collect baseline, clinical and 
treatment characteristics. BMI was calculated from recorded preoperative height and 
weight and categorised according to national guidelines (3).
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504323-L-bw-Smits
24
CHAPTER 2
Outcomes 
The primary outcome was perioperative morbidity, defined as all complications 
occurring during surgery and within the first 30 days after surgery. Complications 
were evaluated individually and subsequently graded according to the Clavien-Dindo 
classification (13). Wound problems were defined as wound infection, dehiscence, 
and delayed healing requiring additional care. Antibiotics use entailed the use of an 
antibiotic for any type of infection, excluding prophylactic treatment. In addition, we 
assessed secondary outcomes such as hospital stay, estimated blood loss (EBL), 
transfusion requirements, conversion to laparotomy in laparoscopic cases, and 
30-day mortality. Outcomes were compared across the following BMI groups: <30 
kg/m², 30-39.9 kg/m², and ≥40 kg/m². 
Statistical analysis
Data were analysed with IBM SPSS statistical software (14). Means and standard 
deviations were calculated for continuous variables. Data were compared using the 
Kruskal-Wallis test or Median test for continuous data, and the Pearson Chi-square 
test and the Fisher’s Exact test for categorical data. Logistic regression models 
were used while controlling for possible confounders. P-values less than 0.05 were 
considered significant. 
Systematic review
Search strategy and selection criteria
This review was done according to Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines (15), and in accordance with the principles 
outlined in the Cochrane Handbook (16). Eligible for inclusion were all study designs 
evaluating the primary association between BMI and surgical complications in EC 
patients.
Participants; adult women undergoing open or laparoscopic surgery for all stage EC.
Primary outcome; surgical morbidity in terms of complications.
Secondary outcomes: other surgical outcomes including operating time (OR time), 
EBL, hospital stay, transfusion and conversion to laparotomy. 
We performed systematic searches in Medline (1946 until May 2015), Embase (1980 
until May 2015), and the Cochrane Trial Register. Search strategies were adapted 
accordingly (Appendix 1).
Data collection and analysis
Selection of studies
Two reviewers (AS and KG) assessed titles and abstracts of studies independently. 
Potentially relevant studies were retrieved in full text, and were further reviewed for 
eligibility by both reviewers. The risk of bias instrument recommended by the Cochrane 
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Non-Randomised Studies Methods Group was used for non-randomised comparative 
studies (17). Additionally, main confounders were identified a priori and included age, 
Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, 
stage and grade of disease, type and approach of surgery.
Results
Primary study 
A total of 627 EC patients were identified, of which 548 patients had undergone 
surgical management. Excluded were 17 women who received treatment elsewhere, 
eight women with incomplete data on their perioperative course, six women with 
leiomyosarcoma, and a further three women with an unknown BMI preoperatively. 
Consequently, our study population consisted of 514 patients (Figure 1). 
 Characteristics of the study population are summarised in Table 1. The median 
age was 66 years with a range of 27 – 93 years. Ninety-nine patients (19.3%) had a 
BMI <25 kg/m2, 150 patients (29.2%) were overweight, 195 patients (37.9%) had a 
BMI 30-39.9 kg/m², and 70 patients (13.6%) were morbidly obese. Two women were 
underweight and were included in the BMI <25 kg/m² group. Most patients were 
diagnosed with stage I disease (83.7%). Obese women were more likely to be younger 
(P=0.005) and the proportion of early stage disease increased with escalating BMI 
(P=0.004). Furthermore, a higher BMI was associated with a worse ECOG status 
Figure 1  Flow chart of recruitment
Study population;
514 women
Excluded: 
  - No surgical management (N=79) 
Excluded:
 
  
- Treatment elsewhere (N=17)
- Incomplete data on 
 perioperative course (N=8)
- Leiomyosarcoma (N=6)
- Unknown BMI (N=3)
 
548 women received
surgical treatment 
627 women diagnosed with
endometrial cancer 
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Table 1  Baseline and clinical characteristics according to BMI groups
BMI <30 kg/m²
N=249
BMI 30-39.9 kg/m²
N=195
BMI ≥40 kg/m²
N=70
Analysis
P-value
Age 
Median (range) 67 (31-93) 65 (35-88) 63 (27-83)
0.005*
ECOG 
   0
   1
   2-4
   Unknown
162 (65.1%)
36 (14.5%)
14 (5.6%)
37 (14.9%)
117 (60.0%)
35 (17.9%)
14 (7.2%)
29 (14.9%)
23 (32.9%)
24 (34.3%)
12 (17.1%)
11 (15.7%)
<0.001*
Smoking status
   Yes
   No
   Unknown
23 (9.2%)
224 (90.0%)
2 (0.8%)
13 (6.7%)
182 (93.3%)
0 (0%)
6 (8.6%)
64 (91.4%)
0 (0%)
0.675
Comorbidities
   None
   One
   Two or more
   Unknown
67 (26.9%)
66 (26.5%)
115 (46.2%)
1 (0.4%)
38 (19.5%)
37 (19.0%)
119 (61.0%)
1 (0.5%)
7 (10.0%)
12 (17.1%)
51 (72.9%)
0 (0%)
0.001*
Stage
    1
    2
    3
    4
    Unknown
191 (76.7%)
23 (9.2%)
24 (9.6%)
10 (4.0%)
1 (0.4%)
171 (87.7%)
10 (5.1%)
10 (5.1%)
4 (2.1%)
0 (0%)
68 (97.1%)
1 (1.4%)
1 (1.4%)
0 (0%)
0 (0%)
0.004*
Grade
   1
   2
   3
   Unknown
81 (32.5%)
82 (32.9%)
83 (33.3%)
3 (1.2%)
70 (35.9%)
74 (37.9%)
51 (26.2%)
0 (0%)
32 (45.7%)
28 (40.0%)
10 (14.3%)
0 (0%)
0.019*
ASA
   1 + 2
   3 + 4
   Unknown
192 (77.1%)
39 (15.7%)
18 (7.2%)
146 (74.9%)
42 (21.5%)
7 (3.6%)
27 (38.6%)
38 (54.3%)
5 (7.1%)
<0.001*
Type of surgery
   Open
   Laparoscopic
   Vaginal
129 (51.8%)
118  (47.4%)
2  (0.8%)
110 (56.4%)
81  (41.5%)
4 (2.1%)
36 (51.4%)
33 (47.1%)
1 (1.4%)
0.560
Time since diagnosis
Mean (SD) 48 (32.3) 49 (30.7) 43 (27.7)
0.495
*: P<0.05; ASA: American Association of Anesthesiologists; SD: standard deviation
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(P<0.001), more comorbidities (P=0.001), and a higher ASA (American Society of 
Anesthesiologists) score (P<0.001). Other baseline and clinical characteristics did 
not differ between the BMI groups. 
 There were no significant differences in surgical approach among BMI groups 
(P=0.560). In total, 54% of women underwent an open procedure, which is a reflection 
of the change in standard management. 
BMI and surgical complications 
Overall, obese and morbidly obese women experienced significantly more complications 
than non-obese women (P=0.010; Table 2).  
Intra-operative complications
In total, eight patients developed an intra-operative complication, but incidence rates 
showed no significant difference among BMI groups (Table 2). 
Postoperative complications
Obese patients and morbidly obese patients developed more complications when 
compared to non-obese patients (P=0.005) (Table 2). The severity of complications 
according to the Clavien-Dindo classification varied significantly among BMI groups 
(P=0.021), with obese and morbidly obese women having more grade 2-4 complications 
(P=0.004), which persisted after adjustment for confounders (P=0.001). 
 There was a significant difference in the incidence of wound complications and 
antibiotics use among the different BMI groups (P<0.001 and P=0.001). The overall 
rate of wound complications were 8.7% and 15.7%, for BMI of 30-39.9 kg/m² and ≥40 
kg/m2, compared to 2.8% in non-obese patients. The majority of wound problems 
were infections (89%), ten women experienced wound or fascia dehiscence and 
three women had wound problems requiring additional care. These differences in 
wound complications and antibiotics use persisted (P=0.025; OR 3.011 CI 1.145-7.920 
and P=0.010; OR 2.116 CI: 1.200-3.731) when comparing the obese groups (BMI ≥30 
kg/m²) to the non-obese group while adjusting for age, ECOG status, comorbidities, 
American Society of Anesthesiologists (ASA) score, stage and grade of disease. 
Further analyses evaluating open surgery and laparoscopic surgery groups 
separately, revealed that the significant increase in wound complications and 
antibiotics use among obese women occurred in open surgery (P<0.001, P=0.002), 
but not in laparoscopic surgery (P=0.811, P=0.112). Other complications showed no 
significant differences overall (Table 2), or according to surgical approach (data not 
shown). In addition, 30-day mortality did not vary significantly among groups 
(P=0.732), with an average rate of 0.6%. 
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CHAPTER 2
Table 3  Characteristics of included studies in the systematic review
Study Study design No Patients BMI groups Outcomes measures Conclusion
Akbayir et al. 
(20)
Retrospective study
Open surgery
346 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
≥ 30 kg/m² 
1. GIS, vascular and nerve injury 
2. Wound infection, hernia, lymphatic complications
3. OR time, EBL, hospital stay
1. NS
2. NS
3. BMI ≥ 30  OR time 
Erkanli et al.
(21)
Retrospective study
Open surgery
42 EC (I-IV) < 30 kg/m² 
30-39.9 kg/m²
≥ 40 kg/m² 
1. Overall rate, ureteral, bowel, bladder and vessel injury
2.  Overall rate, wound dehiscence, wound infection, UTI, ileus,  
DVT, sepsis, pneumonia, cardiac or lymphatic complication, 
death 
3. OR time, EBL, hospital stay, ABT
1. NS
2. BMI ≥ 40  wound dehiscence
3. BMI ≥ 40  OR time
Everett et al.
(22)
Retrospective study
Open surgery
396 EC (I-IV) < 30 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1.  Overall rate, haemorrhage, ureteral, vessel, bowel and bladder 
injury, arrhythmia 
2.  Overall, wound separation, wound infection, UTI, sepsis, 
pneumonia, ileus, small bowel obstruction, DVT, failed voiding 
trial, cardiac complication, DVT, mortality
3. OR time, EBL, hospital stay, ICU stay, ABT
1. NS
2. BMI ≥ 40  wound separation
3. BMI ≥ 40  OR time and  EBL 
Ghezzi et al.
(26)
Prospective cohort study
Laparoscopic surgery
101 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Overall rate
2. Overall rate
3. OR time, EBL, hospital stay, conversion to laparotomy
1. NS
2. NS 
3. NS
Gunderson et al.
(10)
Ancillary data analysis of RCT
Open and laparoscopic surgery
2510 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
30-34.9 kg/m²
35-39.9 kg/m²
≥ 40 kg/m²
1.  Overall rate, bowel, vessel, bowel, bladder and ureter injury, 
others
2.  Overall rate, UTI ,fever, pelvic cellulitis, abscess, VTP, PE, bowel 
obstruction, ileus, pneumonia, wound infection, antibiotics use, 
urinary fistula, bowel fistula, congestive heart failure, arrhythmia, 
re-operation, death
3.  ABT, hospital stay,  readmission
1. NS
2.   BMI  total complications,  
VTP, wound infection and 
antibiotics use  
3. BMI ≥ 40  hospital stay
Kerimoglu et al.
(25)
Prospective study 
Open surgery
94 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Bladder, urethral, vascular or bowel injury
2. Wound infection, ileus, atelectasis, haemorrhage
3. OR time, hospital stay, ABT
1. NS
2. NS
3. NS
Litta et al.
(18)
Unknown design
Laparoscopic surgery
75 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Overall rate
2. Vaginal cuff dehiscence, DVT, lymphatic complication
3. OR time, EBL, hospital stay
1. NS
2. NS
3. NS
Mahdi et al.
(7)
Retrospective study
Open and laparoscopic surgery
3947 EC
Stage unknown
18-29.9 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1. Not in article
2.  Overall rate, number, surgical complication, non-surgical 
complication, infection, SSI, wound disruption, peripheral nerve 
injury, pneumonia, sepsis, septic shock, renal, pulmonary or 
cardiac complication, re-operation, 30-day mortality 
3. OR time, hospital stay, ABT
1. NIA
2.  BMI ≥ 40  total complications, 
infection, SSI and wound 
disruption, BMI 30-39.9  sepsis
3. BMI ≥ 30  OR time, and  ABT
O’Hanlan et al.
(19)
Retrospective study
Laparoscopic surgery
88 EC (I-IV) and 
hyperplasia
< 18.5 kg/m²
18.5-25 kg/m²
25-29.9 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1&2. Overall rate combined
3. OR time, EBL, hospital stay, ABT
1&2. NS
3. NS
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Table 3  Characteristics of included studies in the systematic review
Study Study design No Patients BMI groups Outcomes measures Conclusion
Akbayir et al. 
(20)
Retrospective study
Open surgery
346 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
≥ 30 kg/m² 
1. GIS, vascular and nerve injury 
2. Wound infection, hernia, lymphatic complications
3. OR time, EBL, hospital stay
1. NS
2. NS
3. BMI ≥ 30  OR time 
Erkanli et al.
(21)
Retrospective study
Open surgery
42 EC (I-IV) < 30 kg/m² 
30-39.9 kg/m²
≥ 40 kg/m² 
1. Overall rate, ureteral, bowel, bladder and vessel injury
2.  Overall rate, wound dehiscence, wound infection, UTI, ileus,  
DVT, sepsis, pneumonia, cardiac or lymphatic complication, 
death 
3. OR time, EBL, hospital stay, ABT
1. NS
2. BMI ≥ 40  wound dehiscence
3. BMI ≥ 40  OR time
Everett et al.
(22)
Retrospective study
Open surgery
396 EC (I-IV) < 30 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1.  Overall rate, haemorrhage, ureteral, vessel, bowel and bladder 
injury, arrhythmia 
2.  Overall, wound separation, wound infection, UTI, sepsis, 
pneumonia, ileus, small bowel obstruction, DVT, failed voiding 
trial, cardiac complication, DVT, mortality
3. OR time, EBL, hospital stay, ICU stay, ABT
1. NS
2. BMI ≥ 40  wound separation
3. BMI ≥ 40  OR time and  EBL 
Ghezzi et al.
(26)
Prospective cohort study
Laparoscopic surgery
101 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Overall rate
2. Overall rate
3. OR time, EBL, hospital stay, conversion to laparotomy
1. NS
2. NS 
3. NS
Gunderson et al.
(10)
Ancillary data analysis of RCT
Open and laparoscopic surgery
2510 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
30-34.9 kg/m²
35-39.9 kg/m²
≥ 40 kg/m²
1.  Overall rate, bowel, vessel, bowel, bladder and ureter injury, 
others
2.  Overall rate, UTI ,fever, pelvic cellulitis, abscess, VTP, PE, bowel 
obstruction, ileus, pneumonia, wound infection, antibiotics use, 
urinary fistula, bowel fistula, congestive heart failure, arrhythmia, 
re-operation, death
3.  ABT, hospital stay,  readmission
1. NS
2.   BMI  total complications,  
VTP, wound infection and 
antibiotics use  
3. BMI ≥ 40  hospital stay
Kerimoglu et al.
(25)
Prospective study 
Open surgery
94 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Bladder, urethral, vascular or bowel injury
2. Wound infection, ileus, atelectasis, haemorrhage
3. OR time, hospital stay, ABT
1. NS
2. NS
3. NS
Litta et al.
(18)
Unknown design
Laparoscopic surgery
75 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1. Overall rate
2. Vaginal cuff dehiscence, DVT, lymphatic complication
3. OR time, EBL, hospital stay
1. NS
2. NS
3. NS
Mahdi et al.
(7)
Retrospective study
Open and laparoscopic surgery
3947 EC
Stage unknown
18-29.9 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1. Not in article
2.  Overall rate, number, surgical complication, non-surgical 
complication, infection, SSI, wound disruption, peripheral nerve 
injury, pneumonia, sepsis, septic shock, renal, pulmonary or 
cardiac complication, re-operation, 30-day mortality 
3. OR time, hospital stay, ABT
1. NIA
2.  BMI ≥ 40  total complications, 
infection, SSI and wound 
disruption, BMI 30-39.9  sepsis
3. BMI ≥ 30  OR time, and  ABT
O’Hanlan et al.
(19)
Retrospective study
Laparoscopic surgery
88 EC (I-IV) and 
hyperplasia
< 18.5 kg/m²
18.5-25 kg/m²
25-29.9 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1&2. Overall rate combined
3. OR time, EBL, hospital stay, ABT
1&2. NS
3. NS
Processed on: 12-7-2016
504323-L-bw-Smits
32
CHAPTER 2
Other operative outcomes 
In 32 patients, laparoscopic surgery was converted to a laparotomy, and rates were 
significantly higher among obese and morbidly obese patients (P=0.006). Conversion 
rate remained significantly higher in patients with BMI ≥30 kg/m² after adjustment for 
other factors including age, ECOG status, comorbidities, ASA score, stage and grade 
(P=0.004). Furthermore, EBL was significantly higher in both obese and morbidly 
obese patients undergoing laparoscopic surgery when compared to non-obese 
patients (P<0.001), which persisted after correction for the above mentioned factors 
(P=0.002). Other operative outcomes including transfusion requirements and hospital 
stay did not show significant differences. 
Systematic review
The search strategy identified 915 references, and after screening titles and abstracts 
46 articles were retrieved in full text and were further assessed for eligibility. 
Subsequently, 11 studies were considered eligible for this review, and a search of the 
grey literature identified a further two eligible studies. 
Table 3  Continued
Study Study design No Patients BMI groups Outcome measures Conclusion
Pavelka et al.
(23)
Retrospective study
Open surgery
339 EC (I-IV) < 30 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1.  Vascular, bladder, bowel or ureteral injury
2.  Ileus, wound infection, wound break-down, unspecified febrile 
morbidity, nerve injury, lymphatic complication, VTE, pneumonia, 
30-day mortality
3.  OR time, EBL, hospital stay, ABT
1. NS
2.  BMI ≥ 40  wound infection and 
wound breakdown
3.  BMI ≥ 40  OR time,  
BMI ≥ 30  EBL
Pellegrino et al.
(24)
Retrospective study
Laparoscopic surgery 
75 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1.  Overall rate
2.  Fever, VTE,  paraesthesia, cardiac, lymphatic, and renal 
complications, re-operation, 
3.  OR time, EBL, hospital stay, ABT, conversion rate
1. NS
2. NIA
3. BMI ≥ 30  EBL
Rabischong et al.
(11)
Retrospective study
Laparoscopic surgery
207 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1.  Overall rate, haemorrhage, bladder injury, emphysema, gas 
embolism
2.  Overall rate, hemoperitoneum, phlebitis, PE, intestinal 
obstruction, vesico-vaginal fistula, lymphatic complication, 
port-site hernia, obturator neuropathy, vaginal cuff dehiscence, 
abdominal wall hematoma
3.  OR time, hospital stay, ABT, conversion
1. NS
2. NS
3. NS
Santoso et al.
(12)
Prospective study
Open surgery
233 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
30-34.9 kg/m²
≥ 35 kg/m²
1.  Bowel or bladder injury, obturator vein bleed
2.  Fever requiring antibiotics,  fascial dehiscence, DVT, UTI, kidney 
stone, acute renal insufficiency, neurogenic bladder or cardiac 
complication
3.  OR time, EBL, hospital stay, ABT
1. NS
2. NS
3.  BMI  OR time and  EBL
EC: endometrial cancer; DVT: deep venous thrombosis; GIS: gastrointestinal system; ICU: intensive care unit;  
NS: not significant; PE: pulmonary embolism; SSI: surgical site infection; UTI: urinary tract infection;  
VTE; venous thrombo-embolism; VTP: venous thrombo-phlebitis;
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Included studies
The characteristics of the 13 studies included in the review are illustrated in Table 3. 
Eight studies were retrospective studies and four used prospectively collected data. 
One study used data from a randomised controlled trial (RCT), in which patients were 
randomised according surgical approach (10). One study did not define its study 
design (18). All studies combined resulted in a total of 8453 EC patients. Most studies 
included all stage EC patients, although one also included women with hyperplasia 
(N=19) (19), and another did not define which stages of disease were included (7). 
Six studies evaluated open surgery, five evaluated laparoscopic surgery and two 
included both open and laparoscopic management. 
BMI and intra-operative complications
Almost all articles reviewed the incidence of intra-operative complications except for 
Mahdi et al. (7). None of the articles found a significant association between BMI and 
the incidence of overall or individual intra-operative complications. 
Table 3  Continued
Study Study design No Patients BMI groups Outcome measures Conclusion
Pavelka et al.
(23)
Retrospective study
Open surgery
339 EC (I-IV) < 30 kg/m²
30-39.9 kg/m²
≥ 40 kg/m²
1.  Vascular, bladder, bowel or ureteral injury
2.  Ileus, wound infection, wound break-down, unspecified febrile 
morbidity, nerve injury, lymphatic complication, VTE, pneumonia, 
30-day mortality
3.  OR time, EBL, hospital stay, ABT
1. NS
2.  BMI ≥ 40  wound infection and 
wound breakdown
3.  BMI ≥ 40  OR time,  
BMI ≥ 30  EBL
Pellegrino et al.
(24)
Retrospective study
Laparoscopic surgery 
75 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1.  Overall rate
2.  Fever, VTE,  paraesthesia, cardiac, lymphatic, and renal 
complications, re-operation, 
3.  OR time, EBL, hospital stay, ABT, conversion rate
1. NS
2. NIA
3. BMI ≥ 30  EBL
Rabischong et al.
(11)
Retrospective study
Laparoscopic surgery
207 EC (I-IV) < 30 kg/m²
≥ 30 kg/m²
1.  Overall rate, haemorrhage, bladder injury, emphysema, gas 
embolism
2.  Overall rate, hemoperitoneum, phlebitis, PE, intestinal 
obstruction, vesico-vaginal fistula, lymphatic complication, 
port-site hernia, obturator neuropathy, vaginal cuff dehiscence, 
abdominal wall hematoma
3.  OR time, hospital stay, ABT, conversion
1. NS
2. NS
3. NS
Santoso et al.
(12)
Prospective study
Open surgery
233 EC (I-IV) < 25 kg/m²
25-29.9 kg/m²
30-34.9 kg/m²
≥ 35 kg/m²
1.  Bowel or bladder injury, obturator vein bleed
2.  Fever requiring antibiotics,  fascial dehiscence, DVT, UTI, kidney 
stone, acute renal insufficiency, neurogenic bladder or cardiac 
complication
3.  OR time, EBL, hospital stay, ABT
1. NS
2. NS
3.  BMI  OR time and  EBL
EC: endometrial cancer; DVT: deep venous thrombosis; GIS: gastrointestinal system; ICU: intensive care unit;  
NS: not significant; PE: pulmonary embolism; SSI: surgical site infection; UTI: urinary tract infection;  
VTE; venous thrombo-embolism; VTP: venous thrombo-phlebitis;
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BMI and postoperative complications
All included studies assessed postoperative complications, with most studies 
evaluating individual complications (7, 10-12, 18, 20-25). The significant increase in 
postoperative complications in our study was confirmed by findings of the randomised 
controlled trial of Gunderson et al., showing a significant increase in the total number 
of postoperative complications with increasing BMI (10). In addition, the largest 
retrospective study comprising 3947 patients identified morbidly obese women at 
increased risk (7). 
 A significant increase of non-infectious wound complications in morbidly obese 
women was reported in all retrospective studies including both open and laparoscopic 
surgery (7, 21-23). However, the association between obesity and wound infection 
was not uniformly reported. The RCT stated that increasing BMI was associated with 
a rise in incidence of wound infections, and two retrospective studies combining a 
total of 4286 women specifically identified morbidly obese women being at increased 
risk after open surgery (7, 10, 23). In addition, Gunderson et al. reported a significant 
increase in infection complications after open surgery, a higher incidence of venous 
thrombo-phlebitis in women with BMI ≥25 kg/m², and increased use of antibiotics in 
the morbidly obese group, concurring with our findings (10). In several studies the 
association between infectious wound complications and BMI was not apparent. 
However, they did not include morbid obesity as a separate group, which may explain 
the lack of uniformity in reporting postoperative wound infections (20, 25). 
 Other individual complications did not show a significant association with BMI, 
and no differences were found in postoperative mortality rates, similar to the results 
of our institutional study (7, 10, 22, 23). 
BMI and other operative outcomes
The association between BMI and OR time was assessed by twelve studies. The 
majority of studies assessing open surgery were of retrospective design. They found 
that obese women and especially morbidly obese women required significantly 
longer operating times (7, 20-23), which was also confirmed by the prospective study 
of Santoso et al. (12). Studies assessing laparoscopic surgery did not report a 
significant association between operating time and BMI (11, 18, 19, 24, 26). 
 We found a significant increase in EBL among the obese and morbidly obese in 
laparoscopic surgery, mirroring the results of Pellegrino et al. (24). Two retrospective 
studies and one prospective study evaluating open surgery, found a higher EBL with 
increasing BMI (12, 22, 23). However, four retrospective and one prospective study 
including both open and laparoscopic surgery failed to show an association (18-21, 
26). The increased conversion rates among obese and morbidly obese patients in 
our study was not found in other studies including a total of 383 patients, but was not 
evaluated by the RCT (11, 24, 26).
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 BMI did not affect hospital stay in any study except for the RCT, where a 
significantly longer stay was reported in the morbidly obese group compared to 
women with BMI <25 kg/m² (10). However, they did not correct for possible 
confounders such as surgical approach, and its distribution among the BMI groups 
was not specified (10). Transfusion rates were not associated with BMI in any of the 
studies (7, 10-12, 19, 21-25). 
Risk of bias and confounding
The majority of studies were non-randomised with a retrospective design, leading to 
a high risk of bias associated with non-randomisation, selective reporting and patient 
attrition. Only two studies reported on possible confounders and adjusted for this in 
their analysis. None of the studies reported their complications according to 
international scoring systems such as the Clavien-Dindo classification. In addition, 
the majority of studies did not define a timeframe within which the postoperative 
complications would occur, and several studies did not specify the numbers of 
complications for each BMI group. 
Discussion
Endometrial cancer is strongly associated with obesity, resulting in the majority of 
patients being obese (27). The aim of this study was to give a comprehensive 
overview of the current literature on the impact of BMI on the surgical complications 
and outcomes of EC patients, and to provide guidance for clinical care and future 
studies. 
 The institutional study showed that obesity is a risk factor for overall and 
postoperative surgical complications, including wound complications and increased 
use of antibiotic treatment specifically after open surgery. The review confirmed our 
findings of a higher incidence of wound and infectious complications among obese 
women with EC. In addition, the review showed that the total number of complications 
increased with BMI, identifying morbidly obese at a particularly high risk. BMI was not 
associated with other perioperative complications or postoperative mortality, and our 
rates were consistent with other reported rates (7, 23). 
 Increasing BMI was significantly associated with longer operating times in open 
surgery in the review. The increased conversion rates in women with BMI ≥30 kg/m² 
in the institutional study was not confirmed by studies in the review. However, 
considering the size of our study population and the number of conversions, we 
believe this requires further assessment by future studies. 
 We therefore confirm the association between obesity and surgical morbidity in 
EC, showing that morbidly obese women are especially at significant risk. This 
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association is more pronounced in the open surgical approach with increased 
postoperative complications in obese women in both the institutional study and the 
review. Obese women will therefore benefit most from laparoscopic surgery in terms 
of postoperative outcomes, and this should be the favoured approach. A recent 
Cochrane review showed that laparoscopy has similar survival outcomes and 
reduced operative morbidity compared to laparotomy in EC (28). Furthermore, obese 
women are not at increased risk of intra-operative morbidity or mortality, contrary to 
common clinical perception. Still, efforts should be made to minimise adverse 
outcomes with special attention to this group of patients. Peri-operative complications 
adversely affect recovery and may delay adjuvant treatment, and should therefore 
receive due attention. Enhanced recovery programmes have already been proposed 
but not routinely evaluated in standard practise to improve operative outcomes, and 
therefore require further assessment (29). 
 Risk factors for postoperative wound complications are well recognised and 
extensive precautions are already being undertaken by surgical and anaesthetic 
teams in terms of skin preparation, suturing techniques, prophylactic antibiotics, 
tissue perfusion, fluid management and cardiopulmonary support. However, patient- 
related risk factors including age, smoking, physical and nutritional condition, obesity 
and comorbidities such as diabetes and cardiovascular disease, still pose significant 
threats to postoperative wound healing and recovery (30). We therefore recommend 
the assessment of prehabilitation programmes, comprising the optimisation of 
patients prior to surgical treatment, to improve modifiable risk factors. Although 
implementation remains a challenge because of a restricted time period between 
diagnosis and treatment, previous studies have shown promising results (31-35). 
Strengths and limitations
Strengths of the institutional study include the study size, and the inclusion of all 
histological subtypes and stages, increasing its applicability. Additionally, the inter-
nationally validated Clavien-Dindo classification was used for systematic grading of 
postoperative complications and we corrected for possible confounders. However, 
our study still has limitations inherent to its retrospective design, including non- 
randomization, possible selection bias and completeness of previously recorded 
data. 
Completeness and applicability of evidence of the systematic review
The majority of women were diagnosed with stage I disease, consistent with reported 
incidence rates (36). The studies evaluated a variety of surgical complications of 
which the majority could be compared. 
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Quality of evidence 
The majority of studies were susceptible to a high risk of bias, mainly because of their 
retrospective design. Only one study used data collected from a RCT and a further 
three used prospectively collected data. Most studies did not adjust for possible 
confounders. In addition, there was a lack of uniformity in reporting surgical morbidity 
and in categorisation of BMI groups, with several studies not describing BMI ≥40 kg/m² 
as a separate group. 
Potential biases in review process
A comprehensive literature search was performed by the reviewers (AS and KG), 
including a search of the grey literature. Reviewers assessed potentially eligible 
articles independently, and differences were resolved by appeal to a third reviewer 
(AL). 
Future research
Ideally, prospective designs and large study populations are preferred to further 
clarify to what extent obesity impacts surgical morbidity and outcomes. Particular 
attention needs to be paid to the morbidly obese, as they can comprise up to 36% of 
the EC population and are at highest risk of postoperative complications impairing 
recovery and possibly long-term outcomes (5). Classification of complications 
according to internationally validated systems, such as the Clavien-Dindo system, 
should be highly recommended to improve comparability across studies. Moreover, 
future studies should focus on minimising adverse outcomes, possibly through 
 prehabilitation programmes and improving postoperative care pathways.
Conclusion
The results of our institutional study and systematic review confirm that obesity is 
associated with an increased risk of surgical morbidity in EC patients. This association 
is most profound in open surgery and among the morbidly obese. Laparoscopic 
surgery may prevent the majority of postoperative complications in this group of 
patients, and should therefore be advocated for obese women. In addition, we 
propose the evaluation of prehabilitation programmes as a means to minimise 
surgical morbidity and improve outcomes of EC patients. 
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Appendix 1 – Search Strategy
 1. endometrium AND cancer 
 2. ENDOMETRIUM CANCER
 3. endometr* cancer 
 4. uter* cancer 
 5. endometr* neoplasm 
 6. uter* neoplasm 
 7. endometr* carcinoma 
 8. uter* carcinoma 
 9. BODY MASS INDEX 
 10. OBESITY/ OR MORBID OBESITY 
 11. BMI 
 12. body mass index 
 13. weight 
 14. obes* 
 15. quetelet* index 
 16. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
 17. 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 
 18. GYNECOLOGICAL OPERATION/ OR GYNECOLOGY SURGERY
 19. surger* 
 20. operati* 
 21. 18 OR 19 OR 20
 22. POSTOPERATIVE COMPLICATIONS/ OR COMPLICATION 
 23. PEROPERATIVE COMPLICATION 
 24. operative complication* 
 25. surg* complication* 
 26. complication* 
 27. postoperative complication* 
 28. operative morbid* 
 29. surg* morbid* 
 30. DEATH 
 31. death. 
 32. mortality 
 33. morbidity 
 34. SURVIVAL 
 35. survival
 36. operative outcom* 
 37. surg* outcom* 
 38. 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 
  34 OR 35 OR 36 OR 37
 39. 16 AND 17 AND 21 AND 38 
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Abstract
Objective
To assess the impact of body mass index (BMI) on radiotherapy toxicities in 
endometrial cancer patients.
Methods
This was a retrospective cohort study of women diagnosed with endometrial cancer 
between January 2006 and December 2014 at the Royal Cornwall Hospital Trust. 
Women who received radiotherapy as part of treatment, including external beam 
radiotherapy (EBRT) and/or vaginal brachytherapy were included. Radiation-related 
toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) 
guidelines. Toxicity outcomes were compared across BMI groups; non-obese (BMI 
< 30 kg/m²) and obese (BMI ≥ 30 kg/m²), according to radiotherapy treatment received 
(EBRT, brachytherapy or a combination).
Results
A total of 159 women received radiotherapy of which 110 could be included. Sixty-three 
women had a BMI < 30 kg/m² and 47 women were obese. Obese women had poorer 
ECOG performance status (P=0.021) and more comorbidities (P<0.001) compared 
to the non-obese group. Overall toxicity rates were 60.3%, 72.7% and 52.0% for EBRT 
and brachytherapy (N=63), single mode EBRT (N=22) and brachytherapy (N=25) 
respectively. BMI was not associated with the incidence of acute and late radiation 
toxicities in the different radiotherapy groups. There were no differences in individual 
complications between the BMI groups.
Conclusion
Obesity does not negatively impact the incidence of radiation toxicities in endometrial 
cancer. However, toxicities remain an important challenge as they are common and 
negatively influence the quality of life (QoL) of survivors. Future studies need to 
further explore the role of possible interventions to improve toxicities and QoL.
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Background
Endometrial cancer (EC) is the most common gynaecological cancer, affecting more 
than 8000 women annually in the United Kingdom (1). Radiotherapy plays an important 
role in the management of EC, with vaginal brachytherapy and/or pelvic external 
beam radiotherapy (EBRT) being part of treatment of all stages of the disease (2). 
Evidence supports the use of radiotherapy to significantly reduce tumour relapse 
rates, although this may not result in an overall survival benefit in early stage disease 
(3-6). Treatment-related toxicities occur frequently, with reported rates up to 75%, and 
therefore remain of particular concern as they may severely impact the quality of life 
(QoL) of survivors (7). 
 It is important to acknowledge the potential toxicity burden of radiotherapy and 
to identify possible contributing factors. Toxicity rates have been known to vary among 
the different radiotherapy modalities, with higher reported rates in EBRT compared to 
brachytherapy alone (8, 9). 
 Obesity is an important risk factor for EC, and a significant health issue in the 
majority of women diagnosed (10, 11). Obesity negatively affects the treatment of EC, 
with obese women (BMI ≥ 30 kg/m²) posing significant surgical challenges and 
having a higher risk of surgical complications (12, 13). However, there is a lack of 
evidence regarding the effect of obesity on radiotherapy complications, despite 
radiotherapy being one of the cornerstones of the current adjuvant treatment in EC. 
 It is important to understand the influence of obesity on radiotherapy management 
to provide specific clinical guidance for this growing patient group. In this study, 
we assessed the impact of body mass index (BMI) on radiotherapy toxicities in 
endometrial cancer patients.
Methods
Study population 
This was a retrospective cohort study of women diagnosed with EC between January 
2006 and December 2014 at the Royal Cornwall Hospital Trust. We included women 
with a histological EC diagnosis, who received radiotherapy treatment including 
pelvic external beam radiotherapy (EBRT), vaginal brachytherapy, or a combination 
of the modalities. Exclusion criteria were an unknown BMI at time of diagnosis, age 
≤ 18 at time of diagnosis, treatment in the palliative setting, and incomplete data on 
radiotherapy treatment and outcomes. The study had full Trust approval and Ethical 
approval was obtained through the London – Fulham Ethical committee. 
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Data collection
Women were identified through the South West Intelligence Service cancer registry. 
Patients’ demographic and clinical characteristics were collected from medical files 
and included age at diagnosis, marital and smoking status, Eastern Cooperative 
Oncology Group (ECOG) performance status, comorbidities, FIGO (International 
Federation of Gynecology and Obstetrics) stage and grade of disease, and treatment. 
Details of radiotherapy treatment plans included modality (EBRT and brachytherapy), 
total dose, technique, and EBRT mean dose (Gy) and volume (cm³) of organs at risk 
(OAR) including; bladder, bowel, rectum and femurs. BMI at time of diagnosis (weight 
(kg) / [height (m)]²) was collected as part of standard practice and categorised into 
‘non-obese’ (BMI < 30 kg/m²) and ‘obese’ (BMI ≥ 30 kg/m²). 
Technique
Prior to November 2013 patients received EBRT using 3D conformal radiotherapy 
(3D-CRT), which covered the planned target volume using a 4-field box technique 
with 10 MV (Mega Voltage) x-rays, with marked coverage of adjacent bladder and 
bowel. The box technique was based on bony landmarks or planned target volume 
including lymph node basins and parametrium depending on practise at that time. 
Bowel was contoured using the bowel bag technique. From November 2013 onwards, 
EBRT was delivered using Intensity Modulated Radiotherapy (IMRT) using volumetric 
modulated arc therapy (VMAT) with 6 MV x-rays and on-set Image Guidance 
Radiotherapy (IGRT). Standard doses varied from 45 to 50.4 Gy in 25-28 fractions 
over a period of five to 5.5 weeks. Deviations from standard practice included doses 
of 54 Gy in 30 fractions for pelvic recurrent disease. Vaginal vault brachytherapy was 
administrated through Low Dose Rate (LDR) brachytherapy or High Dose Rate (HDR) 
brachytherapy under image guidance. LDR brachytherapy was delivered as 15 Gy in 
one fraction in conjunction with EBRT, or as a single insertion of 27 to 30 Gy when 
given as a single mode therapy. HDR brachytherapy was given as single mode 
treatment consisting of 22 Gy given in four fractions, or in conjunction with doses 
varying from 5.5 to 8 Gy in 1-2 insertions. From 2014 onwards, all patients received 
brachytherapy using HDR administration. 
Outcomes
Radiation-related toxicities and other reported adverse events were collected from 
patients’ medical records. Toxicities were graded according to the Radiation Therapy 
Oncology Group (RTOG) guidelines by two clinicians (14). Acute toxicities were 
defined as toxicities occurring from the start of radiation treatment and within 90 days 
post-treatment. Late toxicities comprised of toxicities occurring later than three 
months post-treatment. Toxicities were graded on a scale varying from 0-5, with 0 
being no symptoms and 5 being death directly related to radiation effects. 
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Lymphoedema was not included in the RTOG guidelines, but was considered an 
important adverse event. Toxicity outcomes were compared across BMI groups; non- 
obese and obese, according radiotherapy treatment received (EBRT, brachytherapy 
or a combination). Overall survival (OS) and disease-free survival (DFS) were used for 
survival comparison. OS was defined as the time from diagnosis to death from all 
causes. DFS was defined as the time between diagnosis and the first clinical, 
pathologic or radiographic evidence of loco-regional or distant recurrent disease. 
Statistical analysis
Continuous data were presented as means and standard deviations (SD) and were 
compared using the Mann-Whitney U test. Categorical variables were presented as 
frequencies and proportions, and compared using the Pearson’s Chi-Square and 
Fisher’s exact test. Unknown data were excluded from analysis. Lymphoedema 
was not included in the RTOG guidelines, but was analysed as a grade ≥ 2 late 
complication. Survival analyses were performed using the Kaplan-Meier method 
using the log-rank test. P-values were regarded significant if P<0.05 and tests were 
two-sided. Data analysis was performed using IBM SPSS statistics software (15).
Results
In total, 626 women were diagnosed with EC in the period January 2006 – December 
2014. We identified 159 patients who received radiotherapy as part of management. 
We excluded twenty-four women who received palliative radiotherapy, sixteen women 
with an unknown BMI, eight women with insufficient follow-up data, and one woman 
who received her radiotherapy treatment elsewhere. This resulted in a study population 
of 110 women (Figure 1).
 The median age of the study population was 67 years (range 27-84). The majority 
of women (80%) were diagnosed with early stage disease (I/II). Twenty-eight women 
had a BMI of < 25 kg/m², 35 women were overweight (BMI 25-29.9 kg/m²) and 47 
women were obese (BMI ≥ 30 kg/m²) at time of diagnosis. Ten women were morbidly 
obese (BMI ≥ 40 kg/m²), with five women having a BMI ≥ 45 kg/m². 
 Obese and non-obese women were similar in terms of age, ethnicity, marital 
and smoking status, and clinical characteristics including stage, grade, treatment 
and recurrent disease (Table 1). However, obese women had significantly more 
comorbidities (P<0.001) and a poorer ECOG performance score (P=0.021) compared 
to non-obese women. 
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Figure 1  Flow chart of recruitment
Study population;
110 women 
Excluded: 
  - No radiotherapy (N=467) 
Excluded: 
  - Palliative setting (N=24) 
  - Unknown BMI (N=16) 
  - Insufficient data (N=8) 
  - Treatment elsewhere (N=1) 
159 women received
radiotherapy 
626 women diagnosed with
endometrial cancer  
Table 1  Demographic and clinical characteristics according to BMI groups
BMI < 30 kg/m²
N=63
BMI ≥ 30 kg/m²
N=47
Analysis
P-value
Age
   < 70 years
   ≥ 70 years
37 (58.7%)
26 (41.3%)
26 (55.3%)
21 (44.7%)
0.721
Ethnicity
   White
   Other
61 (96.8%)
2 (3.2%)
47 (100%)
0 (0%)
0.506
Marital status
    Married
    Not married
    Widowed
    Unknown
44 (69.8%)
9 (14.3%)
8 (12.7%)
2 (3.2%)
34 (72.3%)
5 (10.6%)
6 (12.8%)
2 (4.3%)
0.860
Comorbidities
    None
    One
    Two or more
23 (36.5%)
17 (27.0%)
23 (36.5%)
2 (4.3%)
14 (29.8%)
31 (66.0%)
<0.001*
ECOG status
   0
   1
   2-4
   Unknown
51 (81.0%)
4 (6.3%)
1 (1.6%)
7 (11.1%)
28 (59.6%)
7 (14.9%)
5 (10.6%)
7 (14.9%)
0.021*
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The majority of women (N=63) received a combination of pelvic EBRT and 
brachytherapy, 22 women received EBRT and 25 women received brachytherapy. 
Most women were treated using 3D-CRT (89%). EBRT total doses varied from 45 to 
54.0 Gy (median 45.0 Gy). Brachytherapy varied from 8 to 30 Gy, with the exception 
of one woman who received a single fraction of 5.5 Gy. There was no significant 
difference in radiotherapy treatment (P=0.170), EBRT and brachytherapy dose 
(P=0.169, P=0.590), nor the technique used (P=1.000) (Table 2). The mean volume 
of bowel at risk was significantly higher in the obese group (P=0.014), which is 
reflected in a significantly lower mean dose received by the bowel in obese women 
(P=0.002). Other OAR volumes and doses did not significantly differ (Table 2).
Table 1  Continued
BMI < 30 kg/m²
N=63
BMI ≥ 30 kg/m²
N=47
Analysis
P-value
Smoking status
   Yes
   No
   Unknown
7 (11.1%)
56 (88.9%)
0 (0%)
1 (2.1%)
45 (95.8%)
1 (2.1%)
0.135
FIGO Stage
   I/II
   III/IV 
49 (77.8%)
14 (22.2%)
39 (83.0%)
8 (17.0%)
0.631
Grade
   1
   2
   3
7 (11.1%)
17 (27.0%)
39 (61.9%)
4 (8.5%)
20 (42.6%)
23 (48.9%)
0.232
Surgical treatment
   Yes
      TLH + BSO
      TAH + BSO
   No
62 (98.4%)
25 (39.7%)
37 (58.7%)
1 (1.6%)
45 (95.7%)
12 (25.5%)
33 (70.2%)
2 (4.3%)
0.575
Chemotherapy
   Yes
   No
17 (27.0%)
46 (73.0%)
10 (21.3%)
37 (78.7%)
0.491
Recurrence
   Yes
      Local
      Distant
   No
11 (17.5%)
4 (6.4%)
7 (11.1%)
52 (82.5%)
7 (14.9%)
4 (8.5%)
3 (6.4%)
40 (85.1%)
0.652
Time since diagnosis
Mean (SD) 59.3 (33.3) 57.0 (33.8)
0.646
SD: standard deviation; *: P<0.05
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The overall toxicity rate in the study population was 60.9%, with an overall rate of 
60.3%, 72.7% and 52.0% for EBRT and brachytherapy, single mode EBRT, and 
brachytherapy respectively. Forty-six women (41.8%) experienced an acute toxicity, 
of which the 21 women (45.7%) reported a grade 2 toxicity or higher. Data on late 
toxicities was available for 106 women, as four women were excluded because they 
died within 90 days after the end of radiotherapy treatment or because of insufficient 
long-term follow-up data. Thirty-six women (34.0%) experienced a late toxicity, of 
which the majority (55.6%) were grade ≥ 2 toxicities. Four women reported lymph - 
oe dema as a late effect. There were no radiation-related deaths reported in our 
population.
 Toxicity rates were compared across the BMI groups according to each 
radiotherapy modality; EBRT and brachytherapy, EBRT or brachytherapy alone 
(Table 3, 4 and 5). There were no differences in the incidence of overall, acute and 
late toxicities between the BMI groups receiving a combination of EBRT and 
brachytherapy (P=0.565, P=0.645, P=0.557). Sixty-two percent of non-obese 
women reported a grade ≥ 2 acute toxicity versus 33.3% in obese women, although 
this did not significantly differ (P=0.158). The most common acute toxicities involved 
the lower gastro-intestinal (GI) tract and pelvis (N=16), or the genito-urinary system 
Table 2  Radiotherapy details according to BMI groups
BMI < 30 kg/m²
N=63
BMI ≥ 30 kg/m²
N=47
Analysis
P-value
Radiotherapy treatment
   EBRT
   EBRT + brachytherapy
   Brachytherapy
10  (15.9%)
35 (55.6%)
18 (28.6%)
12 (25.5%)
28 (59.6%)
7 (14.9%)
0.170
EBRT Technique
   3D-Conformal
   IMRT
40 (88.9%)
5 (11.1%)
37 (90.0%)
4 (10.0%)
1.000
EBRT OAR mean volume (cm³)
   Bladder
   Bowel
   Rectum
   Femurs
145.35 (90.83)
1597.97 (552.82)
73.58 (40.69)
86.61 (16.55)
115.81 (64.95)
2100.50 (1060.84)
76.09 (49.45)
80.27 (20.43)
0.171
0.014*
0.702
0.220
EBRT OAR mean dose (Gy)
   Bladder
   Bowel
   Rectum
   Femurs
42.42 (8.25)
28.87 (5.73)
39.96 (7.69)
33.36 (7.89)
43.77 (9.47)
25.34 (6.45)
39.63 (9.78)
34.57 (8.55)
0.244
0.002*
0.835
0.469
EBRT: external beam radiotherapy; Gy: Gray; OAR: organs at risk; *: P<0.05
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(N=10), and incidences did not differ between groups (P=0.948, P=0.740). Incidence 
of late toxicities did not differ between groups, of which the majority comprised 
intestinal (P=0.597) and bladder toxicities (P=1.000, data not shown) and 59% of 
women had a grade 2 toxicity or higher.
There was no difference in overall toxicities, acute toxicities or late toxicities between 
the BMI groups in the EBRT treatment group (Table 4). The most prevalent acute 
toxicities of single mode EBRT were lower GI and pelvis, and genito-urinary 
complications, with the former being reported by four non-obese women and seven 
obese women (P=0.670), and genito-urinary complications by one in the non-obese 
group and three obese women (P=0.594). We found no significant differences 
between groups in terms of individual acute and late toxicities (data not shown). For 
brachytherapy, acute toxicities were more prevalent than late toxicities, but did not 
show an association with BMI (Table 5). Furthermore, individual complications did 
not significantly differ among groups (data not shown). 
Table 3  Radiation toxicities of EBRT and brachytherapy according to BMI groups
BMI < 30 kg/m²
N=35
BMI ≥ 30 kg/m²
N=28
Analysis
P-value
Overall toxicities
   Yes
   No
20 (57.1%)
15 (42.9%)
18 (64.3%)
10 (35.7%)
0.565
Acute toxicities
   Yes
   No
13 (37.1%)
22 (62.9%)
12 (42.9%)
16 (57.1%)
0.645
Acute toxicity grade
   1
    ≥ 2
5 (38.5%)
8 (61.5%)
8 (66.7%)
4 (33.3%)
0.158
Late toxicities
   Yes
   No
13 (39.4%)
20 (60.6%)
9 (32.1%)
19 (67.9%)
0.557
Late toxicity grade
   1 
    ≥ 2
6 (46.2%)
7 (53.8%)
3 (33.3%)
6 (66.7%)
0.674
*: P< 0.05
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Table 4  Radiation toxicities of EBRT according to BMI groups
BMI < 30 kg/m²
N=10
BMI ≥ 30 kg/m²
N=12
Analysis
P-value
Overall toxicities
   Yes
   No
6 (60.0%)
4 (40.0%)
10 (83.3%)
2 (16.7%)
0.348
Acute toxicities
   Yes
   No
4 (40.0%)
6 (60.0%)
9 (75.0%)
3 (25.0%)
0.192
Acute toxicity grade
   1
   ≥ 2
3 (75.0%)
1 (25.0%)
3 (33.3%)
6 (66.7%)
0.266
Late toxicities
   Yes
   No
3 (33.3%)
6 (66.7%)
3 (27.3%)
8 (72.7%)
1.000
Late toxicity grade
   1
   ≥ 2
0 (0%)
3 (100%)
0 (0%)
3 (100%)
1.000 
*: P< 0.05
Table 5  Radiation toxicities of brachytherapy according to BMI groups
BMI < 30 kg/m²
N=18
BMI ≥ 30 kg/m²
N=7
Analysis
P-value
Overall toxicities
   Yes
   No
10 (55.6%)
8 (44.4%)
3 (42.9%)
4 (57.1%)
0.637
Acute toxicities
   Yes
   No
7  (38.9%)
11 (61.1%)
1 (14.3%)
6 (85.7%)
0.362 
Acute toxicity grade
   1
   ≥ 2
5 (71.4%)
2 (28.6%)
1 (100%)
0 (0%)
1.000 
Late toxicities
   Yes
   No
6 (33.3%)
12 (66.7%)
2 (28.6%)
5 (71.4%)
1.000 
Late toxicity grade
   1
    ≥ 2
4 (66.7%)
2 (33.3%)
1 (50%)
1 (50%)
1.000 
*: P< 0.05
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There was no significant difference in OS (P=0.467) and DFS (P=0.793) between 
obese and non-obese women (data not shown). In addition, recurrence rates did not 
differ between groups, with a rate of 17.5% in non-obese women and 14.9% in obese 
women (P=0.652) (Table 1).
Discussion
The majority of women diagnosed with EC are overweight or obese (10). Despite 
extensive evidence on the negative effect of increasing BMI on surgery and adjuvant 
chemotherapy, its effect on radiotherapy has somehow been neglected (13, 16). 
Therefore, in this study we assessed the effect of BMI on radiotherapy toxicities in EC 
patients.
 Our study showed that BMI does not negatively impact the incidence or severity 
of acute and late toxicities of radiotherapy treatment for EC. Furthermore, there were 
no significant differences in individual acute and late complications between obese 
and non-obese women. In our population, obese women had a significantly poorer 
ECOG performance status and more comorbidities compared to the non-obese 
group. Despite these known patient-related risk factors for radiation toxicities, obese 
women did as well as their non-obese counterparts.
 Our findings are supported by several studies stating that the incidence of 
radiotherapy toxicities is not associated with BMI (17, 18). A retrospective study 
(N=268) by Martra et al. showed that BMI was not significantly correlated with 
common acute toxicities including gastro-intestinal, genito-urinary and cutaneous 
toxicities after EBRT (17). Al Asiri et al. also reported no significant association 
between BMI and radiation toxicities. Their study reviewed 66 women receiving a 
combination of EBRT and brachytherapy, with a large subset of the population 
consisting of morbidly obese women (36.4%) (18). 
 In contrast, a recent study by Dandapani et al. assessing acute toxicities of 68 
EC patients reported that a higher BMI was associated with increased frequency of 
acute grade 1 and 2 gynaecological and cutaneous toxicities (7). The authors stated 
that the gynaecological toxicities increase occurred with a BMI > 45.2 kg/m². This 
may explain why our study did not find an association as only 5 of the 110 included 
women had BMI > 45.2 kg/m². An important limitation of the study of Dandapani et al. 
was that it was a small study of 68 patients and heterogeneous study population 
comprising women receiving EBRT and/or brachytherapy. The authors did not 
differentiate by radiotherapy treatment received despite the known significant 
variation of toxicity rates among the radiotherapy modalities. 
 Von Gruenigen et al. retrospectively reviewed data from a randomised controlled 
trial of 187 patients and showed that increased BMI was significantly correlated with 
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less gastro-intestinal and more cutaneous toxicities after EBRT (19). However, they 
did not provide BMI cut-off values for clinical guidance, and as a consequence it 
remains unclear which BMI categories of women are at risk of more toxicities. 
Following these results, we have identified a clear need for future large prospective 
studies assessing the effect of BMI on radiotherapy toxicities and outcomes. This will 
also provide the opportunity to assess specific subgroups at risk such as the morbidly 
obese and the super obese (BMI ≥ 50 kg/m²). 
 It is interesting to see that obesity does not impact radiotherapy outcomes, 
despite that it has been shown to significantly impact on the rate of malpositioning 
and size of positioning errors in EC (18, 20, 21). Lin et al. reported that an increasing 
BMI was found to be associated with increased setup errors and larger margin 
requirements, which has been confirmed by other studies in EC and other cancer 
sites (21-25). Authors attributed this significant association to the higher concentrations 
of abdominal fat causing large shifts in their tattoos because of shifting skin (21). This 
may force clinicians to adopt larger margins for planned target volume during EBRT 
planning, and suggests that specifically obese patients may benefit more from daily 
image guidance. A recent study showed that particularly obese women benefit from 
the use of field-in-field (FIF) technique compared to 3D-CRT in terms of improved 
dose homogeneity and dose reductions (26). In addition, in our study there was a 
significant difference of 3.53 Gy in mean dose received by the bowel, although this 
did not translate in a toxicity difference.
 Survival outcomes did not significantly differ among the two BMI groups, 
although the study size precludes any strong conclusions. The effect of obesity on 
the survival of EC patients has been much debated, with studies reporting conflicting 
results (27, 28). A recent systematic review has stated that increased BMI is 
significantly associated with increased all-cause mortality, with morbidly obese 
women being at highest risk. The authors reported that a 10% increase in BMI resulted 
in a 9.2% increase in the odds of all-cause mortality (27). Moreover, we did not find 
an association between recurrent disease and BMI, which is in accordance with the 
existing literature (29). 
 Following that EC generally has a good prognosis with a 10-year survival of 78%, 
QoL is an important outcome for survivors (30). Radiotherapy has been known to 
negatively impact several aspects of QoL, including physical, social and role 
functioning as well as sexual functioning, with treatment-related symptoms persisting 
well into patients’ survivorship years (31-34). Despite finding no significant difference 
in toxicity outcomes across BMI groups, it would be interesting to see whether BMI 
influences reported QoL impairments following radiotherapy treatment, as obesity 
has been shown to negatively affect the QoL of EC survivors (31, 35). 
 New radiotherapy techniques such as IMRT and IGRT have allowed decreased 
radiation exposure to structures adjacent to the clinical target regions, and may 
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consequently reduce treatment toxicity (36, 37). Furthermore, adaptive planning, 
comprising an adaptive radiotherapy plan which responds to changes in anatomy 
and tumour biology throughout the course of treatment, will allow clinicians to further 
individualise and tailor radiotherapy treatment (38, 39). However, reports on long-term 
outcomes are limited, and the impact of BMI on new techniques has yet to be 
assessed. Future large prospective studies are therefore needed to assess the role 
of BMI in order to develop specific clinical guidelines for their use in the obese 
population. Moreover, interventions aiming to improve toxicity complications and 
QoL should be encouraged, as the majority of patients will experience toxicities (3, 6). 
Exercise has been known to improve the QoL of cancer patients during adjuvant 
treatment (40, 41). It has been suggested that exercise may also improve radiation-re-
lated toxicities (42). Proposed mechanisms of a beneficial effect of exercise include 
an increase in endorphins and insulin-related growth factors mediating the acute 
radiation reaction, and possibly a systemic anti-inflammatory effect (42). Unfortunately 
within EC, exercise intervention studies are still in their infancy and should therefore 
be a focus of future investigations (43). 
 To our knowledge, this was the first study to date to assess the effect of BMI on 
toxicity rates while differentiating for different radiotherapy treatments in EC. Strengths 
of the study include the homogeneity of the study population and the evaluation of 
toxicities according to the international and validated RTOG guidelines by two 
clinicians (14). 
 Study limitations include the retrospective design and the relatively small study 
population. A large proportion of toxicities were grade 1 toxicities, which may be less 
likely to be reported. In addition, there was a variation of EBRT and brachytherapy 
treatment doses, although we believe this is a reflection of clinical practice and its 
change over time. The overall toxicity rates of EBRT and the combination EBRT and 
brachytherapy varied slightly, with interestingly a lower overall rate in the combination 
group. We believe this may be a result of the study size, even though it generally 
concurred with previously reported rates (3, 6, 7). 
Conclusion
In this study we show that BMI does not influence the occurrence of radiation toxicities 
in EC. However, radiation related toxicities remain prevalent and are of particular 
concern for EC patients, as they may severely impact their QoL. In addition, obesity 
remains a challenge in the treatment of EC. Future studies need to further explore the 
role of obesity in radiotherapy management to provide specific clinical guidelines 
and assess possible interventions to improve toxicities and QoL.
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CHAPTER 4
Abstract
Background
Survivorship and quality of life issues are becoming increasingly relevant in endometrial 
cancer as a result of the marked increase in incidence of the disease combined with 
excellent and improving long term survival.
Objective
The purpose of this study was to evaluate the effect of obesity (BMI ≥ 30 kg/m²) on 
quality of life (QoL) in endometrial cancer survivors.
Methods 
Participants were endometrioid endometrial cancer survivors diagnosed between 
2008 and 2013. Quality of life was measured through the European Organisation for 
Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30, 
version 3.0). Associations between BMI and quality of life were determined by means 
of multivariate analyses.
Results
322 women diagnosed with endometrioid endometrial cancer were invited to 
participate. Excluded were 15 women with unknown BMI, 40 with non-endometrioid 
histology and 10 with concurrent cancer. The QLQ-C30 questionnaire was completed 
by 158 (61.5%) women, of which 63 women (40%) were obese (BMI ≥ 30–39.9 kg/m²), 
and 30 women (19%) were morbidly obese (BMI ≥ 40 kg/m²). Morbidly obese women 
reported worse physical, role and social functioning and more somatic complaints.
Conclusion
Morbid obesity is associated with poorer quality of life in endometrial cancer survivors. 
Lifestyle interventions such as exercise programs and diet interventions could be 
viable means to improve the quality of life of obese endometrial cancer survivors. 
Future research should focus on means to improve quality of life in obese endometrial 
cancer survivors.
Processed on: 12-7-2016
504323-L-bw-Smits
63
BMI AND QUALITY OF LIFE OF ENDOMETRIAL CANCER SURVIVORS
4
Background
Endometrial cancer is the fourth most common cancer in the United Kingdom, 
accounting for 5% of all female cancers. The five year survival rate for endometrial 
cancer (77.3%) is among the highest of the most common cancers in England. While 
the incidence of several other cancers has levelled or declined in the last decades, 
rates for endometrial cancer have increased by over 40% since the 1990s (1). One of 
the main reasons for this rise is the growing obesity epidemic (2).
 In 2011, 33% of adult women in England were overweight (BMI 25-29.9 kg/m²) 
with a further 26% being obese (BMI of 30 kg/m² or greater), showing a rapid rising 
trend over time (2). The risk of endometrial cancer is directly related to weight increase 
(3–5), with higher incidence of endometrial cancer among obese women accounting 
for 38% up to 81% of endometrial cancer patients being obese (BMI ≥ 30 kg/m²), and 
12% to 17% being morbidly obese (BMI ≥ 40 kg/m²) (6–9).
 As the group of endometrial cancer survivors continues to grow due the rising 
incidence and the relatively good prognosis, there is an increasing interest in 
enhancing the quality of life of survivors (10). Recent studies suggest that obesity 
negatively impacts quality of life in early stage endometrial cancer survivors (6, 7, 
11, 12). In addition, obesity is associated with higher cancer related and all-cause 
mortality, and disease recurrence, although this is not uniformly reported (8, 9, 13–16). 
 In this study we aimed to investigate the effect of obesity on quality of life in survivors 
of endometrioid endometrial cancer using a validated quality of life questionnaire 
(EORTC QLQ-C30, version 3.0).
METHODS
Study population
Women diagnosed with endometrial cancer at the Royal Cornwall Hospital (RCHT) 
between January 2008 and May 2013 were identified from the cancer registry of 
the South West Cancer Intelligence Service. Eligible women were those with 
endometrioid pathology who were still alive, with no history of concurrent malignancy, 
and in whom weight and height had been recorded at the time of diagnosis. They had 
been approached to participate in a departmental review of the follow up care either 
at their follow up appointments or by post, with an introduction letter explaining the 
nature of the survey. The letter was accompanied by a general questionnaire as well 
as a quality of life questionnaire. Consent was obtained at their review appointment 
or by post.
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Data collection
Patient characteristics such as age at diagnosis, date of diagnosis, histology, stage, 
grade, treatment, and other characteristics were collected from the patients’ medical 
records. Staging was performed through surgery using the International Federation 
of Gynecology and Obstetrics (FIGO) 2009 staging, including systematic lymph-
adenectomy (17). Patients who did not undergo surgery (disseminated disease with 
poor performance status) were staged according to their radiological appearance 
and characteristics using the clinical staging adopted by FIGO in 1971 (18). 
Recurrence was defined as clinical, pathological, or radiographic evidence of disease 
recurrence. Information about recurrent disease was collected from the medical 
records of women who were included in the study, and of 35 women with endometrioid 
endometrial cancer who had died by the time of data collection.
 The BMI (weight (kg) / [height (m)]²) at the time of diagnosis was recorded, and 
categorised according to national guidelines: underweight (≤ 18.5 kg/m²), normal 
range (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), obese (≥ 30–39.9 kg/m²) and 
morbidly obese (≥ 40 kg/m²) [19). The project was a secondary analysis of outcomes 
of a departmental review audit of the follow up service and therefore did not require 
ethical review.
Outcome measures
Quality of life was assessed using the European Organisation for Research and 
Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30, version 3.0). 
This is a validated 30-item cancer-specific questionnaire composed of both multi-item 
scales and single-item measures, covering several areas of quality of life; physical, 
emotional, cognitive, social and role functioning as well as symptoms and global 
quality of life. All items were rated on a 4-point scale from 1 (“not at all”) to 4 (“very 
much”), with the exception of global health and QoL which were rated on a 6-point 
scale from 1 (“very poor”) to 6 (“excellent”) (20).
Statistical analysis
For analysis purposes, BMI data were grouped into the three categories, respectively 
“non-obese” (< 30 kg/m²), “obese” (≥ 30–39.9 kg/m²) and “morbidly obese” (≥ 40 kg/m²) 
and repeated with “non-obese” combined with “obese” as one group to compare 
against “morbidly obese”. Data were analysed with SPSS statistics version 20.0. 
Continuous outcomes were presented as means with standard deviations (SD), 
categorical outcomes were presented as frequencies and proportions. Demographic 
and clinical data were compared using independent samples t-test and one-way 
ANOVA for continuous data and Pearson Chi-Square for categorical variables. The 
EORTC QLQ-C30 outcomes were analysed according to scoring procedures and 
were linearly transformed into 0–100 scales. Higher scores for quality of life functional 
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scales and global health status represent a higher level of functioning and a high 
quality of life. Higher scores for symptom scales or items represent a higher level of 
symptomatology (21). Multivariate analyses were used to assess associations 
between outcome measures and BMI, while correcting for patient characteristics. 
P-values were regarded significant if P<0.05 and tests were two-sided.
Results
A total of 397 women were diagnosed with endometrial cancer at the RCHT between 
January 2008 and May 2013, of which 75 women were deceased at the time of the 
study and were therefore excluded. Consequently, 322 women diagnosed with 
endometrial cancer were invited to participate. Excluded from further analysis in this 
study were 15 women with unknown BMI, 40 women with non-endometrioid histology 
and 10 women with concurrent cancer. Of the remaining 257 women with endometrioid 
endometrial cancer, 158 (61.5%) completed the questionnaire (the participants) and 
99 failed to return them (the non-participants) (Figure 1).
Figure 1  Flow chart of recruitment to the study
Excluded: 
    - Deceased (75) 
Excluded: 
    - BMI unknown (15) 
    - Different histology (40)  
    - Concurrent cancer (10) 
158 participants (61.5%) 99 non-participants  
Questionnaires sent to 322 women 
diagnosed with endometrial cancer 
as part of departmental audit  
397 women diagnosed with 
endometrial cancer between January 
2008 and May 2013  
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Baseline and clinical characteristics
The mean age of both participants and non-participants combined was 66 years (SD 
9.74). The majority (94.9%) was diagnosed with early stage (I and II) endometrial 
cancer. Almost all women had undergone surgery (98.1%), and a small number 
received chemotherapy and/or radiotherapy. The median time since diagnosis was 
30 months (range 2–81). There was no significant difference in the baseline and 
clinical characteristics between the participants in the study compared to those who 
failed to return the questionnaire (Table 1).
Table 1  Baseline and clinical characteristics of participants and non-participants
Participants
N=158
Non-participants
N=99
Analysis
P-value
Age (mean, SD) 70.0 (8.85) 64.7 (10.92) 0.076
Performance status (ECOG) 0.116
   0 98 (62.0%) 47 (47.5%)
   1 30 (19.0%) 24 (24.2%)
   2 6 (3.8%) 4 (4.0%)
   3 4 (2.5%) 1 (1.0%)
   4 0 (0.0%) 1 (1.0%)
   Unknown 20 (12.7%) 22 (22.2%)
Body mass index 0.847
   Non-obese (< 30 kg/m²) 65 (41.1%) 42 (42.4%)
   Obese (30-39.9 kg/m²) 63 (39.9%) 41 (41.4%)
   Morbidly obese (≥ 40 kg/m²) 30 (19.0%) 16 (16.2%)
Stage 0.194
   Early (1-2) 149 (94.3%) 95 (96%)
   Late (3-4) 7 (4.4%) 1 (1.0%)
   Unknown 2 (1.3%) 3 (3.0%)
Grade 0.312
   1 70 (44.3%) 40 (40.4%)
   2 69 (43.7%) 40 (40.4%)
   3 19 (12.0%) 18 (18.2%)
   Unknown 0 (0.0%) 1 (1.0%)
Operation 0.945
   Yes 155 (98.1%) 97 (98.0%)
   No 3 (1.9%) 2 (2.0%)
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Table 2 compares the baseline and clinical characteristics of the 158 women who 
returned the questionnaire according to their BMI status. Sixty-five (41%) were 
non-obese (mean BMI 25.7, minimum 18), 63 (40%) were obese (mean BMI 34.3), and 
30 women (19%) were morbidly obese (mean BMI 44.9, maximum 64). Non-obese 
women were significantly older than the obese and morbidly obese women at the 
time of diagnosis (P=0.042). The morbidly obese women had a significantly worse 
Table 1  Continued
Participants
N=158
Non-participants
N=99
Analysis
P-value
Type of operation 0.220
   TAH + BSO 52 (32.9%) 42 (42.4%)
   TLH + BSO 98 (62.0%) 48 (48.5%)
   LAVH + BSO 4 (2.5%) 4 (4.0%)
   Other 1 (0.6%) 3 (3.0%)
   None 3 (1.9%) 2 (2.0%)
Chemotherapy 0.330
   Yes 6 (3.8%) 2 (2.0%)
   No 152 (96.2%) 96 (97.0%)
   Unknown 0 (0.0%) 1 (1.0%)
Radiotherapy 0.445
   Yes 28 (17.7%) 18 (18.2%)
   No 130 (82.3%) 80 (80.8%)
   Unknown 0 (0.0%) 1 (1.0%)
Time since diagnosis 0.961
   < 1 year 32 (20.3%) 19 (19.2%)
   1 - < 2 years 35 (22.2%) 23 (23.2%)
   2 - < 3 years 35 (22.2%) 18 (18.2%)
   3 - < 4 years 27 (17.1%) 18 (18.2%)
   4 - < 5 years 22 (13.9%) 17 (17.2%)
   ≥ 5 years 7 (4.4%) 4 (4.0%) 
Recurrence 0.559
   Yes 3 (1.9%) 3 (3.0%)
   No 155 (98.1%) 96 (97.0%)
BSO: bilateral salpingo-oophorectomy; ECOG: Eastern Cooperative Oncology Group; LAVH: laparoscopic 
assisted vaginal hysterectomy; SD: standard deviation; TAH: total abdominal hysterectomy; TLH: total laparo-
scopic hysterectomy
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Table 2   Baseline and clinical characteristics of participants according  
to BMI categories
Non-obese 
(< 30 kg/m2)
N=65 
Obese 
(30-39.9 kg/m2)
N=63
Morbidly obese 
(≥ 40 kg/m2)
N=30
Analysis
P-value
Age (mean, SD) 69.0 (10.05) 66.0 (8.30) 64.6 (6.12) 0.042*
Performance status <0.001*
   0 47 (72.3%) 42 (66.7%) 9 (30.0%)
   1 6 (9.2%) 16 (25.4%) 8 (26.7%)
   2 3 (4.6%) 2 (3.2%) 1 (3.3%)
   3 0 (0.0%) 0 (0.0%) 4 (13.3%)
   4 0 (0.0%) 0 (0.0%) 0 (0.0%)
   Unknown 9 (13.8%) 3 (4.8%) 8 (26.7%)
Stage 0.035*
   Early (1-2) 61 (93.8%) 60 (95.2%) 28 (93.3%)
   Late (3-4) 4 (6.2%) 3 (4.8%) 0 (0.0%)
   Unknown 0 (0.0%) 0 (0.0%) 2 (6.7%)
Grade 0.734
   1 27 (41.5%) 32 (50.8%) 11 (36.7%)
   2 30 (46.2%) 24 (38.1%) 15 (50.0%)
   3 8 (12.3%) 7 (11.1%) 4 (13.3%)
Operation 0.085
   Yes 64 (98.5%) 63 (100%) 28 (93.3%)
   No 1 (1.5%) 0 (0.0%) 2 (6.7%)
Type of operation 0.445
   TAH + BSO 22 (33.8%) 20 (31.7%) 10 (33.3%)
   TLH + BSO 41 (63.1%) 39 (61.9%) 18 (60.0%)
   LAVH + BSO 1 (1.5%) 3 (4.8%) 0 (0.0%)
   Other 0 (0.0%) 1 (1.6%) 0 (0.0%)
   None 1 (1.5%) 0 (0.0%) 2 (6.6%)
Chemotherapy 0.481
   Yes 3 (4.6%) 3 (4.8%) 0 (0.0%)
   No 62 (95.4%) 60 (95.2%) 30 (100%)
Radiotherapy 0.064
   Yes 17 (26.2%) 8 (12.7%) 3 (10.0%)
   No 48 (73.8%) 55 (87.3%) 27 (90.0%)
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performance status compared to the obese and non-obese women (P<0.001). None 
of the morbidly obese women was diagnosed with late stage disease (P=0.035) 
though in two cases the stage was not known.
Quality of life
Mean scores of reported outcomes of the QLQ-C30 questionnaire in endometrial 
cancer survivors according to BMI categories are described in Table 3. The global 
quality of life of endometrial cancer survivors was highest among non-obese women, 
but not significantly different from obese and morbidly obese women. Outcomes of 
obese women did not significantly differ from non-obese women in any quality of life 
subscale. However, women who were morbidly obese (BMI ≥ 40 kg/m²) at time of 
diagnosis reported significantly worse physical functioning (P=0.002) but had similar 
outcomes in all other functioning scales when compared to non-obese and obese 
women. They also had significantly more dyspnoea (P=0.016) and diarrhoea (P=0.030) 
but did not differ from non-obese and obese women in other symptom distress scores. 
 In addition, we have compared quality of life outcomes of the morbidly obese 
women to the women with a BMI below 40 kg/m² (non-obese and obese groups 
combined). This showed a significantly worse physical, role and social functioning 
(P=0.001, P=0.017 and P=0.023), and significantly more dyspnoea, pain and 
diarrhoea (P=0.037, P=0.025 and P=0.009) in morbidly obese women (Table 3).
Table 2   Continued
Non-obese 
(< 30 kg/m2)
N=65 
Obese 
(30-39.9 kg/m2)
N=63
Morbidly obese 
(≥ 40 kg/m2)
N=30
Analysis
P-value
Time since diagnosis 0.708
   <1 year 12 (18.5%) 13 (20.6%) 7 (23.3%)
   1 - < 2 years 15 (23.1%) 15 (23.8%) 5 (16.7%)
   2 - < 3 years 11 (16.9%) 14 (22.2%) 10 (33.3%)
   3 - < 4 years 13 (20.0%) 12 (19.0%) 2 (6.7%)
   4 - < 5 years 11 (16.9%) 6 (9.5%) 5 (16.7%)
   ≥ 5 years 3 (4.6%) 3 (4.8%) 1 (3.3%)
Recurrence 0.361
   Yes 2 (3.1%) 0 (0.0%) 1 (3.3%)
   No 63 (96.9%) 63 (100%) 29 (96.7%)
BSO: bilateral salpingo-oophorectomy; ECOG: Eastern Cooperative Oncology Group; LAVH: laparoscopic 
assisted vaginal hysterectomy; SD: standard deviation; TAH: total abdominal hysterectomy; TLH: total lapa-
roscopic hysterectomy; *: P<0.05
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Obesity, quality of life and stage of disease
BMI did not have a significant effect on global quality of life in women with early stage 
endometrial cancer. However, morbidly obese women reported significantly worse 
physical functioning compared to non-obese and obese women with early stage 
disease (P=0.007). In addition, obese and morbidly obese women experienced 
significantly more dyspnoea and diarrhoea than non-obese women with early stage 
disease (P=0.007 and P=0.013). In total, seven women were diagnosed with late 
stage endometrioid endometrial cancer, of which four women were non-obese and 
three women were obese. There were no morbidly obese women diagnosed with late 
stage endometrial cancer (Table 2).
Table 3   Outcomes of QLQ-C30 questionnaires of participants according  
to BMI categories
Non-obese Obese Morbidly 
obese
Analysis BMI < 40 kg/m²  
vs. morbidly obese
N=65 N=63 N=30
Mean (SD) P-value P-value
Global quality of life 79 (18) 75 (22) 68 (25) 0.077 NS
Functional scales
    Physical functioning 85 (17) 81 (17) 66 (29) 0.002* 0.001*
    Role functioning 87 (20) 83 (26) 71 (33) 0.052 0.017*
    Emotional functioning 88 (17) 83 (21) 88 (21) 0.512 NS
    Cognitive functioning 91 (14) 90 (15) 81 (31) 0.513 NS
    Social functioning 91 (18) 89 (21) 78 (31) 0.073 0.023*
Symptom scales
    Fatigue 20 (20) 24 (22) 31 (25) 0.071 NS
    Nausea and vomiting 3 (7) 5 (10) 7 (17) 0.667 NS
    Pain 13 (21) 18 (27) 26 (29) 0.086 0.025*
    Dyspnoea 10 (19) 17 (22) 24 (28) 0.016* 0.037*
    Insomnia 27 (28) 22 (30) 15 (19) 0.112 NS
    Appetite loss 6 (14) 5 (15) 4 (12) 0.927 NS
    Constipation 16 (23) 9 (19) 10 (22) 0.077 NS
    Diarrhoea 3 (11) 4 (12) 9 (15) 0.030* 0.009*
    Financial difficulties 5 (16) 7 (23) 6 (20) 0.917 NS
*: P-value <0.05; NS: not significant
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Obesity and recurrence
There was no significant effect of obesity on recurrent disease in the 292 women 
diagnosed with endometrioid endometrial cancer (data not shown). Recurrence rates 
among non-obese, obese and morbidly obese women were respectively 6.6% (N=8), 
2.5% (N=3) and 7.7% (N=4).
Discussion
The prognosis for women with endometrial cancer is good, with the age-standardised 
relative survival rates in England during 2005–2009 showing that 74.4% of women are 
surviving ten years or more (1). As such, survivorship and quality of life issues are 
very relevant to their care. Cancer survivorship entails the maintenance of physical, 
social, sexual, spiritual, and economic wellbeing. Assessment of factors that impact 
quality of life in endometrial cancer survivors is important to develop a tailored 
survivorship programme and excellent quality of care.
 Endometrial cancer and obesity are inextricably associated with one another. 
Weight of endometrial cancer survivors does not seem to change over time and 
cancer survivors find it difficult to implement lifestyle changes (22–24). Therefore 
novel approaches dealing with obese endometrial cancer patients are important to 
help maintain a high QoL for long-term survivors.
 In this study, 59% of endometrial cancer survivors had a BMI of ≥ 30 kg/m², and 
19% were morbidly obese (BMI ≥ 40 kg/m²), which is consistent with previously 
reported data (6-9). Morbidly obese women had a significantly worse performance 
status compared to non-obese and obese, probably because of their functional 
limitations and comorbidities due to their excessive weight (25, 26). Measures that 
improve the performance status at diagnosis including pre-operative optimisation 
and prehabilitation should be considered.
 Previous studies have reported a significantly poorer quality of life in endometrial 
cancer survivors with a BMI of ≥ 30 kg/m², which further deteriorates as BMI increases 
(6, 7, 11, 12). However, our study indicates that significant quality of life deterioration 
is reported by morbidly obese endometrial cancer survivors but that obese women 
with BMI below 40 kg/m² do not experience poorer quality of life compared to the 
non-obese.
 Morbidly obese women reported significantly worse physical functioning 
compared to non-obese and obese endometrial cancer survivors, which is in line 
with previous research (7, 11, 12). A recent study by Oldenburg et al. found that 
women with a higher BMI reported lower physical function, lower vitality and more 
fatigue symptoms (12). Two other studies also associated higher BMI with lower 
physical functioning, but found no significant effect on symptom distress (7, 11). In 
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our study, morbidly obese endometrial survivors experienced more dyspnoea, pain 
and diarrhoea when compared to non-obese and obese women combined, although 
this was not found in other studies (6, 7, 11, 12).
 Morbidly obese women reported significantly worse social and role functioning. 
Other studies did not report a significant relationship between BMI and social 
functioning (6, 11, 12). The effect of BMI on role functioning has not been assessed 
by other studies due to the fact that they used different questionnaires (6, 9, 11, 12). 
Furthermore, morbidly obese women reported significantly more pain and diarrhoea 
(P = 0.025 and P = 0.009), these symptoms are known to be associated with obesity 
(27, 28).
 How obesity affects quality of life still remains unclear. We can hypothesize that 
obesity affects quality of life through limited mobility, decreased physical endurance 
and its associated comorbidities, as well as through social discrimination (25, 27, 28). 
Lifestyle interventions may improve the quality of life in obese endometrial cancer 
survivors. There is considerable evidence that lifestyle modifications lead to improved 
general health and quality of life in other cancer sites such as colorectal, breast and 
prostate cancer (29–31). Thus far, there has only been one study that evaluated a 
lifestyle intervention in obese endometrial cancer survivors, stating that a lifestyle 
intervention programme in endometrial cancer survivors is feasible and that behaviour 
change and weight loss are achievable (32,33).
 Strength of our study is the use of an internationally well-established and 
validated instrument to evaluate quality of life. Secondly, data of both participants and 
non-participants were presented and showed no significant differences, which 
increase the applicability of our results. The response rate was 61.5%, and is generally 
in line with response rates found in other studies (6, 7, 12). Reasons for not returning 
the questionnaires have not been reported. However, we were able to contact by 
phone five women who did not return the questionnaire, two explained that they just 
misplaced the forms, two claimed to have forgotten to complete the questionnaire 
and send it back one felt that she did not have a good experience while in the hospital 
but did not want to fill the questionnaire and express her dissatisfaction with the care 
she received by the ward staff.
 In addition, measured height and weight were used to calculate BMI, which 
enhances the validity of our results. Weight of endometrial cancer survivors does not 
seem to change over time and cancer survivors find it difficult to implement lifestyle 
changes, therefore BMI at time of diagnose was found representable (22–24). Finally, 
we have assessed recurrence rates in all women diagnosed with endometrioid 
endometrial cancer, which improves the completeness and validity of our results.
 Potential limitations of this study are the relatively small sample size and the 
absence of socio-demographic information, which prohibited adjustment for potential 
confounding by socio-demographic characteristics. In addition, other variables such 
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as comorbidities and sexual function that are known to influence quality of life in 
endometrial cancer survivors have not been assessed in this study (12, 34). Another 
potential limitation is the use of a generic quality of life questionnaire without the 
validated endometrial cancer specific QLQ-EN24 module (35). This module was not 
used in the previously described audit and therefore not available for this study.
Conclusion
Our study demonstrates that morbid obesity is associated with poorer quality of life 
in endometrial cancer survivors. Irrespective of the BMI levels at which quality of life 
deterioration occurs, weight loss should be recognised as an important goal for 
obese endometrial cancer survivors. Survivorship programmes including lifestyle 
interventions such as exercise programs and diet interventions could be viable 
means to improve the quality of life of obese endometrial cancer survivors. Studies 
evaluating the effects of lifestyle interventions on quality of life are needed, because 
all endometrial cancer survivors deserve to live to the fullest.
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CHAPTER 4
Abstract
Background
Obesity is a risk factor for developing endometrial cancer and known to negatively 
affect outcomes and survival. However, the association between obesity and quality 
of life of endometrial cancer survivors remains unclear.
Objectives
To assess the association between body mass index (BMI) and the quality of life of 
endometrial cancer survivors. In addition, we assessed the associations between 
BMI and anxiety, depression and sexual function of endometrial cancer survivors.
Methods
The review was performed according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines, and the Cochrane Handbook for 
Systematic Reviews of Interventions. We performed a search of Medline (1946-2014), 
Embase (1980-2014), Cinahl (1981-2014), and PsycInfo (1806-2014) to identify studies 
that reported on the association between BMI and quality of life outcomes in 
endometrial cancer survivors. 
Results
Seven studies fulfilled the inclusion criteria, of which four studies could be included in 
the analysis. The four studies which included 1362 patients, showed that obese 
survivors had a significantly poorer physical functioning (P=0.001, MD: -11.61, 95% 
CI -18.66 to -4.55), social functioning (P=0.01, MD -4.37, 95% CI -7.75 to -1.00) and 
role functioning (P=0.002, MD -5.44 95% CI -8.90 to -1.98) when compared to 
non-obese women. Emotional and cognitive functioning did not show significant 
differences (P=0.18, P=0.21).
Conclusion
Obesity is associated with poorer quality of life outcomes in endometrial cancer 
survivors, including poorer physical, role and social functioning. Future research 
should be directed at lifestyle interventions aiming to enhance the quality of life of this 
group of survivors.
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Background
Endometrial cancer is the most common gynaecological cancer in the United 
Kingdom, accounting for 5% of all female cancers with a five-year survival of 77.3% 
(1). As the incidence is rising, resulting in an increasing number of survivors, the 
interest of research has evolved beyond clinical endpoints to include the quality of life 
and psychological health of patients.
 Obesity (body mass index (BMI) ≥ 30 kg/m²) has been generally suggested to 
have an important influence on quality of life outcomes and is a major risk factor for 
developing endometrial cancer (2). This inextricable association has resulted in up to 
81% of endometrial cancer patients being obese (3-5). In addition, women with high 
BMI tend to develop endometrial cancer at a younger age, resulting in a group of 
women for who survivorship will encompass decades (6).
 We have recently evaluated the association between BMI and quality of life of 
endometrial cancer survivors at our institution, and found that only morbidly obese 
women (BMI ≥ 40 kg/m²) had a poorer quality of life (3). In addition, obese women 
with a BMI < 40 kg/m² reported similar quality of life outcomes as non-obese survivors, 
contradictory to previous reports describing significant deteriorations at a BMI level 
of 30 kg/m² (3, 4, 7). Although the inverse association between BMI and quality of life 
seems evident, a definite BMI level at which clinically important deterioration occurs 
has not yet been identified nor established. In addition, the affected quality of life 
domains vary among studies causing the magnitude of the association to remain 
unclear.
 A systematic review will clearly identify the BMI levels at which quality of life 
outcomes are affected and therefore help plan appropriate care for women at risk. 
In addition, we believe other outcomes influencing quality of life, such as anxiety, 
depression and sexual function should be taken into account (8-11). We have therefore 
performed a systematic review on the association between BMI and quality of life 
outcomes of endometrial cancer survivors.
Objectives:
- To assess the association between BMI and quality of life of endometrial cancer 
survivors.
- To assess the association between BMI and anxiety and depression in endometrial 
cancer survivors.
- To assess the association between BMI and sexual function of endometrial cancer 
survivors.
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Methods
Criteria for considering studies for this review
This review was done according to Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines (12), and in accordance with the principles 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions (13). 
Studies evaluating the association between BMI and quality of life, anxiety, depression 
or sexual function in endometrial cancer survivors were identified. Eligible study designs 
include; randomised controlled trials, controlled clinical trials, case-control studies, 
cross-sectional studies and cohort studies.
Types of participants
- Adult women (age ≥ 18 years) diagnosed with endometrial cancer. 
- Women who have completed treatment.
Primary outcomes 
Quality of life measured using a scale that has been validated through reporting of 
norms, such as;
- European Organisation for Research and Treatment of Cancer quality of life 
questionnaire (EORTC QLQ-C30) 
- EORTC Endometrial cancer specific quality of life module (EORTC QLQ-EN24)
- Functional Assessment of Cancer Therapy (FACT) 
- Medical Outcome Study Short Form-36 (SF-36) 
Secondary outcomes
Anxiety, measured using a scale that has been validated through reporting of norms 
such as;
- Hospital Anxiety and Depression Scale (HADS)
- State Trait Anxiety Inventory (STAI)
Depression, measured using a scale that has been validated through reporting of 
norms such as;
- Hospital Anxiety and Depression Scale (HADS)
- Centre for Epidemiologic Studies - Depression Scale (CES-DS)
- Beck Depression Inventory (BDI)
Sexual function, measured using a scale that has been validated through reporting of 
norms, such as;
- Female Sexual Function Index (FSFI)
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Search methods for identification of studies
The protocol for the systematic review was based on the PRISMA statement (12). 
We performed systematic searches of respectively; BMI and the primary outcome 
(quality of life), and BMI and secondary outcomes including anxiety, depression, and 
sexual function. Searches were performed in Medline (1946 until October 2014), 
Embase (1980 until October 2014), Cinahl (1981 until October 2014), PsycInfo (1806 
until October 2014) and the Cochrane Gynaecological Cancer Collaborative Review 
Group’s Trial Register. Search strategies were adapted accordingly to each database. 
The Medline, Embase, Cinahl, PsycInfo and the Cochrane Trial Register search 
strategies based on terms related to the review topic are presented in Appendix 1 and 
Appendix 2 respectively. In addition we searched abstracts of scientific meetings 
as well as manually checking the reference lists of eligible studies to identify any 
additional studies to include in the review. No other resources were utilised for the 
identification of studies.
Data collection and analysis
Selection of studies
Eligible studies included all studies examining original data on the association 
between BMI and quality of life outcomes in women treated for endometrial cancer. 
Two reviewers (AS and KG) independently assessed titles and abstracts of all 
identified studies. Those studies that clearly did not meet the inclusion criteria were 
excluded. Potentially relevant studies were retrieved in full text, and were further 
reviewed for eligibility by the reviewers. Differences were resolved by discussion on 
appeal to a third review author (AL). The risk of bias instrument recommended by the 
Cochrane Non-Randomised Studies Methods Group was used for non-randomised 
comparative studies (14). Additionally, the main confounders for the primary and 
secondary outcomes included baseline and clinical characteristics, which were 
identified a priori. The main confounders identified were age, performance status, 
time from diagnosis, treatment, recurrent disease and concurrent comorbidities.
 Outcome scales of quality of life measures were transformed into scales 
comparable across different measures where possible (15). The social functioning 
scale of FACT-G was not suitable for equating to the social functioning scale of the 
EORTC-C30 (15). The SF-36 consisted of two role functioning scales and was 
therefore not used in the role functioning comparison. Cognitive functioning was only 
a subscale of the EORTC-C30 and was not assessed as a scale in the FACT-G or 
SF-36.
 For analysis purposes, we have grouped BMI categories into respectively; 
‘’non-obese’’ (BMI < 30 kg/m²) and ‘’obese’’ (BMI ≥ 30 kg/m²). In addition we created 
the groups; BMI < 40 kg/m² and ‘’morbidly obese’’ (BMI ≥ 40 kg/m²) for further analysis. 
Average weighted means and combined standard deviations were calculated for 
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grouped BMI categories. Raw data of the study by Smits et al. (3) was used for means 
and standard deviations of the grouped BMI categories. General quality of life and 
symptom distress scores were excluded from analysis as we found no evidence for 
their comparability among the different quality of life measures.
Results
The primary search strategy evaluating BMI and quality of life identified 69 references 
in Medline, 178 in Embase, fourteen in Cinahl and three in PsycInfo (Figure 1). Search 
results were merged into Endnote and duplicates were removed, resulting in 198 
unique studies. After reviewing titles and abstracts, thirteen articles were retrieved in 
full. Full text screening further excluded six articles, resulting in seven studies being 
eligible for this review (Table 1). 
Figure 1  PRISMA Flow diagram
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The secondary search identified 198 references in Medline, 494 in Embase, 25 in 
Cinahl and six in PsycInfo. After removal of duplicates and review of abstracts, five 
articles were retrieved in full. Full text screening resulted in one eligible article 
evaluating the association between BMI and sexual function, which had already been 
selected through the primary search strategy. 
 Corresponding authors of three papers were contacted for additional data 
needed for inclusion in this review (7, 8, 16).
Included studies
In total, seven studies met the inclusion criteria, of which four studies could be 
included in the analysis. Characteristics of the studies are illustrated in Table 1. Two 
of the included studies were cross-sectional surveys (17, 18), one was a retrospective 
study (3) and one analysed prospectively collected data (4). All four studies combined 
included 1362 endometrial cancer survivors. Courneya et al. and Oldenburg et al. 
included only early stage (I and II) endometrial cancer survivors (17, 18), while the 
other two studies included all-stage survivors of which the majority (72.2% - 94.3%) 
had early stage disease (3, 4). BMI was categorised in different groups among the 
included studies, and taken at time of diagnosis or at time of completion of the 
questionnaires. Two studies used measured height and weight (3, 4), and the 
remaining studies used self-reported height and weight (17, 18). Quality of life 
measures used varied among studies and included the FACT-G, EORTC-C30, 
EORTC-EN24 and SF-36. 
Body mass index and quality of life
Meta-analysis of the included studies comparing non-obese to obese endometrial 
cancer survivors is illustrated in Figure 2. We found a statistically significant difference 
in physical functioning (P=0.001), with obese survivors having poorer physical 
functioning (MD: -11.61, 95% CI -18.66 to -4.55). Social functioning was significantly 
associated with increasing BMI, with poorer outcomes in obese endometrial cancer 
survivors when compared to non-obese women (P=0.01, MD -4.37, 95% CI -7.75 to 
-1.00). In addition, role functioning was also significantly poorer in obese women 
(P=0.002, MD -5.44 95% CI -8.90 to -1.98), while emotional functioning and cognitive 
did not show a significant difference (P=0.18 and P=0.21).
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Figure 2   Forest plots of comparison non-obese versus obese on  
quality of life outcomes
Physical functioning
Emotional functioning 
Social functioning
Role functioning
Cognitive functioning
Processed on: 12-7-2016
504323-L-bw-Smits
86
CHAPTER 4
In addition, we compared morbidly obese women to women with a BMI < 40 among 
studies, which showed that morbidly obese women had significantly poorer physical 
functioning (P=0.002, MD: -4.78, 95% CI -7.79 to -1.77), social functioning (P=0.03, 
MD -12.80, 95% CI -24.50 to -1.10) and role functioning (P=0.002, MD -10.03, 95% CI 
-16.24 to -3.82). 
Figure 3   Risk of bias and confounding of included studies
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Body mass index and sexual function 
Oldenburg et al. evaluated the association between BMI and sexual functioning 
through the EORTC-EN24, showing an inverse association with a higher BMI resulting 
in less sexual/vaginal problems. This effect persisted after adjustment for patient 
characteristics. However, sexual interest, sexual activity and sexual enjoyment were 
not associated with BMI (17). 
Risk of bias and confounding
Figure 3 summarises the risk of bias and confounding for all included studies. All 
studies were non-randomised with a cross-sectional or retrospective design, leading 
to a high risk of bias associated with non-randomisation, patient attrition, and selective 
reporting. With regards to confounding factors, all studies reported data on a variety 
of possible confounders and corrected for this in their statistical analysis. Three out 
of the four study corrected for adjuvant treatment (chemotherapy and/or radiotherapy). 
However, only Oldenburg et al. adjusted for socio-demographic variables, clinical 
variables and comorbidities, with the other studies frequently omitting comorbidities 
and socio-demographic characteristics. Quality of evidence was not assessed using 
GRADE, as the included studies mainly comprised retrospective studies. 
Discussion
To our knowledge, this is the first review to identify the evidence on the association 
between BMI and quality of life outcomes of endometrial cancer survivors. The results 
of this systematic review and meta-analysis suggest a significant deterioration in 
quality of life outcomes of obese survivors compared to non-obese survivors. There 
was a statistically significant difference in several quality of life outcomes, with obese 
women having poorer physical functioning, poorer social functioning and poorer role 
functioning when compared to non-obese women. In addition, quality of life outcomes 
showed a further significant deterioration in these domains when BMI increased to 
morbidly obese. 
 Thus far, the evidence has been accumulating, but failed to provide uniform 
guidance for clinical care. Our review provides a focus for future research and 
interventions to support obese women at risk of poorer quality of life during their 
survivorship. Unlike the results of our initial study, this review shows that significant 
deterioration occurs at a BMI level of 30 kg/m². In addition, we have identified that 
obesity does not just affect physical functioning but is also associated with poorer 
social and role functioning, contrary to the results of most individual studies (4, 7, 8, 
16-18). Future interventions should also aim to improve social and role functioning, as 
they are significantly impaired in obese survivors.
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 Although it is difficult to quantify clinically important differences in quality of life 
scores as they vary in clinical context, minimal clinically important differences for the 
EORTC QLQ-C30 have been proposed by Osoba et al. and King et al. They defined 
a minimal difference in the EORTC scores varying from 2 to 5 (depending on domain) 
as clinically important, which validates the results of our meta-analysis as clinically 
significant (19, 20). 
 The influence of BMI on quality of life has received a lot of interest within 
endometrial cancer following its inextricable relation with obesity. As the burden of 
obesity on society continues to grow, the association between BMI and quality life 
has also been under increasing attention in other cancer sites. In breast, colorectal, 
bladder and prostate cancer, several studies have reported similar results of 
significant poorer quality of life of obese survivors, substantiating the relevance and 
importance of the association between obesity and poorer quality of life (21-25). 
 We can hypothesise that obesity negatively impacts quality of life areas through 
limited mobility, decreased physical endurance, associated comorbidities and social 
discrimination (26-28). Additionally, obesity may be associated with more treatment 
related symptoms and perioperative morbidities in endometrial cancer patients (29).
Quality of life is paramount to women surviving endometrial cancer and our review 
confirms the significant role of obesity in the quality of life of survivors. The majority 
of endometrial cancer patients are obese and are generally diagnosed with Type 1 
disease, which has a favourable prognosis with improved survival (30, 31). In addition, 
young obese women will be at risk of developing endometrial cancer at a pre- 
menopausal age, which may result in a survivor group that could face quality of life 
impairments for decades to come (6). 
 Recently, steps have been undertaken to develop novel interventions to improve 
patients’ wellbeing after cancer treatment, frequently involving exercise and lifestyle 
interventions (32-36). These interventions are suggested to have a positive impact on 
quality of life and may influence survival outcomes as obesity has been shown to 
negatively influence survival (37, 38). 
Completeness and applicability of evidence
We initially identified seven eligible studies for this review, of which three studies 
required additional data from authors. We contacted corresponding authors for each 
study, without any response. The majority of women included were diagnosed with 
early stage endometrial cancer, which is consistent with reported incidence rates (1, 
39). In addition, disease stage has not been associated with poorer quality of life 
outcomes in gynaecological cancer survivors (40, 41). 
 We found one study that evaluated sexual outcomes across different BMI 
categories in endometrial cancer survivors through a validated subscale of 
EORTC-EN24 consisting of three questions. No evidence was found on the relation 
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between BMI and psychological outcomes such as anxiety and depression, even 
though this relationship has been well-established in the general population (42, 43). 
Quality of evidence 
The included studies had high risk of bias, largely because of their cross-sectional or 
retrospective designs, despite correcting for possible confounding factors. We therefore 
recommend that well-designed prospective studies further assess the associations 
between body mass index and quality of life outcomes. Furthermore, there was lack 
in uniformity of methods among the studies, even though all used internationally 
established and validated measures to evaluate quality of life (44-47). We were able 
to equate several of the measures according to existing evidence (15), but there may 
still be some discrepancy between the different measures. There is need for an 
assessment of the equivalence of different quality of life measures in cancer patients 
including the EORTC-C30, FACT-G and SF-36. 
Potential biases in review process
We performed a comprehensive search of the literature, including a search of the 
grey literature, and data were evaluated independently by two reviewers. Unfortunately 
we were unable to include three studies because additional data were needed for 
analysis. However, all three studies showed that a higher BMI was associated with 
poorer quality of life outcomes, namely physical functioning and role functioning (7, 
8, 16). We therefore do not expect that these data will significantly change the findings 
of our review. 
Conclusion
Obesity is associated with poorer quality of life outcomes in endometrial cancer 
survivors, including poorer physical, role and social functioning. These quality of life 
outcomes deteriorate even further as BMI increases. Future research should be 
directed at lifestyle interventions aiming to enhance the quality of life of this group of 
survivors. In addition, we have identified a need for uniformity among quality of life 
measures used in the cancer population. This too needs to be addressed in future 
research.
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Appendix 1
Search strategy primary outcome:
 1. endometrial cancer 
 2. endometrial neoplasm 
 3. endometrial carcinoma 
 4. uterine cancer 
 5. uterine neoplasm
 6. uterine carcinoma 
 7. endometrium cancer 
 8. endometrium carcinoma 
 9. endometrium neoplasm 
 10. endometrioid cancer 
 11. endometrioid neoplasm 
 12. endometrioid carcinoma 
 13. body mass index 
 14. BMI 
 15. weight 
 16. (obesity OR obese) 
 17. quetelet* index 
 18. quality of life 
 19. life qualit* 
 20. (“well being” OR wellbeing) 
Appendix 2
Search strategy secondary outcomes:
 1. endometr* cancer
 2. uter* cancer
 3. endometr* neoplasm
 4. uter* neoplasm
 5. endometr* carcinoma 
 6. uter* carcinoma
 7. body mass index
 8. BMI
 9. Weight
 10. (obesity OR obese)
 11. quetelet* index
 12. fatigue
 13. tired
 14. lethargy
 15. lassitude
 16. pain
 17. analgesia 
 18. fear 
 19. anxiet* 
 20. nervousness 
 21. psychologic* stress* 
 22. psychologic* distress* 
 23. emotional stress 
 24. mental suffering 
 25. depression* 
 26. (“psychologic* wellbeing”  
OR “psychologic* well being”)
 27. depress* symptom* 
 28. mental disorder* 
 29. sexual* 
 30. sex* disorder* 
 31. sex* dysfunction* 
 32. sex* function* 
 33. sex* malfunction* 
 34. dyspareun* 
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CHAPTER 5
Abstract
Introduction
Despite the established link between obesity and chronic inflammation, the association 
between body mass index (BMI), inflammatory biomarkers and their prognostic value 
in endometrial cancer remains unclear.
Objectives
To evaluate the prognostic value of pre-operative inflammatory biomarkers and BMI 
in women with endometrial cancer. 
Methods
This was a retrospective cohort study of endometrial cancer patients diagnosed 
between January 2006 and January 2015 at the Royal Cornwall Hospital Trust. 
Levels of inflammatory markers including leukocytes, lymphocytes, myeloid cells, 
CRP, neutrophil:lymphocyte ratio (NLR) and platelet:lymphocyte ratio (PLR) were 
compared across BMI groups. Associations between inflammatory marker levels, 
BMI and overall survival (OS) were evaluated in univariate and multivariate analyses. 
Results
A total of 490 women were included in the study. Obesity (BMI ≥ 30 kg/m²) was 
significantly associated with higher levels of inflammatory markers, including 
leukocytes (P=0.002), lymphocytes (P<0.001), eosinophils (P<0.001), basophils 
(P=0.002), CRP (P<0.001), and a lower PLR (P<0.001) compared to non-obese 
women. The majority of inflammatory markers were associated with OS in univariate 
analyses, with higher inflammatory cell counts and higher ratios correlating to a 
poorer OS. After multivariate analysis, CRP ≥ 5.0 (mg/L) remained significantly 
associated with poorer OS (P=0.025). 
Conclusion
Obesity is associated with inflammatory biomarkers in endometrial cancer patients. 
These markers are associated with prognostic factors including stage, grade and 
LVSI, with CRP as an independent prognostic factor for overall survival. Future studies 
are needed to further assess these associations, evaluating the potential usefulness 
of interventions targeting inflammations as a means to improve cancer outcomes. 
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Background
Endometrial cancer is the most common gynaecological cancer, with an incidence 
of around 8500 women in the United Kingdom. Over the past 20 years, incidence 
rates have increased by 48% (1). Obesity has been identified as one of the main 
contributing factors to rise in incidence, and currently affects over one third of adults 
in the UK (2).
 Obesity causes chronic inflammation through a low-grade chronic inflammatory 
response in the adipose tissue. This involves multiple proinflammatory immune cell types, 
and is characterised by an infiltration of lymphocytes and myeloid cells including 
neutrophils, eosinophils and macrophages (3). It is well established that inflammation 
contributes to the process of carcinogenesis, and it has been proposed that obesity- 
related chronic inflammation plays an important role in the genesis of endometrial 
cancer (4, 5). Despite the established link between obesity and inflammation, few studies 
have assessed the association between body mass index (BMI) and inflammatory 
biomarkers in endometrial cancer.
 Furthermore, recent studies have suggested that inflammatory response biomarkers 
such as leukocytes, platelet:lymphocyte ratio (PLR) neutrophil:lymphocyte ratio (NLR) 
and C-reactive protein (CRP) may be of prognostic value in endometrial cancer (6-8). 
Therefore, the possible prognostic significance of inflammatory markers in endometrial 
cancer needs to be further evaluated. In this study, we have investigated the prognostic 
value of pre-operative inflammatory biomarkers and the assocation with BMI in women 
with endometrial cancer. 
Methods 
Study population 
This was a retrospective cohort study of endometrial cancer patients diagnosed 
between January 2006 and January 2015 at the Royal Cornwall Hospital Trust. The 
study population included women who received surgery for histologically confirmed 
primary endometrial cancer. Exclusion criteria were; i) age under 18 years at time of 
diagnosis, ii) an unknown preoperative BMI, iii) incomplete pre-operative full blood 
count results within a timeframe of 31 days prior to surgery, and iv) incomplete data 
on treatment course. Ethical approval was obtained through the London – Fulham 
Ethical committee and the study had full Trust approval.
Data collection
We identified patients through the Cancer Registry of the South West Intelligence 
Service which included their current status (alive versus deceased, including date of 
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death). Baseline and clinical characteristics were collected from patients’ medical 
records. These included age at diagnosis, Eastern Cooperative Oncology Group 
(ECOG) performance status, medical co-morbidities, marital status and smoking 
status, FIGO (International Federation of Gynecology and Obstetrics) stage, grade 
and lympho-vascular space invasion (LVSI). BMI at time of diagnosis was calculated 
from recorded preoperative height and weight, and categorized into three groups; 
BMI < 25 kg/m2 (normal), BMI 25-29.9 kg/m2 (overweight) or BMI ≥ 30 kg/m2 (obese), 
respectively.
Outcomes
Full blood count data for each patient were collected within a timeframe of <31 days 
prior to surgery as part of standard clinical practice. Inflammatory markers included 
total white cell count (leukocytes), lymphocytes, neutrophils, eosinophils and basophils. 
PLR and NLR were defined as respectively; absolute platelet count divided by absolute 
lymphocyte count, and absolute neutrophil count divided by absolute lymphocyte count. 
CRP was collected within a timeframe of <8 weeks prior to surgery. Inflammatory 
markers and ratios were analysed as continuous variables and separately divided 
into high and low groups based on cut-off values. The cut-off values were previously 
defined in other endometrial cancer studies or are known clinical cut-off values; NLR 
2.4, NLR 4.68, PLR 240, PLR 250, CRP 5.0 (mg/L), CRP 8.2 (mg/L), leukocytes 9000 
(10³/µl) and neutrophils 7200 (10³/µl) (6-9). Overall survival (OS) was used for survival 
comparison and was defined as the time from diagnosis to death from all causes. 
Statistical analysis
Data normality was assessed using Kolmogorov-Smirnov tests. Continuous data 
were compared using the Mann-Whitney U test, Kruskal-Wallis test or Median test, 
followed by post-hoc Mann Whitney U-tests. Bonferroni’s correction was applied for 
multiple comparisons, as appropriate. Categorical data were assessed using the 
Pearson Chi square or Fisher’s exact test.  Survival analyses were performed using 
the Kaplan-Meier method using the log-rank test, and the Cox proportional hazards 
models for univariate and multivariate survival analyses. Data were analysed using 
IBM SPSS statistical software (10). Unknown data were excluded during the analysis. 
P-values of <0.05 were regarded as statistically significant and tests were two-sided.
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Results
We identified a total of 522 women who received surgical management for 
histologically confirmed endometrial cancer between January 2006 and January 
2015. We excluded 20 women with incomplete pre-operative blood results, nine 
women with incomplete data on their treatment course, and a further three with an 
unknown preoperative BMI. This resulted in a study population consisting of 490 
patients. 
Baseline and clinical characteristics of study population 
The median age of the study population was 65 years (range 27-93). The majority of 
women (83.5%) were diagnosed with stage I disease. Ninety-five women had a of 
BMI < 25 kg/m², 143 women were overweight (BMI 25-29.9 kg/m²) and 252 women 
were obese (BMI ≥ 30 kg/m²) of which 66 were morbidly obese (BMI ≥ 40 kg/m²). 
Characteristics of the study population according to BMI groups are shown in Table 1. 
 There were no differences between BMI groups in terms of age, ethnicity, parity, 
marital status and smoking status (Table 1). A higher BMI was associated with 
increased number of comorbidities (P=0.002) and poorer ECOG performance status 
(P=0.006). Significantly more obese women were diagnosed with stage I disease 
compared to the normal and overweight group (P=0.002), and obese women were 
found to have significantly less LVSI (P<0.001). Adjuvant therapy including 
chemotherapy (P=0.018) and radiotherapy (P=0.023) also varied significantly among 
BMI groups, reflecting the difference in stage.
Inflammatory markers and BMI
The values of individual inflammatory markers and NLR were available for all patients, 
and PLR was available for 488 women. CRP was available for 315 women as it was 
not routinely performed prior to 2009, after which it became part of standard 
pre-operative assessment as per hospital policy. However, prior to 2009, the 
availability of CRP was not associated with demographic or clinical characteristics 
(data not shown). Preoperative inflammatory markers and their associations with BMI 
are shown in Table 2.
 A higher BMI was significantly associated with rising counts of several inflammatory 
markers including leukocytes (P=0.002), lymphocytes (P<0.001), eosinophils (P<0.001) 
and basophils (P=0.002). CRP levels were significantly higher in obese women 
(P<0.001). Higher BMI was also significantly associated with lower PLR ratios in 
obese women compared to the normal weight and overweight groups (P<0.001). 
No significant association was found between NLR and BMI, although there was a 
trend towards decreased NLR with increasing BMI (P=0.089). Furthermore, platelet 
counts did not significantly vary among BMI groups (P=0.754, data not shown).
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Table 1   Baseline and clinical characteristics according to BMI groups
BMI < 25 kg/m²
N=95
BMI 25-29.9 kg/m²
N=143
BMI ≥ 30 kg/m²
N=252
Analysis
P-value
Age
   < 70 years
   ≥ 70 years
58 (61.1%)
37 (38.9%)
86 (60.1%)
57 (39.3%)
171 (67.9%)
81 (32.1%)
0.234
Ethnicity
   White
   Other
   Unknown
93 (97.9%)
2 (2.1%)
0 (0%)
143 (100%)
0 (0%)
0 (0%)
247 (98.0%)
3 (1.2%)
2 (0.8%)
0.276
Marital status
    Married
    Not married
    Widowed
    Unknown
61 (64.2%)
15 (15.8%)
10 (10.5%)
9 (9.5%)
92 (64.3%)
15 (10.5%)
18 (12.6%)
18 (12.6%)
159 (63.1%)
40 (15.9%)
28 (11.1%)
25 (9.9%)
0.688
Parity
    None
    One or more
21 (22.1%)
74 (77.9%)
23 (16.1%)
120 (83.9%)
45 (17.9%)
207 (82.1%)
0.490
Comorbidities
    None
    One
    Two or more
    Unknown
29 (30.5%)
29 (30.5%)
37 (38.9%)
0 (0%)
37 (25.9%)
33 (23.1%)
72 (50.3%)
1 (0.7%)
45 (17.9%)
49 (19.4%)
157 (62.3%)
1 (0.4%)
0.002*
ECOG status
   0
   1
   2-4
   Unknown
68 (71.6%)
7 (7.4%)
8 (8.4%)
12 (12.6%)
88 (61.5%)
26 (18.2%)
5 (3.5%)
24 (16.8%)
137 (54.4%)
51 (20.2%)
24 (9.5%)
40 (15.9%)
0.006*
Smoking status
   Yes
   No
   Unknown
10 (10.5%)
83 (87.4%)
2 (2.1%)
10 (7.0%)
133 (93.0%)
0 (0%)
19 (7.5%)
233 (92.5%)
0 (0%)
0.541
FIGO Stage
   I
   II
   III
   IV
70 (73.7%)
9 (9.5%)
12 (12.6%)
4 (4.2%)
112 (78.3%)
13 (9.1%)
12 (8.4%)
6 (4.2%)
227 (90.1%)
12 (4.8%)
8 (3.2%)
5 (2.0%)
0.002*
Grade
   1
   2
   3
   Unknown
29 (30.5%)
32 (33.7%)
34 (35.8%)
0 (0%)
48 (33.6%)
46 (32.2%)
47 (32.9%)
2 (1.4%)
96 (38.1%)
93 (36.9%)
63 (25.0%)
0 (0%)
0.243
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Table 1   Continued
BMI < 25 kg/m²
N=95
BMI 25-29.9 kg/m²
N=143
BMI ≥ 30 kg/m²
N=252
Analysis
P-value
Histology
   Endometrioid
   Non-endometrioid
   Mixed   
75 (78.9%)
17 (17.9%)
3 (3.2%)
108 (75.5%)
29 (20.3%)
6 (4.2%)
209 (82.9%)
31 (12.3%)
12 (4.8%)
0.276
LVSI
   Yes
   No
   Unknown or N/A
33 (34.7%)
57 (60.0%)
5 (5.3%)
34 (23.8%)
107 (74.8%)
2 (1.4%)
39 (15.5%)
211 (83.7%)
2 (0.8%)
<0.001*
Cytoreduction  
(stage III-IV)
   Complete
   Optimal
   Suboptimal  
15 (93.8%)
1 (6.3%)
0 (0%)
15 (83.3%)
0 (0%)
3 (16.7%)
11 (84.6%)
0 (0%)
2 (15.4%)
0.325
Chemotherapy
   Yes
   No
18 (18.9%)
77 (81.1%)
20 (14.0%)
123 (86.0%)
21 (8.3%)
231 (91.7%)
0.018*
Radiotherapy
   Yes
   No
33 (34.7%)
62 (65.3%)
38 (26.6%)
105 (73.4%)
52 (20.6%)
200 (79.4%)
0.023*
*: P-value <0.05
Table 2   Inflammatory markers and their associations with BMI
BMI < 25 kg/m² BMI 25-29.9 kg/m² BMI ≥ 30 kg/m² Analysis 
Median (range) P-value
Leukocytes 7.0 (4.2-22.5) 7.3 (2.7-33.5) 7.7 (3.5-16.5) 0.002*
Lymphocytes 1.73 (0.78-3.67) 1.80 (0.64-3.72) 2.11 (0.74-5.84) <0.001*
Neutrophils 4.59 (2.33-19.33) 4.66 (1.04-30.19) 4.93 (0.56-12.38) 0.128
Eosinophils 0.10 (0.02-0.41) 0.12 (0.02-1.40) 0.17 (0-0.83) <0.001*
Basophils 0.04 (0-0.10) 0.04 (0-0.24) 0.05 (0-0.23) 0.002*
NLR 2.51  (1.24-11.15) 2.46 (0.71-20.37) 2.30 (0.34-8.84) 0.089
PLR 172.7 (73.6-510.8) 167.9 (54.9-588.5) 139.4 (43.8-656.8) <0.001*
CRP 1.2 (0.1-99.0) 2.3 (0.2-58.0) 4.9 (0.2-87.0) <0.001*
*: P-value <0.05
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 When separately assessing the morbidly obese (BMI ≥ 40 kg/m²), analyses 
showed that CRP, (P<0.001), leukocytes (P<0.001), lymphocytes (P=0.001), 
neutrophils (P=0.003) and eosinophils (P=0.013) were significantly higher in morbidly 
obese women compared to BMI 30-39.9 kg/m². Furthermore, PLR was found to be 
significantly lower (P=0.001) in women with BMI ≥ 40 kg/m². NLR did not vary 
significantly among the obese groups (0.901).
Inflammatory markers and prognostic variables
We assessed the relation between inflammatory markers and prognostic variables, 
which showed that advanced stage disease (III/IV) was associated with higher levels 
of NLR (P<0.001), PLR (P<0.001), CRP (P=0.025) and neutrophils (P=0.009). In 
addition, the presence of LVSI was associated with both a higher NLR (P=0.003) and 
PLR (P<0.001). A higher histological grade was associated with elevated PLR 
(P=0.034), and lower lymphocyte counts (P=0.036). Elevated NLR (P=0.048), CRP 
(P=0.011) and leukocyte counts (P=0.025) were also associated with a poorer ECOG 
performance status. In addition, elevated CRP (P=0.007), leukocytes (P<0.001), 
lymphocytes (P=0.003), neutrophils (P=0.005), eosinophils (P=0.002) and basophils 
(P=0.010) were proportionally correlated with the number of comorbidities, and PLR 
was inversely correlated with comorbidities (P=0.012). None of the inflammatory 
markers were associated with age. 
 The inflammatory profile associated with obesity (BMI ≥ 30 kg/m²) consisting of 
increased leukocytes, lymphocytes, eosinophils, basophils and CRP, and a 
decreased PLR, corresponded generally with both the favourable histopathological 
characteristics (stage and LVSI) and the associated ECOG performance status and 
comorbidities. We therefore performed an additional analysis of only women with 
stage 1, low grade endometrioid endometrial cancer (N=145), which showed that 
obese women had significantly increased inflammatory markers including WCC 
(P=0.039), lymphocytes (P=0.042), eosinophils (P=0.003), basophils (P=0.044), 
and CRP (P<0.001), and a significantly lower PLR (P=0.003) compared to non-obese 
women.
Inflammatory markers and survival
The median OS of the study population was 50 months (range 0-116), with a 1-year 
and 5-year OS of 95.8% and 74.9% respectively. Inflammatory markers including 
leukocyte count (P=0.001), neutrophil count (P<0.001), NLR (P=0.008), PLR 
(P=0.019) and CRP (P<0.001) were significantly associated with OS. Lymphocytes 
(P=0.458), eosinophil counts (P=0.876) and basophil counts (P=0.933) did not 
show an association.
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Figure 1   Forest plots of comparison non-obese versus obese on  
quality of life outcomes
NLR cut-off value 2.4
NLR cut-off value 2.7
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Figure 1   Continued
PLR cut-off value 240
PLR cut-off value 250
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 The predefined cut-off values NLR 2.4, NLR 2.7 PLR 240, PLR 250, CRP 5.0 (mg/L) 
showed a significant association with OS (Figure 1). Values of NLR ≥ 2.4 (P=0.009), 
NLR ≥ 2.7 (P=0.039), PLR ≥ 240 (P=0.021), PLR ≥ 250 (P=0.007) and CRP ≥ 5.0 
(mg/L) (P=0.015) were associated with poorer OS (Table 3). Other cut-off values did 
not show significant differences in OS. After multivariate analysis, only the CRP cut-off 
value of 5.0 (mg/L) remained significantly associated with OS (P=0.024) (Table 3). 
Furthermore, we did not find a significant difference in OS between the BMI groups 
(P=0.886). 
Figure 1   Continued
CRP cut-off value 5.0 (mg/L)
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Table 3   Inflammatory markers cut-off values and overall survival
Univariate analysis Multivariate analysis¹
Hazard ratio (CI) P-value Hazard ratio (CI) P-value
NLR 
   < 2.4
   ≥ 2.4
Referent
1.894 (1.172-3.062) 0.009*
Referent
1.275 (0.757-2.148) 0.361 
NLR 
   < 2.7
   ≥ 2.7
Referent
1.635 (1.026-2.605) 0.039*
Referent
1.052 (0.627-1.765) 0.849
NLR
   < 4.68
   ≥ 4.68
Referent
1.299 (0.595-2.837) 0.512
N/A N/A
PLR 
   < 174
   ≥ 174
Referent
1.354 (0.834-2.174) 0.209
N/A N/A
PLR 
   < 240
   ≥ 240
Referent
2.029 (1.112-3.703) 0.021*
Referent
1.341 (0.698-2.579) 0.379 
PLR
   < 250
   ≥ 250
Referent
2.424 (1.274-4.611) 0.007*
Referent
1.413 (0.688-2.904) 0.347
CRP (mg/L)
   < 5.0
   ≥ 5.0
Referent
2.176 (1.166-4.061) 0.015*
Referent
2.188 (1.103-4.340) 0.025*
CRP (mg/L)
   < 8.2
   ≥ 8.2
Referent
1.822 (0.959-3.459) 0.067
N/A N/A
Leukocytes (10³/µl)
   < 9.0 
   ≥ 9.0
Referent
1.499 (0.912-2.464) 0.111
N/A N/A
Neutrophils (10³/µl)
   < 7.2
   ≥ 7.2
Referent
1.635 (0.878-3.043) 0.121
N/A N/A
1: Corrected for age, stage, grade and LVSI; *: P-value < 0.05; NA: not applicable; NS: not significant
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Discussion
Obesity is an important risk factor for endometrial cancer, and obesity-related chronic 
inflammation has been suggested to contribute to carcinogenesis (4, 5). However the 
role of this chronic inflammation in the development of endometrial cancer is still 
poorly understood. This study investigated the association between pre-operative 
inflammatory biomarkers and BMI in endometrial cancer patients, and the prognostic 
value of inflammatory biomarkers in endometrial cancer. 
 We found that BMI is significantly associated with levels of inflammatory markers, 
with elevated counts of leukocytes, lymphocytes, myeloid cells and CRP, and a 
decreased PLR in obese women in comparison to normal and overweight women. 
This is the first study to extensively assess the relation between BMI and different 
inflammatory markers within endometrial cancer. Previous studies have only reported 
on CRP, stating that elevated CRP levels are associated with an increased risk of 
endometrial cancer and that these elevated levels correlate with increasing BMI (11, 12). 
 In our study, inflammatory markers were associated with prognostic variables 
such as stage, grade and LVSI, with advanced stage disease being associated with 
higher levels of NLR, PLR, CRP and neutrophils, a higher grade correlating with 
elevated PLR, and LVSI being associated with higher NLR and PLR. This supports 
growing evidence relating inflammatory markers to clinic-pathological  characteristics 
in endometrial cancer. A recent study by Li et al. showed that high PLR, NLR and CRP 
are associated with advanced stage disease and non-endometrioid histology. The 
authors also found elevated CRP to be associated with higher grade of disease (7). 
Concurrently, others have reported that both high PLR and NLR correlated with a 
higher stage of disease and LVSI, and that increased NLR was associated with 
non-endometrioid histology (8, 9). However, significant associations between NLR, 
PLR and higher grade were not uniformly reported in these studies (7-9). A further 
study has identified neutrophilia (≥ 7200 10³/ńl) as a significant predictor of advanced 
stage and LVSI, and leukocytosis (≥ 9000 10³/ńl) as a predictor of advanced stage 
disease (6).
 The majority of inflammatory markers were associated with OS, with higher 
inflammatory cell counts and higher ratios correlating to a poorer OS. However, we 
only identified CRP as an independent prognostic variable after multivariate analysis, 
mirroring findings of previous studies (6, 7, 13). Contradictory to our findings, two 
studies have reported NLR and PLR as independent prognostic values for overall 
survival (8, 9). Moreover, in other cancer sites the prognostic value of both NLR and 
PLR is well supported (14, 15). The difference in findings between studies may be 
partly attributable to the variance in cut-off values used and the fact that the majority 
modelled their values based on their own population. In addition, our study was 
comprised of a predominantly Caucasian population, while three other studies 
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assessed Asian populations (6, 7, 9). Further studies should determine optimal cut-off 
values, which are applicable to the general endometrial cancer population. 
 The influence of BMI on survival of endometrial cancer patients has been much 
debated (16). Despite a strong association between inflammatory markers and BMI, 
confirming the pro-inflammatory milieu in obese endometrial cancer patients, we 
found no significant association between BMI and OS. We did however, show that the 
inflammatory profile of obese women was linked to the prognostically favourable his-
topathological tumour characteristics, including early stage disease without LVSI, 
while advanced stage disease (III/IV) was associated with higher levels of NLR and 
PLR (17-19). This may explain the similar survival outcomes among BMI groups, 
another possibility for the lack of survival differences between BMI groups is the 
length of follow-up. As the majority of obese women diagnosed have a favourable 
prognosis, it is possible that significant differences will only become apparent over a 
longer period of time. However, differences in long-term survival may establish 
themselves through inflammatory-driven comorbidities associated with obesity, as 
they can surpass the risk of mortality from endometrial cancer (20-22). 
 Several inflammatory markers have been shown to be prognostic factors, and it 
is therefore important to assess whether these are modifiable factors. It is well 
established that both exercise and caloric restrictions have an anti-inflammatory 
effect, and that they may reduce the risk of several cancers including endometrial 
cancer (23-26). Studies in breast and colon cancer have shown that exercise may 
improve overall and disease specific survival (27). However, in endometrial cancer, 
lifestyle intervention studies are still in their infancy, and the role of inflammation has 
yet to be explored. Furthermore, anti-inflammatory drugs such as non-steroidal an-
ti-inflammatory drugs (NSAIDS) have been suggested to be protective for obesity-as-
sociated carcinogenesis, although data remains tentative (28). 
 Strengths of our study include the study size and validation of cut-off values 
defined by other studies. Our study is the first to evaluate BMI and inflammatory 
markers within the endometrial cancer setting, and we assessed a large range of 
inflammatory markers. Moreover, we corrected for variables known to influence 
survival to establish the independent value of the different inflammatory markers 
including age, stage, grade and LVSI. We did not include adjuvant therapies as a 
confounder as these are inherent to stage and grade of disease. The main limitations 
of the study are inherent to its retrospective design, which include possible selection 
bias and completeness of previously recorded data. Measurement of CRP prior to 
surgery was implemented since 2009 as routine practice, which may suggest a 
possible bias prior to 2009. 
 Future studies are needed to further assess the association between inflammatory 
biomarkers and obesity, especially within obesity-related cancers such as endometrial 
cancer. Ideally this should also include other markers such as cytokines interleukin 1 
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and 6 (IL-1 and IL-6) and tumour necrosis factor-α (TNF-α), which have been 
suggested to play an important role in inflammation and obesity (3, 5). Smith et al. 
recently indicated that an abundance of IL-6 and/or TNF-α produced locally by the 
tumour may identify a subset of endometrial cancer patients at greatest risk for 
treatment failure (29). However, current evidence remains limited. Furthermore, the 
prognostic value of inflammatory markers requires further evaluation and validation, 
to establish relevant cut-off values to identify women with worse prognosis. These 
women may be offered lifestyle counselling, and referrals to nutritionist, weight loss 
programmes or bariatric specialists where appropriate. Finally, we would like to 
recommend future lifestyle intervention studies to include an evaluation of the effect 
on inflammatory markers, as there is a clear need to define the role of inflammation 
within cancer outcomes such as survival. 
Conclusion
This study shows that obesity is associated with inflammatory biomarkers in 
endometrial cancer patients. Several inflammatory markers are associated with 
prognostic factors such as stage, grade and LVSI, and we have identified CRP as an 
independent prognostic factor for overall survival. Future studies are needed to 
further assess the association between BMI and inflammatory markers, and 
determine its exact role in the pathogenesis and prognosis of endometrial cancer. In 
addition, further studies are required to establish relevant cut-off values of 
inflammatory markers, and to assess the potential usefulness of interventions 
targeting inflammations as a means to improve cancer outcomes.
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CHAPTER 6
Abstract
Objectives
To evaluate the effect of body mass index (BMI) on the surgical outcomes of ovarian 
cancer patients. In addition, we performed a systematic review to compare our outcomes 
to the current literature.
Design
Retrospective cohort study and a systematic review of the literature.
Setting
Gynaecology department at the Royal Cornwall Hospital Trust.
Population 
Surgically managed stage I-IV ovarian cancer patients between September 2006 and 
September 2014. 
Methods
Primary and secondary outcome measures were evaluated across BMI categories; 
BMI <25 kg/m², BMI 25-29.9 kg/m², BMI ≥30 kg/m² and BMI ≥40 kg/m². A systematic 
review was performed according to Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines. 
Main outcome measures
The primary outcome measure was surgical complications. Secondary outcome 
measures were other intra- and post-operative outcomes. 
Results
In total, 228 women were included in the study, of which 84 women had a BMI <25 kg/m², 
84 women had a BMI 25-29.9 kg/m², and 60 women were obese (BMI ≥30 kg/m²), 
of which 13 were morbidly obese. Morbid obesity was associated with increased 
rates of wound complications. However, BMI did not show an association with other 
outcomes. In the review, an increasing BMI was associated with increased rates of 
wound complications and hospital stay, but did not impact other surgical outcomes.
Conclusion
Obesity is associated increased rates of wound complications and a prolonged 
hospital stay, but does not appear to affect other operative outcomes including 
cytoreduction status and 30-day mortality. Therefore, operative management and 
post-operative care require a multifactorial approach to minimise adverse outcomes. 
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Background
Ovarian cancer is the seventh most common cancer in women worldwide, with nearly 
239.000 new cases diagnosed in 2012 (1). Surgical management is important for 
both staging and treatment of ovarian cancer. Surgery is usually extensive with the 
aim of removing all visible disease (complete cytoreduction), as this is an important 
prognostic factor for survival (2). 
 Obesity affects more than one third of women in the United Kingdom, which is 
reflected in the current ovarian cancer population (3, 4). Obese patients undergoing 
surgery are considered to be at increased surgical risks compared to their normal 
weight counterparts (5). In addition, obese patients are more likely to have 
comorbidities that may significantly increase risk of surgical and anaesthetic 
morbidity and mortality (6, 7). However, the influence of obesity on surgical morbidity 
and outcomes in ovarian cancer has not yet been clearly defined. Kumar et al. 
recently identified a BMI ≥40 kg/m² as a possible independent prognostic factor of 
severe surgical morbidity and mortality, but other reports have failed to show an 
association between BMI and surgical morbidity and outcomes (8, 9). It is therefore 
important to establish whether BMI is a clinically relevant factor in predicting 
short-term surgical morbidity and mortality in ovarian cancer.
 We therefore embarked on assessing the effect of body mass index on surgical 
morbidity and other surgical outcomes in ovarian cancer patients at our institution. In 
addition, we performed a systematic review to compare our results to the current 
literature.
Methods
Institutional study
Study population
We performed a retrospective study of surgically managed ovarian cancer patients 
between September 2006 and September 2014 at the Royal Cornwall Hospital Trust 
(RCHT). We included women who were diagnosed with primary ovarian cancer 
(including fallopian tube and primary peritoneal cancer) who had undergone surgery 
as part of their treatment. Exclusion criteria were an unknown BMI at time of diagnosis, 
and age under 18 years. Ethical approval was obtained through the Northampton 
Ethics committee and the study had full hospital approval. 
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Data collection
Baseline and clinical characteristics were retrieved retrospectively from patients’ 
medical records. Body mass index (weight (kg)/[height (m)]²) at time of diagnosis 
was categorised according to national guidelines, respectively; underweight (<18.5 
kg/m²), normal weight (18.5-24.9 kg/m²), overweight (25-29.9 kg/m²) obese category 
I (30-34.9 kg/m²), obese category II (35-39.9 kg/m²) and category III (morbidly obese; 
≥40 kg/m²) (6). 
Outcomes
Operative morbidity was graded according to the Clavien-Dindo classification (10), 
and assessed as individual complications for the meta-analysis. In addition, we 
assessed intra- and post-operative outcomes including estimated blood loss (EBL), 
debulking status (complete cytoreduction: no macroscopic visible disease, optimal 
cytoreduction: <1 cm visible disease, or suboptimal cytoreduction: ≥1 cm visible 
disease), blood transfusion requirements, length of hospital stay, 30-day readmission, 
30-day and 90-day mortality. Outcomes were compared according to grouped BMI 
categories; BMI <25 kg/m², BMI 25-29.9 kg/m², BMI ≥30 kg/m² and BMI ≥40 kg/m² 
respectively. 
Statistical analysis
Data were analysed with SPSS statistics version 20.0 (11). Patient characteristics and 
outcomes were compared across the BMI categories, using nonparametric tests for 
continuous data, and Pearson’s Chi-Square and Fisher’s exact test for categorical 
variables. P-values were regarded significant if P<0.05 and tests were two-sided.
 
Systematic review and meta-analysis
Search strategy and selection criteria
This review was carried out according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines (12), and in accordance with the 
principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(13). Eligible for inclusion were studies evaluating the primary association between 
BMI and surgical morbidity and outcomes in ovarian cancer patients. Eligible study 
designs included; randomised controlled trials, controlled clinical trials, case-control 
studies, cross-sectional studies and cohort studies.
Participants; adult women undergoing surgery for all stage ovarian cancer.
Primary outcome; surgical morbidity in terms of complications.
Secondary outcomes: intra-operative outcomes including operation time, EBL, 
debulking status (complete, optimal and suboptimal), post-operative outcomes 
including hospital stay, blood transfusion rates, 30-day and 90-day mortality.
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 The protocol for the systematic review was based on the PRISMA statement (12). 
We performed systematic searches in Medline (1946 until December 2014), Embase 
(1980 until December 2014), and the Cochrane Gynaecological Cancer Collaborative 
Review Group’s Trial Register. Search strategies were adapted accordingly to each 
database (Appendix S1).
Data collection and analysis
Selection of studies
Two reviewers (KG and AS) independently assessed titles and abstracts of studies 
identified. Potentially relevant studies were retrieved in full text, and were further 
reviewed for eligibility by both reviewers. The risk of bias instrument recommended 
by the Cochrane Non-Randomised Studies Methods Group was used for non- 
randomised comparative studies (14). Additionally, the main confounders included 
baseline and clinical characteristics, which were identified a priori. The main 
confounders identified were age, performance status, ASA (American Society of 
 Anesthesiologists) status, disease stage, tumour involvement, and type and extent of 
surgery.
 For analysis purposes, BMI was grouped into ‘’non-obese’’ (BMI <30 kg/m²) and 
‘’obese’’ (BMI ≥30 kg/m²). Additionally, we compared women with a BMI <25 kg/m² 
(‘’normal’’) to overweight / obese (BMI ≥25 kg/m², including morbidly obese) and to 
morbidly obese (BMI ≥40 kg/m²). Dichotomous outcomes of BMI categories were 
combined, and for continuous outcomes average weighted means and combined 
standard deviations were calculated. Asian WHO defined BMI categories were 
combined with the corresponding international WHO defined BMI categories (15). 
Results
Primary study
We identified 264 women who received surgical treatment for ovarian cancer between 
September 2006 and September 2014. Thirty-six women were excluded of which 
12 women had an unknown BMI at time of diagnosis, 23 women had incomplete 
information regarding their surgical treatment and outcomes, and one woman was 
<18 years. This resulted in the inclusion of 228 women of which 84 women had a BMI 
<25 kg/m², 84 women were overweight (BMI 25-29.9 kg/m²) and 60 women were 
obese (BMI ≥30 kg/m²). 
 There were no differences between the BMI categories in baseline and clinical 
characteristics including age, ethnicity (P=0.196), marital and smoking status 
(P=0.526, P=0.938), performance status (ECOG) and FIGO stage among the BMI 
groups (Table 1). More obese women were ASA grade 3 compared to the other 
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groups (P<0.001). In addition, obese women had significantly more comorbidities 
(P=0.033) including diabetes (P=0.020), with 11.7% of women in the BMI ≥30 kg/m² 
group versus 3.6% and 1.2% in the BMI <25 kg/m² and BMI 25-29.9 kg/m² group 
Table 1   Baseline and clinical characteristics according to BMI categories
BMI <25 kg/m²
N=84
BMI 25-29.9 kg/m²
N=84
BMI ≥30 kg/m²
N=60
Analysis
P-value
Age (median, range) 63.1 (21-88) 65.6 (28-85) 64.6 (19-81) 0.437
Performance status 0.207
    0 56 (66.7%) 55 (65.5%) 30 (50.0%)
    1 14 (16.7%) 11 (13.1%) 16 (26.7%)
    2-4 3 (3.6%) 4 (4.8%) 6 (10.0%)
    Unknown 11 (13.1%) 14 (16.7%) 8 (13.3%)
Comorbidities 0.033*
    None 31 (36.9%) 27 (32.1%) 12 (20.0%)
    One 31 (36.9%) 28 (33.3%) 17 (28.3%)
    Two or more 22 (26.2%) 29 (34.5%) 31 (51.7%)
ASA grade <0.001*
    1 22 (26.2%) 16 (19.0%) 1 (1.7%)
    2 46 (54.8%) 45 (53.6%) 32 (53.3%)
    3 12 (14.3%) 16 (19.0%) 22 (36.7%)
    Unknown 4 (4.8%) 7 (8.3%) 5 (8.3%)
FIGO stage 0.177
    1 24 (28.6%) 21 (25.0%) 17 (28.3%)
    2 6 (7.1%) 5 (6.0%) 10 (16.7%)
    3 46 (54.8%) 44 (52.4%) 22 (36.7%)
    4 8 (9.5%) 13 (15.5%) 10 (16.7%)
    Unknown 0 (0.0%) 1 (1.2%) 1 (1.7%)
Chemotherapy 0.105
    Yes 69 (82.1%) 71 (84.5%) 47 (78.3%)
       Neo-adjuvant 19 (22.6%) 32 (38.1%) 12 (20.0%)
       Adjuvant 50 (59.5%) 39 (46.4%) 35 (58.3%)
    No 15 (17.9%) 13 (15.5%) 13 (21.7%)
*: P-value < 0.05; ASA: American Society of Anesthesiologists; ECOG: Eastern Cooperative Oncology Group; 
FIGO:  International Federation of Gynecology and Obstetrics
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respectively. The majority of women (82%) received chemotherapy as part of their 
treatment, of which 54% adjuvant and 28% neo-adjuvant chemotherapy. 
 Complications did not vary significantly among the different BMI groups as is 
shown in Table 2. Rates of complete and optimal cytoreduction were similar among 
groups (p=0.635), and estimated blood loss increased with higher BMI, although not 
significantly (P=0.271). For women with stage III-IV disease, rates of complete and 
optimal cytoreduction were 57% and 78% respectively, and did not vary among the 
BMI categories (data not shown). Other post-operative outcomes including 
transfusion rates, hospital stay and readmission rates were similar across the BMI 
groups of all patients. Overall 30-day and 90-day mortality were 3.1% and 4.8% 
respectively. The BMI <25 kg/m² group had relatively higher mortality rates but this 
did not vary significantly (30-day mortality; P=0.071, 90-day mortality; P=0.215).
 An additional analysis of the morbidly obese women (BMI ≥40 kg/m²) as a separate 
group (N=13) compared to the other BMI categories revealed a significantly higher 
incidence of wound complications in the morbidly obese group (P=0.027), with two 
women experiencing a wound complication (15.4%). However, there were no other 
significant differences in terms of operative complications, and intra- and post- 
operative outcomes (data not shown).
Systematic review and meta-analysis
The search strategy evaluating BMI, surgical morbidity and secondary outcomes 
identified 602 references, which after removal of duplicates resulted in 435 unique 
studies (Figure S1). After screening titles and abstracts, 42 articles were retrieved in 
full and were further assessed for eligibility. This resulted in five studies being eligible 
for this review. 
 We contacted the corresponding authors of three papers for additional data on 
separate BMI categories needed for comparisons in this review. A search of grey 
literature further identified four studies, but after full text screening none were eligible 
for this review. 
Included studies
In total, six studies including our study were included in the review, and characteris-
tics of the studies are illustrated in Table 3. Five of the six studies were retrospective 
studies (8, 16-18) and one used prospectively collected data (9). All studies combined 
resulted in a total of 2072 ovarian cancer patients. Three studies included all stage 
ovarian cancer (9, 17), the other studies included disease stages varying from stage 
II-IV to IIIc-IV (8, 16, 18). Stage was not associated with BMI in any of the studies. BMI 
was categorised in different groups among the studies, and Suh et al. used Asian 
BMI categories recommended by WHO (15). Surgical radicality in terms of complexity, 
extent and debulking status was assessed in the majority of studies. Kumar et al. 
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Table 2   Intra- and post-operative outcomes according to BMI categories
BMI <25 kg/m²
N=84
BMI 25-29.9 kg/m²
N=84
BMI ≥30 kg/m²
N=60
Analysis
P-value
Surgical morbidity
Complications 0.674
    None 58 (71.6%) 57 (67.9%) 38 (64.4%)
     Clavien-Dindo 1+2 20 (27.7%) 23 (27.4%) 17 (28.8%)
     Clavien-Dindo 3+4 3 (3.7%) 4 (4.8%) 4 (6.8%)
Individual complications 
for meta-analysis*
    Wound 0 (0%) 0 (0%) 2 (3.3%) 0.068
    Ileus 12 (14.3%) 9 (10.7%) 4 (6.7%) 0.392
    VTE 0 (0%) 1 (1.2%) 0 (0%) 1.000
    Infection/sepsis 9 (10.7%) 11 (13.1%) 13 (21.7%) 0.166
    Pneumonia 3 (3.6%) 2 (2.4%) 3 (5.0%) 0.751
     Return to OR 1 (1.2%) 1 (1.2%) 1 (1.7%) 1.000
    Organ failure 3 (3.6%) 1 (1.2%) 2 (3.3%) 0.664
Intra-operative outcomes
Residual disease
(stage II-IV)
0.635
     No residual disease 33 (55.0%) 39 (62.9%) 28 (66.7%)
    Residual disease 27 (45.0%) 23 (37.1%) 14 (33.3%)
         Optimal (< 1 cm) 11 (18.3%) 11 (17.7%) 8 (19.0%)
        Suboptimal (≥ 1 cm) 16 (26.7%) 12 (19.4%) 6 (14.3%)
Estimated blood loss 
Mean (SD)
529.5 (405.3) 619.7 (506.5) 738.9 (657.0) 0.271
Post-operative outcomes
Transfusion need 0.320
    Yes 16 (19.0%) 21 (25.0%) 9 (15.0%)
    No 68 (81.0%) 63 (75.0%) 51 (85.0%)
Hospital stay
Mean (SD)
7.3 (4.7) 7.9 (5.3) 8.7 (9.4) 0.371
Readmission 1.000
    Yes 5 (6.0%) 5 (6.0%) 4 (6.7%)
    No 79 (94.0%) 74 (94.0%) 56 (93.3%)
30-day mortality 5 (6.0%) 0 (0%) 2 (3.3%) 0.071
90-day mortality 7 (8.3%) 2 (2.4%) 2 (3.3%) 0.215
*:  some patients experienced more than one complication; OR: operation room; SD: standard deviation;  
VTE: venous thromboembolism
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found an inverse correlation between complexity and BMI, whereas Fotopoulou et al. 
found increased complexity in women with a higher BMI (8, 9). However, the majority 
did not show major significant differences in surgical radicality. 
Body mass index and surgical morbidity
Data from five of the included studies was available for the meta-analysis comparing 
surgical morbidity of non-obese to obese ovarian cancer patients. Results are 
illustrated in Figure 1 and Figure S2. Obese ovarian cancer patients had an increased 
incidence of wound complications (P<0.001) with an odds rate (OR) of 4.81 
(confidence interval (CI): 2.40 – 9.62). However, there were no significant differences 
in other individual complications including febrile morbidity, ileus, infection or sepsis, 
VTE (venous thromboembolism), pneumonia (Figure S2), return to operating room 
and organ failure, or total complications. Infection or sepsis, return to operation room 
and organ failure could only be assessed with data from our study and did not vary 
significantly (P=0.07, P=0.78, P=0.69), although infection or sepsis did show a trend 
towards a higher incidence among obese patients (P=0.07, OR: 2.05 CI: 0.95 – 4.43).
Body mass index and intra-operative outcomes
There were no differences between non-obese and obese patients in terms of 
operative outcomes including debulking status (complete cytoreduction (P=0.99, 
OR: 1.00 CI: 0.73 – 1.35), optimal cytoreduction (P=0.64, OR: 0.94 CI: 0.72 – 1.23) 
and operation time (P=0.67, OR: -6.11 CI: -34.49 – 22.27) (Figure S3). Estimated 
blood loss during surgery was greater in the obese group, but this did not reach 
significance (P=0.09) due to results of Suh et al. (Figure S3).
Body mass index and post-operative outcomes
Obese patients had a significant longer hospital stay (P=0.004) with a mean 
difference (MD) of 0.71 days (CI: 0.23 – 1.20). However, there was no difference in 
30-day mortality (P=0.81, OR: 1.11 CI: 0.49 – 2.50) and transfusion rates (P=0.39, 
OR: 0.85 CI: 0.58 – 1.24) between the non-obese and obese group.
 Furthermore, we compared BMI <25 kg/m² to morbidly obese patients (BMI ≥40 
kg/m²) in terms of surgical morbidity and outcomes using data available from Kumar 
et al. and our study (8). This revealed a significantly increased rate of organ failure 
(P=0.04 OR: 2.27 CI: 1.05 – 4.91) in the morbidly obese group. No other differences 
were found in other surgical complications, and intra- and post-operative outcomes 
(data not shown). 
 An additional analysis comparing patients with a BMI <25 kg/m² to overweight 
and obese women (BMI ≥25 kg/m²) did not reveal any other significant differences in 
terms of operative morbidity, intra- and post-operative outcomes (Figure S4).
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Risk of bias and confounding 
Included studies were non-randomised with a retrospective design in the majority of 
studies, which leads to a high risk of bias associated with non-randomisation, 
selective reporting and patient attrition. Two studies, Kumar et al. and Fotopoulou 
et al., reported on possible confounding factors and adjusted for this in their analysis 
(8, 9), while the remaining studies only used univariate analyses. The majority of 
Table 3   Characteristics of included studies
Study Study design Number Patients BMI groups Outcomes measures Conclusion
Kumar et al.  
(8)
Retrospective study 620 Stage IIIc-IV BMI <25
BMI 25-39.9
BMI ≥40
Surgical complications
30-day mortality, 90-day mortality, OS, PFS
EBL, OR time, debulking status
Additional data: hospital stay, transfusion
BMI ≥ 40:  grade 3 & 4 complications
90-day mortality worse in BMI <25 and ≥40
No difference in OS or PFS
No difference in EBL, OR time, residual disease
Matthews et al. 
(16)
Retrospective study 304 Stage II-IV BMI <30
BMI ≥30
BMI <18.5
BMI 18.5-24.9
BMI 25-29.9
BMI 30-34.9
BMI ≥35
Surgical complications
OS, PFS, recurrence
EBL, OR time, hospital stay, debulking status, 
transfusion
BMI ≥35:  EBL
BMI ≥30:  wound complications
No difference in other surgical complications
No difference in OS or PFS.
BMI ≥30:  recurrence
No difference in cytoreduction
Suh et al.  
(17)
Retrospective study 486 Stage I-IV Asian categories
BMI <18.5
BMI 18.5-22.9
BMI 23-27.4
BMI ≥27.5
BMI <23.0
BMI ≥23.0
Surgical complications
OS, PFS, recurrence
EBL, OR time, hospital stay, debulking status, 
transfusion (≥ 3 PCS)
BMI≥23:  wound complications
No difference in OS or PFS
No difference in EBL, OR time, residual disease, 
 hospital stay
Fotopoulou et al.  
(9)
Prospective database 
study
306 Stage I-IV BMI <25
BMI ≥25
BMI ≥30
Surgical complications
30-day mortality
OS, PFS, recurrence, debulking status
No difference in complications or 30-day mortality
No difference in OS or PFS
BMI ≥25:  OR time
No difference in residual disease
Wolfberg et al.  
(18)
Retrospective case-
control study
128 Stage III-IV BMI <30
BMI ≥30
Surgical complications
EBL, OR time, hospital stay, ICU admission, 
debulking status, transfusion
No difference in complications
BMI ≥30:  ICU admission,  OR time
No difference in hospital stay or residual disease
Our data Retrospective study 228 Stage I-IV BMI <25
BMI 25-29.9
BMI ≥30
BMI 30-39.9
BMI ≥40
Surgical complications
30-day mortality, 90-day mortality
OS, recurrence
EBL, hospital stay, debulking status, transfusion
No difference in complications, mortality, OS, 
recurrence, hospital stay, residual disease or 
transfusion
EBL: estimated blood loss; ICU: intensive care unit; OR: operating room; OS: overall survival; 
PCS: packed cells; PFS: progression free survival
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studies assessed surgical extent and complexity as a confounder and found no 
major differences between groups. In addition, the studies varied in disease stage 
inclusion, varying from all stage disease (I-IV) to only stage IIIc-IV, leading to 
heterogeneity of studies. We did not assess the quality of evidence using GRADE, as 
included studies were mainly retrospective studies. 
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Figure 1   Meta-analysis of surgical morbidity in non-obese versus  
obese patients
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Discussion
Obesity affects more than one third of all ovarian cancer patients. It is important to 
assess its impact on ovarian cancer management and outcomes in order to improve 
current care, optimise recovery and minimize complications. 
 In current practice, it is a common belief that obese ovarian cancer patients are 
at increased surgical risk and a challenge for surgical feasibility, but a uniform 
guidance for their care is lacking. Studies have been conflicting in their reports on the 
effect of obesity on surgical outcomes in ovarian cancer, and outcomes have not 
been similar or comparable across studies (8, 9, 16-18). In addition, their small 
sample sizes limit the power of their conclusions. 
Main findings
The main outcome of our institutional study is that BMI is associated with wound 
complications which occurred significantly more among the morbidly obese, but not 
other surgical outcomes. In addition, we systematically reviewed the literature on the 
impact of body mass index on surgical morbidity and outcomes in ovarian cancer 
patients. The review showed that an increasing BMI is associated with increased 
rates of wound complications and prolonged hospital stay, but did not influence other 
surgical complications. Surgical outcomes including complete and optimal debulking 
status, and 30-day mortality did not correlate with BMI status in the review. These 
outcomes generally concur with the findings of our institutional study. We did find a 
trend towards a prolonged hospital stay among obese patients in our study, but this 
did not reach significance, which may be due to the relatively small study population. 
In addition, short-term mortality did not differ significantly among the BMI groups, but 
women with BMI <25 kg/m² did have relatively higher mortality rates, which may be 
a result of the study population size.
Figure 1   Continued
Venous thromboembolism
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 The increased rate of wound complications and a prolonged hospital stay among 
obese patients has been well established by the literature (19, 20). Even though these 
are not considered major complications, they may negatively influence recovery and 
delay adjuvant therapy and are therefore important to take into account. 
 In other gynaecological cancers, the majority of studies suggest that mild to 
moderate obesity (BMI 30-39.9 kg/m²) does not result in increased surgical 
complications other than wound complications (20-22). The majority of surgical 
outcomes also appear to be similar to normal weight patients, with varying reports on 
estimated blood loss and operating time (21, 23). Furthermore, the feasibility of 
obtaining complete or optimal cytoreduction and 30-day mortality does not seem to 
vary among different BMI groups (22). Ninety-day mortality is not often used as an 
indicator of mortality post-treatment, even though it is an important outcome 
especially in ovarian cancer where the average 1-year survival is only 72% (24). 
Therefore its use in future studies should be encouraged. 
 Morbidly obese women with ovarian cancer have recently been suggested to be 
at increased risk of severe complications and mortality (8). We found a trend towards 
poorer outcomes in this group, but we cannot provide a definite conclusion due to 
small number of morbidly obese in our study. Unfortunately, most studies in the 
literature have not specifically looked at the influence of morbid obesity (BMI ≥40 kg/
m²).  However, Kumar et al. presented the results of a large homogenous group of 
advanced stage (IIIc-IV) ovarian cancer patients, showing a significantly higher risk 
of operative complications and mortality among the morbidly obese (8). This strongly 
suggests that women at the extremes of weight, i.e. BMI ≥40 kg/m², are at increased 
risk of surgical morbidity and poorer surgical outcomes. In addition, studies in 
endometrial cancer support that especially the morbidly obese patients are at 
increased risk of surgical complications including wound complications, infectious 
complications, venous thrombophlebitis and prolonged hospital stay (20-22, 25). 
Future research should focus specifically on this group within the ovarian cancer 
population, to develop appropriate guidelines for future care.
Strengths and limitations
Completeness and applicability of evidence
The search identified five studies and we included our own study in the review. The 
majority of women were diagnosed with stage II-IV disease, which is consistent with 
reported incidence rates (26). The BMI groups assessed varied significantly among 
studies, and corresponding authors of three studies were contacted for additional 
data. We received the raw data from one (8), leading to an inclusion of five of the six 
studies in the meta-analysis comparing non-obese versus obese patients, five 
studies comparing BMI <25 kg/m² to BMI ≥25 kg/m², and two studies comparing 
BMI <25 kg/m² to morbidly obese. The studies evaluated a variety of surgical 
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complications of which the majority could be equated in the meta-analysis. However, 
several intra- and post-operative outcomes were assessed by few studies, and 
therefore no definite conclusions could be drawn. 
Quality of evidence 
The included studies were at a high risk of bias, mainly because of their retrospective 
design and the fact that the majority did not adjust for possible confounding factors. 
In addition, there was a lack of uniformity in reporting surgical morbidity and 
outcomes. There was considerable heterogeneity among the populations studied, 
especially in terms of stage of disease. As stage of disease and corresponding 
surgical management are well known to correlate with risk of operative morbidity and 
mortality, it is possible that a negative effect of obesity on surgical outcomes is 
weakened by the inclusion of studies evaluating all stage disease. Well-designed 
prospective studies are therefore recommended to assess the impact of obesity on 
operative outcomes, especially in the less prevalent morbidly obese ovarian cancer 
patients, and within high-risk populations such as patients with disseminated disease.
Potential biases in review process
A comprehensive search of the literature was performed by the two reviewers, and 
included a search of the grey literature. Potentially eligible papers were independently 
reviewed by the two reviewers. Differences were resolved by appeal to a third reviewer 
(AL). 
Interpretation
BMI and pre-existing comorbidities are factors used in the pre-assessment for 
ovarian cancer. However, we found no compelling evidence for modifying or limiting 
the extent of surgical radicality based on BMI to reduce operative morbidity and 
adverse outcomes; although there may be some technical limitations to performing 
surgery in some patients. Impaired wound healing is a well-recognised and important 
issue among obese patients, and should be taken into account when planning 
post-operative care.
Conclusion
We found that an increasing BMI is associated with wound complications in ovarian 
cancer surgery. However, BMI does not appear to affect other operative outcomes 
including cytoreduction status and 30-day mortality. We therefore conclude that 
operative management and post-operative care should not be based on body mass 
index alone, but requires a multifactorial approach to minimise adverse outcomes. 
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In addition, the significance of morbid obesity still remains unclear and should be 
assessed in well-designed future studies to determine if this specific group of patients 
is at risk of increased operative morbidity and adverse outcomes.
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Appendix S1 – Search strategy
 1. OVARIAN NEOPLASMS
 2. “ovar* cancer*”
 3. “ovar* neoplasm*”
 4. “ovar* tumour*”
 5. “ovar* tumor*”
 6. 1 OR 2 OR 3 OR 4 OR 5 
 7. OBESITY
 8. obes*
 9. weight 
 10. “body mass index”
 11. “BMI”
 12. BODY MASS INDEX
 13. “quetelet index”
 14. 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13
 15. GYNECOLOGY
 16. surger*
 17. operati*
 18. cytoreduct*
 19. debulk*
 20. 15 OR 16 OR 17 OR 18 OR 19
 21. POSTOPERATIVE COMPLICATIONS
 22. “post operative complication*”
 23. “operative complication*”
 24. “complication*”
 25. “operative morbid*”
 26. “surg* complication*”
 27. “surg* morbid*”
 28. DEATH
 29. death
 30. mortality
 31. morbidity
 32. SURVIVAL
 33. survival
 34. “operative outcom*”
 35. “surgical outcom*”
 36. 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 
34 OR 35 
 37. 6 AND 14 AND 20 AND 36
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Figure S1  PRISMA Flow diagram for selection of studies
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Figure S3   Meta-analysis of intra-operative outcomes of non-obese versus  
obese patients
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Figure S4   Meta-analysis of surgical morbidity and outcomes when comparing 
BMI < 25 kg/m² to BMI ≥ 25 kg/m²
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Figure S4   Continued
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Figure S4   Continued
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Figure S4   Continued
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Abstract
Objective
Recent advances in the treatment of gynaecological cancer have led to improved 
survival rates putting a greater emphasis on issues such as the quality of life. In this 
study, we evaluated the effect of body mass index (BMI) on the quality of life of 
ovarian cancer survivors.
Methods
Women diagnosed with ovarian cancer at the Royal Cornwall Hospital Trust between 
January 2008 and May 2013 were identified. Ovarian cancer survivors were invited to 
participate by completing the EORTC QLQ-C30 (quality of life) questionnaire. 
Univariate and multiple regression analyses were used to determine associations 
between BMI and quality of life outcomes.
Results
176 ovarian cancer survivors were invited to participate of which 133 were eligible for 
this study. In total, 81 ovarian cancer survivors (60.4%) completed the questionnaire, 
of which 26 responders (32.1%) were overweight (BMI 25-29.9 kg/m²) and 27 (33.3%) 
were obese (BMI ≥30 kg/m²). Increasing BMI was significantly associated with poorer 
quality of life outcomes in terms of physical functioning and emotional functioning, 
and this effect persisted for physical functioning after multiple regression analysis. 
Conclusion
Increasing BMI is associated with poorer quality of life outcomes in terms of physical 
and emotional functioning in ovarian cancer survivors. Further research is needed to 
evaluate the association between BMI and quality of life from diagnosis to survivorship 
in order to develop novel interventions.
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Background
Ovarian cancer is the seventh most common cancer in women worldwide with an 
estimated 239,000 new cases diagnosed in 2012. Despite having one of the lowest 
survival rates amongst the common cancers, in the UK the five-year relative survival 
for ovarian cancer has doubled in the last 30 years from 22% in 1976-80 to 43% in 
2005-09 (1), similar to 5 year survival in the USA (44.6%) (2). With improving survival 
rates, there is now a greater emphasis on efforts to maximise the quality of life and 
psychological health of ovarian cancer survivors. 
 Although a high body mass index (BMI) has been shown to negatively impact 
quality of life outcomes in gynaecological cancer survivors (3, 4), there have been no 
studies evaluating the association between BMI and quality of life in ovarian cancer 
survivors. Recent years have witnessed a dramatic increase in obesity in women in 
England with 57% of women being overweight or obese in 2012, and these number 
are still expected to rise (5). Obesity has been shown to negatively affect ovarian 
cancer patients during other aspects of the trajectory of the disease including 
treatment outcomes and survival (6-9).
 In this study, we aimed to assess the effect of body mass index on the quality of 
life of ovarian cancer survivors.
Methods
Study population
Women diagnosed with ovarian cancer at the Royal Cornwall Hospital Trust (RCHT) 
between January 2008 and May 2013 were identified from the Cancer Registry of 
the South West Cancer Intelligence Service. Women who had completed primary 
treatment were approached to participate in a departmental review of follow-up care. 
This evaluated the quality of care and holistic needs assessment of the gynaecological 
oncology service at the RCHT. Women were sent an introduction letter accompanied 
by a patient satisfaction questionnaire as well as a quality of life questionnaire. 
Consent was given by completing and returning the questionnaires to the RCHT with 
a pre-paid envelope. We performed a secondary analysis of factors associated with 
quality of life outcomes in follow-up care. Included in this analysis were women who 
had a known BMI at time of diagnosis. We excluded women with borderline ovarian 
tumors, a history of concurrent cancer, or if they had received treatment elsewhere. 
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Data collection
Baseline and clinical characteristics such as age, performance status at diagnosis 
(ECOG) (10), disease stage (FIGO) (11), grade, treatment, recurrent disease, time 
from diagnosis and other characteristics had been collected retrospectively from the 
patients’ medical records. Body mass index (weight (kg) / [height (m)]²) at time of 
diagnosis was categorized according to national guidelines, respectively; underweight 
(≤18.5 kg/m²), normal (18.5-24.9 kg/m²), obese category I (30-34.9 kg/m²), obese 
category II (35-39.9 kg/m²) and category III (morbidly obese; ≥40 kg/m²) (12). The 
project was a secondary analysis within a departmental service evaluation of the 
follow up care of the RCHT, and therefore did not require formal ethical review. 
Measures
Quality of life was assessed with the 30-item questionnaire (QLQ-C30, version 3.0) of 
the European Organization for Research and Treatment of Cancer (EORTC). This is a 
validated, self-reporting, cancer-specific questionnaire composed of both multi-item 
scales and single-item measures. It covers several areas of quality of life; physical, 
role, emotional, cognitive, and social functioning as well as symptom distress and 
global quality of life (13). Higher scores for functional scales and global quality of life 
represent a higher level of functioning and a high quality of life. Higher scores for 
symptom scales or items represent a higher level of symptomatology (14).
Statistical analysis
Data were analysed with SPSS statistics version 20.0 (15). Body mass index was 
categorized in three categories for analysis purposes, respectively; normal weight 
(18.5-24.9 kg/m²), overweight (25-29.9 kg/m²) and obese (≥30 kg/m²). Continuous 
outcomes were presented as means with standard deviations (SD), categorical 
outcomes were presented as frequencies and proportions. Baseline and clinical 
characteristics were compared using nonparametric tests for continuous data, and 
Pearson’s Chi-Square and Fisher’s exact test for categorical variables. The EORTC 
QLQ-C30 outcomes were analyzed according to scoring procedures and were 
linearly transformed into 0-100 scales (14). Univariate and multiple regression 
analyses were used to assess primary associations between body mass index and 
quality of life outcomes, while taking into consideration other baseline and clinical 
characteristics of influence. P-values were regarded significant if p<0.05 and tests 
were two-sided.
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Results
A total of 352 women were diagnosed with ovarian cancer in the RCHT between 
January 2008 and May 2013, of which 135 were deceased, 34 were discharged from 
follow up, and seven were lost to follow up. Consequently, 176 women diagnosed 
with ovarian cancer were invited to participate in the departmental review. Excluded 
from further analysis in this study were six women with unknown BMI, 30 women with 
borderline tumors (on review of histology), three with concurrent cancer, and four 
women who were treated elsewhere. Of the remaining 133 ovarian cancer survivors, 
81 (60.4%) had completed the questionnaire (the participants) and 52 women had 
failed to return them (the non-participants) (Figure 1).
Baseline and clinical characteristics 
The mean age of women participating in the study was 63 years (SD 11.2). The 
majority (67.9%) of women were diagnosed with late stage (III and IV) ovarian cancer. 
Almost all women had undergone surgery (91.4%) and/or chemotherapy (86.5%). The 
median time from diagnosis to study participation was 20 months (range 0 – 172). 
The overall recurrence rate was 21%, with 12.5% recurrence in women with early 
stage disease and 25.5% in late stage disease (data not shown). The median time to 
Figure 1  Flow chart of recruitment
Excluded for departmental review: 
- Deceased (N=135)
- Discharged (N=34)
- Lost to follow up (N=7)
- Unknown BMI (N=6)
- Borderline tumour (N=30)
- Concurrent cancer (N=3)
- Treated elsewhere (N=4)
Excluded for this study: 
 
176 women invited to participate
in the review of follow-up care
133 women eligible for 
this analysis
81 participants (60.4%) 52 non-participants (39.6%)
352 women diagnosed with
ovarian cancer at the RCHT
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recurrence was 27 months (range 8 - 87). Participants did not differ in baseline and 
clinical characteristics compared to non-participants (data not shown).
 Baseline and clinical characteristics of women who returned the questionnaires 
are presented in Table 1 according the BMI categories. Twenty-eight women (34.6%) 
had a normal BMI, 26 women (32.1%) were overweight and a further 27 women 
(33.3%) were obese. Of the 27 obese women, 17 women were in obese category I 
(BMI 30-34.9 kg/m²), seven women in obese category II (BMI 35-39.9 kg/m²) and 
three women were morbidly obese (category III; BMI ≥40 kg/m²). Overweight women 
were significantly older than women with a normal BMI (P=0.032). Women did not 
significantly differ in other baseline and clinical characteristics among the different 
BMI categories, including the type and complexity of surgical treatment (e.g. lymph-
adenectomy (P=0.083) and bowel resection (P=0.650)). 
Body mass index and quality of life outcomes 
Quality of life outcomes of ovarian cancer survivors are presented as mean scores 
(SD) according to the BMI categories (Table 2). Women with a normal BMI reported 
the highest global quality of life scores, but this did not differ significantly among 
different BMI categories (P=0.525). Women with increased BMI had significantly 
poorer physical functioning (P=0.042), which remained significant in the multiple 
regression analysis (P=0.005) after controlling for significant baseline and clinical 
characteristics including age, disease stage, treatment and recurrence. In addition, a 
higher BMI was associated with significantly poorer emotional functioning (P=0.022), 
but this did not persist in the regression analysis (P=0.051). Appetite loss was 
significantly higher among overweight ovarian cancer survivors (P=0.036). However, 
role, cognitive and social functioning did not vary significantly among the different 
BMI categories, and other symptom distress scores did show a significant association 
with BMI.
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Table 1   Baseline and clinical characteristics participants according to  
BMI categories
Normal
(18.5-24.9 kg/m²)
N=28
Overweight
(25-29.9 kg/m²)
N=26
Obese 
(≥30 kg/m²)
N=27
Analysis
P-value
Age (mean, range) 59 (31 - 84) 67 (44 - 84) 64 (37 - 79) 0.032*
Performance status (ECOG) 0.197
   0 18 (64.3%) 18 (69.2%) 14 (51.9%)
   1 5 (17.9%) 3 (11.5%) 7 (25.9%)
   2-4 0 (0%) 1 (3.8%) 4 (14.8%)
   Unknown 5 (17.9%) 4 (15.4%) 2 (7.4%)
Stage 0.140
   Early (I-II) 10 (35.7%) 3 (11.5%) 11 (40.7%)
   Late (III-IV) 17 (60.7%) 22 (84.6%) 16 (59.3%)
   Unknown 1 (3.6%) 1 (3.8%) 0 (0%)
Grade 0.100
   Low (I) 2 (7.1%) 2 (7.7%) 3 (11.1%)
   High (2/3) 25 (89.3%) 18 (69.2%) 23 (85.2%)
   Unknown 1 (3.6%) 6 (23.1%) 1 (3.7%)
Surgery 0.300
   Yes 26 (92.9%) 22 (84.6%) 26 (96.3%)
   No 2 (7.1%) 4 (15.4%) 1 (3.7%)
Residual disease 0.676
   None 18 (64.4%) 13 (50.0%) 20 (74.1%)
   < 1 cm 3 (10.7%) 4 (15.4%) 2 (7.4%)
   ≥ 1 cm 4 (14.3%) 5 (19.2%) 3 (11.1%)
   Unknown 1 (3.6%) 0 (0%) 1 (3.7%)
   Not applicable 2 (7.1%) 4 (15.4%) 1 (3.7%)
Chemotherapy 0.995
   Yes 25 (89.3%) 23 (88.5%) 24 (88.9%)
   No 3 (10.7%) 3 (11.5%) 3 (11.1%)
Time from diagnosis 0.635
   < 1 year 10 (35.7%) 8 (30.8%) 7 (25.9%)
   1 - < 2 years 8 (28.6%) 8 (30.8%) 5 (18.5%)
   2 - < 3 years 2 (7.1%) 3 (11.5%) 5 (18.5%)
   3 - < 4 years 2 (7.1%) 1 (3.8%) 4 (14.8%)
   ≥ 4 years 6 (21.4%) 6  (23.1%) 6  (22.2%)
Recurrence 0.364
   Yes 4 (14.3%) 5 (19.2%) 8 (29.6%)
   No 24 (85.7%) 21 (80.8%) 19 (70.4%)
*: P-value <0.05
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Discussion
Cancer diagnosis and treatment represent a tremendous impact on the physical and 
mental wellbeing of patients. Quality of life is therefore an important outcome for 
women surviving cancer. Over the past years, the impact of BMI on the quality of life 
of gynaecological cancer survivors has become an important focus of research. In 
women undergoing gynaecological oncology surgery, an increasing BMI has been 
associated with poorer quality of life outcomes (3). 
 In endometrial cancer, which is inextricably associated with obesity, the influence 
of BMI on the quality of life of survivors has been well established, with obese 
endometrial cancer survivors reporting a poorer quality of life in almost all functioning 
scales, especially physical functioning (4, 16-19). We recently reported that this global 
deterioration was most significant in the morbidly obese women in this patient 
population (4). 
 However, no studies have evaluated associations between body mass index and 
quality of life outcomes of ovarian cancer survivors to date. The purpose of this study 
was to assess the association between body mass index and quality of life of ovarian 
cancer survivors. As in previous studies, 34.6% of the participants in our study had a 
normal body mass index, 32.1% were overweight and a further 33.3% were obese at 
time of diagnosis (3, 20).
 Interestingly, BMI did not influence global quality of life and several functioning 
scales in our patient group, unlike in endometrial cancer survivors, as mentioned 
above. This is probably explained by the small number of morbidly obese women 
(3.7%) in the current analysis of ovarian cancer survivors, compared to 19% in our 
endometrial cancer population (4).
 Our study does show that overweight ovarian cancer survivors experience more 
appetite loss than their normal weight or obese counterparts. Although an interesting 
finding, we have not found validation for this in the literature and further investigation 
may be warranted.
 We have found, as with endometrial cancer survivors, that an increasing BMI is 
significantly associated with poorer physical functioning. This effect persists even 
when taking other relevant patient characteristics into account such as stage, 
treatment and recurrent disease, which have been reported to influence the quality of 
life of ovarian cancer survivors (21-24). We can hypothesise that this area of quality of 
life is affected through limited mobility, restricted physical endurance and obesity-as-
sociated comorbidities (25-27). 
 General population studies have reported a reduced physical functioning among 
obese individuals across the obese BMI categories (I, II and III), with mean 
deteriorations of 2.54 (category I) up to 9.72 points (category III) when compared to 
normal weight (28). Therefore, obese women who develop ovarian cancer may have 
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a poorer quality of life than their normal weight counterparts. However, our study 
found a greater deterioration of physical functioning (MD; 19.0 points) among all 
obese women, with the majority being category I. This may reflect the additional 
burden of ovarian cancer on quality of life outcomes in our patients, which causes a 
greater quality of life deterioration among its overweight and obese survivors. 
Therefore, interventions aiming to increase physical activity may have an impact on 
quality of life in ovarian cancer survivors. 
 Trials in cancer survivors have shown that physical activity and a healthy diet 
improve overall cancer outcomes and are associated with improved quality of life 
throughout all BMI categories (29-34). Lifestyle intervention trials introducing exercise 
programs and improved diet in gynaecological cancer survivors are also showing 
promising results, but few have been undertaken in the ovarian cancer population 
even though the majority expressing an interest in participating in such programs 
(35-40). 
 Despite a less distinct effect of BMI on quality of life outcomes in ovarian cancer 
survivors, developing integrative approaches to support healthy lifestyles in ovarian 
cancer survivors is still important; taking into consideration that BMI has an impact 
on overall survival (8, 9). Our preliminary results suggest that novel survivorship 
interventions for maintaining a high quality of life should be directed at the survivor 
population as a whole, and that its focus should not lie on obese ovarian cancer 
survivors alone.  
 The strengths of our study include the use of a well-established and validated 
questionnaire to assess quality of life, and the use of measured weight and height to 
calculate body mass index. In addition, we presented data of both participants and 
non-participants which showed no significant differences, increasing the applicability 
of our study results. 
 A potential limitation of our study is the relatively small sample size, even though 
this is expected because of high mortality rates in ovarian cancer (1). The response 
rate (60.4%) was considered acceptable and in line with previous reported rates (4, 23). 
Furthermore, we did not have information regarding socio-demographic variables, 
sexual function and comorbidities, which may further influence the quality of life of 
ovarian cancer survivors (21, 41, 42). The validated EORTC ovarian cancer (OV28) 
module evaluates sexual functioning, but was not used in the departmental review 
(43). 
 Further evaluation of the relationship between body mass index and quality of life 
of ovarian cancer patients is needed, preferably through prospective studies evaluating 
quality of life throughout the trajectory of the disease. 
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Conclusion
We found that an increasing BMI is associated with poorer quality of life in terms of 
physical functioning of ovarian cancer survivors. Global quality of life and other 
functional scales did not show a significant association with BMI. Even though our 
preliminary study suggests a less defined relation between obesity and quality of life 
outcomes in ovarian cancer survivors, further evaluation of this relationship is needed. 
Development of novel interventions to enhance the quality of life of survivors may be 
an important next step in the care for ovarian cancer survivors, although its exact 
focus still remains unclear.
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CHAPTER 8
Abstract
Objective
To evaluate the association between body mass index (BMI), physical activity (PA) 
and the quality of life (QoL) of ovarian cancer survivors. 
Methods
We performed a two-centre cross-sectional study of women who had been treated 
for ovarian cancer between January 2007 and December 2014 at the Royal Cornwall 
Hospital Trust and the Plymouth Hospitals NHS Trust. QoL was assessed using the 
EORTC QLQ-C30 and QLQ-OV28 questionnaires, and PA using the Godin Leisure 
Time Exercise questionnaire.
Results
In total, 293 ovarian cancer survivors were invited to participate, of which 209 women 
(71.3%) responded. Thirty-five percent of women were overweight and 18% were 
obese, whilst only 21% met recommendations for PA. Obesity was associated with 
significantly poorer global QoL, physical, cognitive and social functioning, a poorer 
body image and more symptomatology. Sedentary behaviour was associated with 
poorer QoL scores including global QoL, physical, role, social and sexual functioning. 
After adjustment, BMI and PA both remained independently associated with QoL 
scores.
Conclusion
Obesity and inactivity are associated with poorer QoL among ovarian cancer 
survivors. Future interventions promoting PA and weight loss should be evaluated as 
possible means to improve the QoL of this population. 
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Background
Ovarian cancer is the fifth most common cancer in the UK, with a five-year survival of 
43% (1). Over the past 30 years, the survival rate has almost doubled due to the 
improving treatment options (2, 3). Research has shown that cancer survivors 
experience poorer health related quality of life (QoL) compared to women in the 
general population, with treatment related-sequelae and the psychological aftermath 
of facing cancer diagnosis (4-6). In several cancer sites including breast and 
endometrial cancer, these poorer QoL outcomes have been linked to increased body 
mass index (BMI) and inactivity, laying the foundation for survivorship interventions 
(7-9).
 In ovarian cancer, more than half of the patients are overweight or obese, and 
studies have shown that two thirds of ovarian cancer survivors are insufficiently active 
(10, 11). It has been hypothesised that obesity and inactivity negatively affect QoL 
through decreased physical endurance, limited mobility, associated comorbidities 
and possibly social discrimination (8). Interestingly, the associations between these 
factors and the QoL of ovarian cancer survivors has somehow been neglected in the 
current literature. We have recently published on the association between BMI and 
QoL, showing that increasing BMI is associated with poorer QoL outcomes in ovarian 
cancer (12). However, the association between physical activity (PA), BMI and QoL 
still remains unclear. 
 In order to accurately design and implement interventions to improve QoL, it is 
important to establish the role of BMI and PA in the QoL of ovarian cancer survivors. 
We have therefore evaluated the relationship between BMI, PA and the QoL of ovarian 
cancer survivors in a two-centre study.   
Methods
Study population
This study was a two-centre cross-sectional study performed at the Royal Cornwall 
Hospital Trust (RCHT) and the Plymouth Hospitals NHS Trust (PHNT). Women who 
had undergone treatment for ovarian cancer (including fallopian tube cancer and 
primary peritoneal cancer) between January 2007 and December 2014 were invited 
to participate by an invitation letter through the post. We excluded women who were 
under 18 years at time of study and who were diagnosed with borderline histology. 
Ethical approval was obtained through the Northampton Ethical committee and the 
study had full Trust approval at both sites.
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Data collection
Women were identified through the cancer registry of the South West Intelligence 
Service which included their current status (alive versus deceased). Women were 
approached for participation through an invitation letter accompanied by an 
information leaflet, two questionnaires assessing QoL and PA, and an additional 
questions sheet covering current height and weight. Women were asked to return the 
completed questionnaires through a provided pre-paid envelope. After three weeks, 
a reminder was sent to women who did not reply to the initial survey. 
 Patient characteristics including age at diagnosis, Eastern Cooperative Oncology 
Group (ECOG) performance status (13), disease stage, BMI at time of diagnosis, 
medical co-morbidities, current smoking status, treatment, the American Society of 
Anaesthesiologists (ASA) score, and recurrent disease were collected from medical 
records. BMI was calculated and categorised according to national guidelines; 
underweight (≤18.5 kg/m2), normal range (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), 
obese (≥30 kg/m2) and morbidly obese (≥40 kg/m2) (14). Incomplete data from 
respondents on their current weight and height were supplemented through review 
of medical files. 
 Physical activity was assessed by the validated Godin Leisure Time Questionnaire. 
This is a four-item questionnaire assessing the amount of mild, moderate and 
strenuous activity per 15 minutes in the past week. Frequency scores of moderate 
and strenuous activity were multiplied with corresponding Metabolic Equivalent 
(MET) values, assigning each patient a leisure score index (LSI) (15, 16). Women 
reporting moderate-to-strenuous LSI ≥24 were classified as active, whereas 
individuals reporting moderate-to-strenuous LSI ≤23 were classified as insufficiently 
active in accordance with public health guidelines (16-19). Women who did not report 
any moderate-to-strenuous exercise (LSI=0) were classified as sedentary.  
Outcome measures
Quality of life was assessed through the validated European Organisation of Research 
and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-OV28 questionnaires (20, 21). 
The QLQ-C30 is a 30-item cancer-specific questionnaire, covering several areas of 
QoL; physical, role, emotional, cognitive and social functioning, as well as symptom 
distress and global QoL (20). A higher score on the functioning scales and global 
health represents a higher level of functioning and a higher QoL, while in symptom 
scales a higher score indicates a higher level of symptomatology (22). The QLQ-OV28 
is a specific ovarian cancer module, covering specifically relevant issues such as 
body image, sexuality and abdominal symptoms (21). 
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Statistical analysis
Data were analysed using IBM SPSS software (23). For analysis purposes, BMI was 
categorized into; <25 kg/m2 (normal), 25-29.9 kg/m2 (overweight) or ≥30 kg/m2 
(obese). PA was categorised into ‘sufficient’, ‘insufficient’ or ‘sedentary’ following LSI 
scores. Reported outcomes of the QLQ-C30 and OV28 were linearly transformed to 
0-100 scores (21, 22). Data were compared using the Pearson Chi square or Fisher’s 
exact test for categorical data, and the Mann-Whitney U test, Kruskal-Wallis test or 
Median test for continuous data. The associations between current BMI, PA, and QoL 
outcomes were analysed using univariate analyses, and where appropriate multiple 
regression analyses were performed while adjusting for other factors including age, 
ECOG status, comorbidities, ASA score, stage, recurrent disease and time since 
diagnosis. P-values were regarded significant if <0.05 and the tests were two-sided. 
Results
In total, 293 women who received treatment for ovarian cancer between January 
2007 and December 2014 at the RCHT and PHNT were alive at time of study. Of the 
women invited to participate, 209 women (71.3%) completed the questionnaires. 
Five women did not fill in their current BMI and PA level. Consequently, outcomes of 
204 women were available for analysis.
 The median age of the study population was 63 years at diagnosis (range 17 - 87), 
and 48.8% had been diagnosed with stage I/II disease. The average time since 
primary diagnosis was 35 months (range 1-189). Almost all women had undergone 
surgery (97.1%) and received chemotherapy (83.7%) as part of their treatment. 
Non-respondents did not show different baseline and clinical characteristics 
compared to respondents including ECOG status (P=0.802), stage of disease 
(P=0.341) and operation (P=0.095). However, there was a significant difference in 
BMI at time of diagnosis (P=0.003), with non-respondents having higher average 
BMI (29.3 kg/m²) compared to respondents (26.7 kg/m²). 
 At the time of our survey, 91 women (46.7%) had a BMI below 25 kg/m2, 69 
women (35.4%) were overweight (BMI 25-29.9 kg/m2) and 35 women (17.9%) were 
obese (BMI ≥30 kg/m2), of which three were morbidly obese (BMI ≥40 kg/m2). 
Fourteen women did not fill in their current weight. PA data were available for 202 
women, of which only 42 women (20.8%) met the national guidelines for PA. The 
remaining 160 women (79.2%) were insufficiently active of which 51 women (25.2%) 
reported some PA, and 109 women (54.0%) reported a sedentary lifestyle. 
 Baseline and clinical characteristics did not differ significantly according to BMI 
groups (Table 1). Obese women had more comorbidities and poorer ECOG 
performance status compared to the normal weight and overweight, but this did not 
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Table 1   Baseline characteristics according to BMI categories 
BMI < 25 kg/m²
N=91 
BMI 25-29.9 kg/m²
N=69
BMI ≥ 30 kg/m²
N=35
Analysis
P-value
Age at diagnosis
Median (range) 63 (21 - 87) 65 (25 - 83) 63 (17 - 81)
0.881
Marital status
   Married
   Not married
   Widow 
   Unknown
62 (68.1%)
8 (8.8%)
4 (4.4%)
17 (18.7%)
36 (52.5%)
15 (21.7%)
3 (4.3%)
15 (21.7%)
22 (62.9%)
4 (11.4%)
3 (8.6%)
6 (17.1%)
0.245
Smoking status
   Yes
   No
4 (4.4%)
87 (95.6%)
5 (7.2%)
64 (92.8%)
3 (8.3%)
32 (91.4%)
0.574
Co-morbidities
   None 
   One
   Two or more
   Unknown
32 (35.2%)
32 (35.2%)
26 (28.6%)
1 (1.1%)
19 (27.5%)
28 (40.6%)
21 (30.4%)
1 (1.4%)
11 (31.4%)
6 (17.1%)
18 (51.4%)
0 (0%)
0.113
ECOG performance status
   0
   1
   2-4
   Unknown
73 (80.2%)
8 (8.8%)
4 (4.4%)
6 (6.6%)
57 (82.6%)
7 (10.1%)
3 (4.3%)
2 (2.9%)
22 (62.9%)
8 (22.9%)
0 (0%)
5 (14.3%)
0.080
FIGO stage
   I-II
   III-IV
   Unknown
44 (48.4%)
44 (48.4%)
3 (3.3%)
34 (49.3%)
35 (50.7%)
0 (0%)
18 (51.4%)
16 (45.7%)
1 (2.9%)
0.656
Surgery
   Yes
   No 
87 (95.6%)
4 (4.4%)
67 (97.1%)
2 (2.9%)
35 (100%)
0 (0%)
0.571
ASA status
    1
    2
    3
    4
    Unknown
25  (28.7%)
41 (47.1%)
11 (12.6%)
0  (0%)
10 (11.5%)
13  (19.4%)
38 (56.7%)
11 (16.4%)
1 (1.5%)
4 (6.0%)
5 (14.3%)
22 (62.9%)
6 (17.1%)
0 (0%)
2 (5.7%)
0.414
Chemotherapy
   Yes 
   No
74 (81.3%)
17 (18.7%)
59 (85.5%)
10 (14.5%)
30 (85.7%)
5 (14.3%)
0.789
Radiotherapy
   Yes
   No 
4 (4.4%)
87 (95.6%)
2 (2.9%)
67 (97.1%)
1 (2.9%)
34 (97.1%)
0.883
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reach statistical significance. At time of study, 72.7% of women had no evidence of 
recurrent disease. When comparing BMI at time of survey to BMI at diagnosis, 72.6% 
of women remained in the same BMI category while 27.4% changed, with 10.2% of 
women having a higher BMI category at time of survey and 17.2% a lower BMI 
category. PA levels varied significantly among BMI groups (P=0.012). In the BMI <25 
kg/m² group, 25% of women was sufficiently active, while this was 19% in the 
overweight group and 17% in the obese group. Seventy-four percent of women in the 
obese group were sedentary as they reported no moderate or strenuous activity, 
while the normal and overweight group reported sedentary rates of 46% and 51% 
respectively.
BMI and quality of life
Obese women reported significantly poorer outcomes in terms of global QoL 
(P=0.008), physical (P=0.003), cognitive and social functioning (P=0.011, P=0.029) 
after adjustment for age, ECOG status, comorbidities, stage, recurrent disease and 
time since diagnosis (Table 2). In addition, obese women reported a poorer body 
image (P=0.023), and experienced significantly more fatigue (P=0.034), neurological 
symptoms (P=0.046), and chemotherapy side-effects (P=0.035) when compared to 
women with normal weight and overweight. Significantly poorer physical functioning 
was present in overweight women (BMI 25-29.9 kg/m²) when compared to women 
with a normal weight (P=0.026). After adjustment for PA levels, BMI still remained 
significantly associated with poorer QoL outcomes including global QoL (P=0.022), 
physical and cognitive functioning (P=0.014, P=0.012), body image (P=0.016) and 
fatigue (P=0.043) (Table 2).
Table 1   Continued 
BMI < 25 kg/m²
N=91 
BMI 25-29.9 kg/m²
N=69
BMI ≥ 30 kg/m²
N=35
Analysis
P-value
Recurrence
   Yes 
   No
23 (25.3%)
68 (74.7%)
18 (26.1%)
51 (73.9%)
11 (31.4%)
24 (68.6%)
0.776
Months since diagnosis 
Median (range) 34 (2 – 189) 36 (1 – 114) 34 (4 – 116)
0.719
Physical activity
   Sufficient
   Insufficient
       Some activity
       Sedentary 
   Unknown
23 (25.3%)
26 (28.6%)
42 (46.2%)
0 (0%)
13 (18.8%)
20 (29.0%)
35 (50.7%)
1 (1.4%)
6 (17.1%)
2 (5.7%)
26 (74.3%)
1 (2.9%)
0.012*
*: P<0.05
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CHAPTER 8
Physical activity and quality of life
Baseline and clinical characteristics did not differ among PA groups, except for 
ECOG status (P=0.020) and ASA score (P<0.001). A higher number of women who 
were sedentary had a poorer ECOG score compared to the other two groups, and 
this was similar for ASA scores (data not shown). 
 After adjustment for possible confounding factors, global QoL was significantly 
worse in women who were insufficiently active (P<0.001), with the poorest QoL being 
reported among sedentary women (Table 3). Women who were sedentary reported 
significantly poorer physical (P<0.001), role (P<0.001) and social functioning 
(P<0.001). In terms of symptom distress, sedentary women reported more fatigue 
(P<0.001), nausea and vomiting (P=0.024), pain (P<0.001), dyspnoea (P=0.006), 
appetite loss (P=0.006) and diarrhoea (P=0.017). In addition, sedentary women had 
a poorer body image (P=0.018) and sexual functioning (P=0.001), more abdominal 
and neurological symptoms (P=0.023 and P<0.001) and more chemotherapy 
side-effects (P<0.001). These deteriorations in QoL outcomes remained significant 
after adjustment for BMI, except for body image (Table 3). 
 Insufficiently active women who were still active to some extent reported 
significantly better QoL in terms of global QoL, physical, role and social functioning 
and less symptom distress when compared the sedentary group (data not shown).
BMI, physical activity and quality of life 
BMI and PA are both independently associated with poorer QoL outcomes. However, 
PA is associated with more QoL outcomes including more functioning domains and 
symptom distress scores compared to BMI (Table 2, Table 3). Within every BMI 
category, we looked at subgroups based on PA levels. There was an additional effect 
of PA within every BMI category, with lower scores in women reporting lower PA levels 
for the majority of functioning and symptom distress scales (data not shown). 
 When looking specifically at obese women who were sedentary, these women 
had the poorest outcomes in almost all functioning domains, with average scores of; 
global QoL 60.0, physical functioning 64.7, role functioning 65.4, emotional functioning 
75.0, cognitive functioning 70.0, social functioning 65.3, and sexual functioning 8.3.
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Discussion
The number of ovarian cancer survivors is increasing; making survivorship issues 
such as QoL an important component of their care. Over the past 15 years, the 
percentage of the general population being either overweight or obese has risen to 
57% in the United Kingdom (14). Increased BMI has been linked to an enhanced risk 
of ovarian cancer, and as this epidemic shows no signs of abating, its impact on the 
outcomes of cancer patients has become a primary focus of research (24). In this 
study, we assessed the association between BMI, PA and the QoL of ovarian cancer 
survivors. 
 In our study, 35.4% of the women were overweight and 17.9% were obese at the 
time of the survey, which is consistent with national reported rates (14). Only 20.8% of 
our population met the recommendations for PA, which is far less than the national 
average of 55% and previously reported numbers of 31.1% for ovarian cancer 
survivors (11, 14). 
 So far there have been few studies addressing the effect of BMI on the QoL of 
ovarian cancer survivors. We recently published that increasing BMI is associated 
with poorer QoL outcomes in terms of physical functioning (12). In the current study, 
we confirm the detrimental association between increasing BMI and QoL outcomes, 
showing that obesity is associated with multiple poorer QoL outcomes of ovarian 
cancer survivors including global QoL, physical, cognitive, and social functioning. 
The significant association between BMI and QoL persisted after controlling for 
PA levels. 
 In addition, we found that significant poorer physical functioning is already 
present in survivors who are overweight (BMI 25-29.9 kg/m2). This is a novel finding, 
as most studies described an effect occurring at a BMI level of ≥30 kg/m2, which may 
imply that poorer physical functioning is present at a lower BMI than is generally 
assumed (25-28). Furthermore, we found that obese women report more sympto- 
matology, including fatigue and neurological symptoms, which has been reported 
by previous studies (28, 29). In addition, obese women reported more chemotherapy 
side-effects. This is contradictory to results of a recent review stating that obese 
women do not experience more toxicities compared to normal-weight individuals 
(30). Moreover, the review suggested that obese women are at increased risk of 
receiving sub-optimal dosages following unfounded concerns about increased 
toxicities (30).
 Studies among endometrial cancer survivors confirm our findings, stating that 
obese women report a poorer QoL including worse physical, social and role 
functioning, and more symptom distress (7, 25-28, 31). In addition, these negative 
effects of increasing BMI on QoL have also been described in the general population 
(32).
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 In our study, ovarian cancer survivors who do not meet the guidelines for PA 
reported significantly poorer QoL. This included global QoL, physical, role, social 
and sexual functioning. In addition, they reported significantly more symptom distress 
in the majority of scales assessed. Women reporting sedentary levels of PA had the 
poorest QoL outcomes and the highest symptomatology, and their outcomes were 
significantly poorer compared to other insufficiently active women who were still 
active to some extent. 
 Our results are supported by previous studies, stating that ovarian cancer 
survivors who do not meet the recommendations for PA have a poorer QoL (11, 33, 
34). Stevinson et al. reported that ovarian cancer survivors who do not meet the 
guidelines for PA scored significantly lower on global QoL and physical, functional, 
emotional well-being and had more symptom distress (11, 34). However, they found 
no difference in QoL between women who do not meet the guidelines and women 
who are sedentary (11). Our study did show a significant difference between 
insufficiently active and sedentary women in QoL outcomes and symptom distress. 
We therefore hypothesise that being active to some extent, even though insufficiently, 
may improve QoL as opposed to being sedentary.
 This hypothesis is strengthened by our results showing that within every BMI 
category, lower PA was associated with poorer QoL. This suggests a cumulative 
detrimental effect of a high BMI and sedentary behaviour, with obese sedentary 
women having the poorest QoL outcomes and highest symptom distress of the 
whole study population. 
 We show that both a high BMI and insufficient PA are independently associated 
with poorer QoL. Interestingly, PA affected more QoL domains, including role and 
social functioning and more symptomatology. Both factors need to be addressed in 
survivorship programmes to evaluate if QoL outcomes of ovarian cancer survivors 
can be modified. Thus far, few interventional studies addressing lifestyle have been 
undertaken in ovarian cancer patients, but have been deemed feasible during active 
treatment and post-treatment (35-37). Newton et al. assessed a walking intervention 
in patients undergoing chemotherapy, and found it was feasible, acceptable and 
safe, with meaningful improvements in QoL (35-37). In addition, von Gruenigen et al. 
reported that a lifestyle intervention consisting of PA and nutrition counselling in 
ovarian cancer patients is feasible, and improved QoL (36). Another study evaluated 
exercise and health education after completion of treatment, and found significant 
improvements in cardiopulmonary function and QoL (37). Other studies among 
gynaecological cancer patients also confirm the feasibility and value of lifestyle 
interventions in improving QoL (38, 39). 
 Future efforts should focus on developing lifestyle interventions to improve the 
outcomes of this patient group. We suggest that these interventions should 
incorporate the promotion of PA and weight loss, as both play significant role in the 
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QoL of survivors and are associated with different aspects of QoL and symptomatology. 
Moreover, high BMI and insufficient PA have both been implicated to negatively affect 
disease-specific survival and overall survival in ovarian cancer patients (40-43). 
Preliminary evidence suggests that weight loss and increasing PA may positively 
influence biomarkers associated with survival (43-45). Lifestyle interventions may 
therefore improve survival outcomes in addition to QoL. 
 Important strengths of the study are the two-centre design and the use of 
validated questionnaires to measure QoL and PA. Third, we used BMI at time of 
survey as opposed to using BMI at diagnosis, as our data revealed that the BMI 
changes over time. In addition, our response rate was 71.3% and we compared 
characteristics of respondents to non-respondents, which showed no significant 
differences in the majority of characteristics. 
 Non-respondents had a higher BMI at time of diagnosis, limiting the representa-
tiveness of our results. Other limitations are the relatively small study population and 
the geographical setting. The number of women who meet the national guidelines for 
PA is smaller than previously reported numbers (11, 33). However, our relatively small 
number of sufficiently active women does demonstrate the current situation and the 
need for interventions to tackle this important health issue. Most ovarian cancer 
patients are diagnosed with advanced stage (III/IV) disease, however the majority of 
our study population comprised of stage I/II disease consistent with reported survival 
rates (3). Therefore our results may not be representative for the whole population of 
ovarian cancer patients, but are a depiction of women surviving ovarian cancer. 
 Self-reported weight, height and PA levels were used to assess associations with 
QoL, as recent evidence shows that these measures are accurate in cancer patients 
and older adults (16, 46). However, we recognise the limitations of self-reported 
measures and therefore recommend the use of objective measures in future 
prospective studies. 
Conclusion
Our study shows that BMI and PA are significantly associated with the QoL of ovarian 
cancer survivors, with obese and sedentary survivors reporting significantly poorer 
QoL. Future efforts should be directed at assessing lifestyle interventions promoting 
both exercise and weight loss as possible means to modify lifestyle, and consequently 
the QoL of ovarian cancer survivors. 
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CHAPTER 9
Abstract
Objectives
We aimed to evaluate the effectiveness of lifestyle interventions in improving the 
quality of life (QoL) of endometrial and ovarian cancer survivors.
Methods
The review was performed according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines, and the Cochrane Handbook for 
Systematic Reviews of Interventions. We performed a search of Medline (1946-2015), 
Embase (1980-2015), Cinahl (1981-2015), PsycInfo (1806-2015) and the Cochrane 
Trial Register to identify studies evaluating the effect of lifestyle interventions on the 
QoL of endometrial and ovarian cancer survivors. 
Results
Eight studies fulfilled the inclusion criteria and comprised a total of 413 patients. 
Three studies were randomised controlled trials (RCTs), which showed that lifestyle 
interventions may improve physical functioning and significantly reduce fatigue in 
endometrial cancer survivors. In addition, lifestyle interventions in endometrial cancer 
survivors resulted in significant weight loss and improved physical activity levels, but 
did not show improvements in global QoL in the meta-analysis (P=0.75, P=0.49). 
Non-randomised trials in ovarian cancer survivors support the feasibility of lifestyle 
interventions and suggest they may result in QoL improvements. 
Authors’ Conclusions
Lifestyle interventions have the potential to improve the QoL of endometrial and 
ovarian cancer survivors, and may significantly reduce fatigue. However, the current 
evidence is limited and there is a need for future studies to further evaluate lifestyle 
interventions and their effect on QoL outcomes.
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Background
Gynaecological cancer accounts for about 1 in 10 of all cancers diagnosed in women, 
and the majority are diagnosed with endometrial cancer or ovarian cancer (1). Over 
the past years there have been great advances in treatment and consequently 
improved survival (2, 3). This has led to an increase in the number of survivors, 
making survivorship programmes an important and integral part of patients’ care.
 Survivors experience poorer health-related quality of life (QoL) compared to 
the general population, with physical and psychological sequelae following cancer 
diagnosis and its treatment (4, 5). These poorer outcomes have been linked to 
physical activity levels, body mass index (BMI), and other lifestyle factors (6-9). 
Currently, the majority of endometrial and ovarian cancer survivors do not meet 
public recommendations for exercise and nutrition, with many engaging in a 
sedentary lifestyle (9, 10). In addition, the majority of women are overweight or obese, 
and experience several obesity-related comorbidities (7, 10, 11). Consequently, 
endometrial and ovarian cancer survivors are particularly at risk of impaired QoL. 
 Strategies aiming to improve QoL have received increasing interest over the 
past years. A recent Cochrane review indicated that exercise may have beneficial 
effects on QoL in cancer survivors (12). However, despite the ample evidence in other 
cancer sites such as breast cancer, there is limited evidence regarding the 
effectiveness of lifestyle interventions in improving the QoL of gynaecological cancer 
survivors (12). 
Therefore, our aim in this systematic review is to evaluate the effectiveness of lifestyle 
interventions in improving the QoL of endometrial and ovarian cancer survivors.
Methods
Criteria for considering studies for this review
This review was performed according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines (13), and in accordance with the 
principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(14). Studies evaluating lifestyle interventions for endometrial and ovarian cancer 
survivors were identified. Eligible study designs included; randomised controlled 
trials (RCTs), controlled clinical trials, pilot studies and feasibility studies.
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Types of participants
- Adult women (age ≥18 years) diagnosed with endometrial cancer having completed 
primary treatment (surgery, chemotherapy or radiotherapy).
- Adult women (age ≥18 years) diagnosed with ovarian cancer having completed 
primary treatment (surgery, chemotherapy or radiotherapy).
Types of interventions and outcome measures
Studies were included if they evaluated any type of lifestyle intervention in endometrial 
or ovarian cancer survivors. Outcome measures included all QoL outcomes measured 
using generic and cancer-site specific scales that have been validated through 
reporting of norms.
Search methods for identification of studies
The protocol was based on the PRISMA statement (13). A systematic search of 
studies evaluating lifestyle interventions in endometrial and ovarian cancer survivors 
was performed in Medline (1946 until July 2015), Embase (1980 until July 2015) Cinahl 
(1981 until July 2015), PsycInfo (1806 until July 2015) and the Cochrane Gynaecological 
Cancer Collaborative Review Group’s Trial Register. The search strategy based on 
terms related to the review topic is presented in Appendix 1, and was adapted 
accordingly to each database. Furthermore, abstracts of scientific meetings and the 
reference lists of eligible studies were searched to identify any additional studies 
eligible for inclusion. 
Data collection and analysis
Two reviewers (AS and KG) independently assessed titles and abstracts of all 
identified studies. Studies that clearly did not meet the inclusion criteria were 
excluded. Potentially relevant studies were retrieved in full text, and were further 
reviewed for eligibility by both reviewers. Differences were resolved by discussion on 
appeal to a third review author (AL). We excluded studies where the majority of 
participants were undergoing active treatment for a primary cancer. The risk of bias 
instruments recommended by the Cochrane Studies Methods Group was used for 
randomised controlled trials and non-randomised comparative studies (15, 16). 
Outcome scales of QoL measures were compared across different studies in the 
meta-analysis where possible. The meta-analysis was performed using the 
random-effects model in the Cochrane Review Manager (RevMan) Software. 
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Results
Results of the search
The search strategy identified 382 references in Embase, 71 in Medline, 25 in Cinahl, 
14 in PsycInfo and one Cochrane review (Figure 1). After reviewing title and abstracts, 
46 articles were retrieved in full. The Cochrane review identified a further six studies 
which were retrieved in full. After full text screening, eight articles were eligible for this 
review. A search of the grey literature further identified three articles, resulting in the 
inclusion of 11 articles in this review, which comprised 8 unique studies. 
Included studies
A total of eight studies met the inclusion criteria and characteristics are illustrated in 
Table 1 and 2. Three studies were RCTs (17-22), one study was a randomised parallel 
intervention trial (23), one was a controlled trial (24), and three were single-arm 
intervention trials (25-27). Four trials included endometrial cancer survivors (17-21, 
25, 26), three trials included ovarian cancer survivors (23, 24, 27), and one study 
Figure 1  PRISMA flow diagram of selection of studies
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evaluated a combination of gynaecological cancer patients (22). One trial also 
included breast cancer survivors (26). All studies combined comprised a total of 413 
cancer survivors, including 255 endometrial cancer survivors and 122 ovarian cancer 
survivors. 
Randomised controlled lifestyle intervention trials
Summary of lifestyle interventions 
Three of the included studies were RCTs, evaluating home-based behavioural lifestyle 
interventions of exercise alone or a combination of exercise and nutrition, with one 
being partly hospital-based for group counselling sessions (Table 1). The duration 
varied from three to six months. Exercise included aerobic training, or a combination 
of aerobic and strength or resistance training. The majority included endometrial 
cancer patients, although Donnelly et al. also included twelve ovarian cancer patients, 
and other gynaecological cancer patients (uterine; N=4, cervical; N=4, mixed; N=2) 
(22). All trials evaluated QoL using the FACT-G questionnaire, and fatigue and 
depression were also assessed as part of QoL. Weight loss was included as an 
outcome in two trials (18, 21). 
Table 1  Summary of included randomised controlled lifestyle intervention trials
Trial Population Intervention Outcome measures & time points Results / conclusion
Donnelly et al.
2011
(22)
33 gynaecological cancer patients  
(OC: 12, EC: 11), stage I-III
Intervention: N=16
Control: N=17
12-week physical activity behavioural 
change intervention, home-based
Fatigue (MFSI-SF & FACIT-F), QoL (FACT-G), 
depression (BDI-II), positive and negative affect 
(PANAS), body composition, physical functioning 
(12-min walk test), sleep dysfunction (PSQI) self-
reported physical activity (7 day PAR)
At baseline, 6, 12 wks and 6 mo
Significant improvement in fatigue, negative effect 
and sleep dysfunction in IG compared to CG. 
No difference in QoL, depression, physical activity, 
BMI and affect. 
McCarroll et al.  
2014
(17, 21)
75 endometrial cancer survivors,  
stage I-II
Intervention: N=41
Control: N=34
6-month behavioural physical activity 
and nutritional counselling on individual 
(3, 6 and 12 mo) and group basis (10 
weekly and 6x biweekly)
Weight loss, self-efficacy (WEL), QoL (FACT-G), 
physical activity, nutrient intake
At baseline, 3, 6 and 12 mo
Significant improvement in physical functioning, 
fatigue and self-efficacy in IG compared to CG.  
Significant improvement in weight, physical activity 
and nutrition in IG compared to CG.
Significant improvement of overall QoL in IG over 
time.
Von Gruenigen et al. 
2009
(18-20)
45 endometrial cancer survivors,  
stage I-II
Intervention: N=23
Control: N=22
6-month behavioural physical activity 
and nutritional counselling (6x weekly, 
2x biweekly, 3x monthly), home-based
QoL (FACT-G, SF-36), fatigue (FACT-F) self-efficacy 
(WEL), eating behaviour (TFEQ), depression (BDI), 
anthropometrics (weight, waist circumference, 
BMI), physical activity, dietary intake 
At baseline, 3, 6, and 12 mo
Significant improvement in self-efficacy and social 
pressure in IG compared to CG.
Significant improvement in weight, physical activity 
and nutrient intake in IG and compared to CG.
No difference in QoL, fatigue and depression 
between groups.
CG: control group; IG: intervention group; mo: months; wks: weeks
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Effects of lifestyle interventions on quality of life
McCarroll et al. reported a significant improvement in global QoL in the intervention 
group over time (21). Fatigue improved significantly in the intervention group of two 
studies (21, 22), and physical functioning improved significantly in one trial (21). 
However, none of the trials reported a significant improvement in global QoL in the 
intervention group over the control group, and a meta-analysis of global QoL scores 
showed a non-significant mean difference of 1.16 (95% confidence interval (CI): -5.91 
– 8.23, P=0.75) and 2.48 (95% CI: -4.63 – 9.58, P=0.49) at three months and six 
months respectively (Figure 2). McCarroll et al. only reported global QoL scores of 
the intervention group and could therefore not be estimated in the meta-analyses. 
 Von Gruenigen et al. failed to show a difference in fatigue and physical functioning 
between groups (18). No other QoL differences were found in the trials, and a 
meta-analysis of other outcomes could not be performed because of insufficient 
available data for individual QoL domains and symptom distress. 
 Self-efficacy was evaluated using the Weight Efficacy Lifestyle (WEL) questionnaire 
and certain aspects improved significantly among the intervention groups (18, 21). 
Furthermore, there was a significant decrease of sleep dysfunction in the intervention 
Table 1  Summary of included randomised controlled lifestyle intervention trials
Trial Population Intervention Outcome measures & time points Results / conclusion
Donnelly et al.
2011
(22)
33 gynaecological cancer patients  
(OC: 12, EC: 11), stage I-III
Intervention: N=16
Control: N=17
12-week physical activity behavioural 
change intervention, home-based
Fatigue (MFSI-SF & FACIT-F), QoL (FACT-G), 
depression (BDI-II), positive and negative affect 
(PANAS), body composition, physical functioning 
(12-min walk test), sleep dysfunction (PSQI) self-
reported physical activity (7 day PAR)
At baseline, 6, 12 wks and 6 mo
Significant improvement in fatigue, negative effect 
and sleep dysfunction in IG compared to CG. 
No difference in QoL, depression, physical activity, 
BMI and affect. 
McCarroll et al.  
2014
(17, 21)
75 endometrial cancer survivors,  
stage I-II
Intervention: N=41
Control: N=34
6-month behavioural physical activity 
and nutritional counselling on individual 
(3, 6 and 12 mo) and group basis (10 
weekly and 6x biweekly)
Weight loss, self-efficacy (WEL), QoL (FACT-G), 
physical activity, nutrient intake
At baseline, 3, 6 and 12 mo
Significant improvement in physical functioning, 
fatigue and self-efficacy in IG compared to CG.  
Significant improvement in weight, physical activity 
and nutrition in IG compared to CG.
Significant improvement of overall QoL in IG over 
time.
Von Gruenigen et al. 
2009
(18-20)
45 endometrial cancer survivors,  
stage I-II
Intervention: N=23
Control: N=22
6-month behavioural physical activity 
and nutritional counselling (6x weekly, 
2x biweekly, 3x monthly), home-based
QoL (FACT-G, SF-36), fatigue (FACT-F) self-efficacy 
(WEL), eating behaviour (TFEQ), depression (BDI), 
anthropometrics (weight, waist circumference, 
BMI), physical activity, dietary intake 
At baseline, 3, 6, and 12 mo
Significant improvement in self-efficacy and social 
pressure in IG compared to CG.
Significant improvement in weight, physical activity 
and nutrient intake in IG and compared to CG.
No difference in QoL, fatigue and depression 
between groups.
CG: control group; IG: intervention group; mo: months; wks: weeks
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group compared to the controls (22). Two studies assessed weight loss, and reported 
significant weight loss as a result of the intervention (18, 21). In addition, Von 
Gruenigen et al. showed a significant improvement in physical activity in the 
intervention group (17, 18). Depression was assessed by two trials using the Becks 
Depression Inventory (BDI), but showed no significant improvements associated with 
the interventions (18, 22).
Other lifestyle intervention studies
Summary of lifestyle interventions
Details of the remaining five non-randomised intervention studies are shown in Table 
2. The majority assessed an exercise programme (24, 25, 27), one trial included an 
exercise and nutritional component (26), and one trial evaluated a dietary intervention 
only (23). The duration of the lifestyle interventions varied from four weeks to six 
months. The majority of interventions were delivered through counselling, with some 
studies incorporating a behavioural component (23, 27). The physical activity 
component included different exercise modes, including aerobic (25), aerobic and 
resistance training (26, 27), and a combination of aerobic, strength and flexibility 
training (24), and were unsupervised. Most exercise interventions aimed to meet the 
recommended physical guidelines of moderate-to-vigorous physical activity for 150 
minutes per week (24-26). The dietary interventions encompassed nutritional 
counselling (26) or a diet (23). The setting of the trials was home-based (23-27). 
Figure 2   Meta-analysis of global quality of life outcomes
Global quality of life at 3 months
Global quality of life at 6 months
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Effect of lifestyle interventions on quality of life
Endometrial cancer
Two single-arm studies have been performed in endometrial cancer survivors (25, 
26). Basen-Engquist et al. evaluated a 6-month exercise intervention in 100 survivors 
and reported significant improvements over time in several QoL outcomes and car-
diorespiratory fitness (Table 2) (25). McCarroll et al. performed a single-arm feasibility 
study of a 4-week lifestyle intervention using an interactive mobile application, and 
deemed it feasible with improvements in BMI and self-efficacy, but did not demonstrate 
improvements in QoL at the end of the intervention (26). 
Ovarian cancer
Three studies have been undertaken among ovarian cancer survivors, including a 
controlled trial, a parallel group trial and a pilot study. The controlled trial evaluated a 
8-week exercise intervention combined with health education, and showed improved 
QoL including physical, social, emotional and functional wellbeing, and improved 
cardiopulmonary fitness in the intervention group (24). The pilot study showed 
increased physical fitness and decreased waist circumference after a 24-week 
exercise intervention, but did not find significant improvements in QoL, fatigue or 
other outcomes assessed (27). The parallel trial compared a low fat high fibre diet 
(LFHF) to a fruit and vegetable juice concentrate (FVJC), and supports the feasibility 
of dietary interventions for ovarian cancer survivors. They also reported an improved 
dietary intake in the LFHF group but found no significant weight change or QoL 
improvements (23). 
Quality of study methods
Three of the included studies were RCTs, all other studies were non-randomised and 
the majority were single-arm intervention trials, leading to a high risk of bias associated 
with non-randomisation, patient attrition, and selective reporting. Following the nature 
of the intervention, it may pose difficulties to blind participants to the intervention 
delivery. However, blinding of outcome assessors was only reported in one RCT, and 
none of the other controlled trials. With regards to confounding factors, only two RCTs 
corrected for possible confounders in their statistical analysis. There was a large 
heterogeneity among studies regarding the selection of patients in terms of stage 
and inclusion criteria. Studies included different cancer sites as well as different 
stages of disease ranging from early stage (I/II) to all stage disease. Two RCT’s only 
included overweight women (BMI ≥ 25 kg/m²) and the other RCT only included 
sedentary women with mild to severe fatigue, resulting in a considerable selection 
bias. Three studies did not exclude women based on BMI or physical activity levels 
(23, 25, 27). Furthermore, some trials included both women undergoing active 
treatment and women having completed treatment (22, 27). 
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Table 2  Summary of non-randomised / single-arm lifestyle intervention studies
Study Study design Participants Intervention Outcome measures & time points Results / conclusion
Endometrial cancer
Basen-Engquist et al. 
2014
(25)
Single-arm 
intervention study
100 endometrial cancer 
survivors, stage I-IIIa
6-month exercise (walking) 
intervention, home-based,  
30 min/day moderate-
intensity ≥5x/week
Exercise minutes, anthropometrics and fitness 
At baseline, 2, 4 and 6 mo
QoL (SF36 & QLACS)  and psychological distress 
(BSI-18 & PSS)
At baseline and 6 mo
Significant improvement in physical activity, waist 
circumference, and QoL including; physical 
functioning, perceived general health, vitality, mental 
health, negative and positive feelings, cognitive 
problems, pain, sexual problems, fatigue, social 
avoidance, perceived benefits and recurrence 
distress. 
Non-obese had significantly better outcomes in 
some QoL domains compared to obese.
McCarroll et al.
2015
(26)
Single-arm feasibility 
trial
19 endometrial cancer survivors, 
26 breast cancer survivors, 5 
endometrial + breast cancer 
survivors, stage I-II
BMI ≥25
4-week exercise and 
nutritional intervention  
through interactive mobile 
application, home-based
Weight change, feasibility outcomes, QoL (FACT-G), 
self-efficacy (WEL), physical activity, daily food 
intake, anthropometrics (waist circumference)
At baseline and 4 wks
Improvement of weight, BMI, waist circumference 
and self-efficacy.
No difference in QoL. 
Ovarian cancer
Hwang et al.  
2014
(24)
Controlled trial 40 ovarian cancer survivors, 
stage I-III
Insufficient physical activity
8-week group education  
and self-help (weekly) 
and home-based exercise 
intervention
Cardiopulmonary function (12-min walk test), 
muscle strength, immune response, QoL (FACT-G)
At baseline and 8 wks
Improvement of cardiopulmonary fitness, muscle 
strength and QoL including, physical, social, 
emotional and functional wellbeing in IG compared 
to CG. 
Moonsammy et al. 
2013
(27)
Single-arm pilot study 19 ovarian cancer patients, 7 
undergoing adjuvant treatment, 
12 survivors, stage I-III
6-month exercise and 
cognitive behavioural 
intervention, home-based
QoL (FACT-O), fatigue (FACIT-Fatigue), effects of 
endocrine treatment (FACT-ES), vigour and mood 
(POMS-SF-V), peripheral neuropathy (FACT-GOG/
NTX), depression (CES-D), anxiety (STAI-Y), post-
traumatic stress symptomology (PCL-C), self-
efficacy (CBI-B), physical activity (GLTI), aerobic 
capacity, body fat percentage, waist circumference
At baseline, 12 and 24 wks
Significant improvements in aerobic capacity and 
waist circumference.
No difference in QoL. 
Paxton et al.
2012
(23)
Randomised non-
controlled parallel 
intervention trial 
51 ovarian cancer survivors, 
stage II-IV
6-month dietary 
intervention (LFHF diet or 
FVJC diet), home-based,  
8 weekly, 4 biweekly,  
2 monthly
Serum carotenoid and alpha-tocopherol levels, 
dietary intake, QoL (SF-36), weight, waist-to-hip 
ratio, QoL, albumin, CA125, feasibility outcomes
At baseline and 6 mo 
Significant improvements in carotenoid and alpha-
tocopherol levels in both groups. 
Improvement in dietary intake in LFHF group.
No difference in QoL or weight. 
CG: control group; FVJC: fruit and vegetable juice concentrate; IG: intervention group; 
LFHF: low fat high fibre; mo: months; wks: weeks
Processed on: 12-7-2016
504323-L-bw-Smits
189
LIFESTYLE INTERVENTIONS AND QUALITY OF LIFE
9
Table 2  Summary of non-randomised / single-arm lifestyle intervention studies
Study Study design Participants Intervention Outcome measures & time points Results / conclusion
Endometrial cancer
Basen-Engquist et al. 
2014
(25)
Single-arm 
intervention study
100 endometrial cancer 
survivors, stage I-IIIa
6-month exercise (walking) 
intervention, home-based,  
30 min/day moderate-
intensity ≥5x/week
Exercise minutes, anthropometrics and fitness 
At baseline, 2, 4 and 6 mo
QoL (SF36 & QLACS)  and psychological distress 
(BSI-18 & PSS)
At baseline and 6 mo
Significant improvement in physical activity, waist 
circumference, and QoL including; physical 
functioning, perceived general health, vitality, mental 
health, negative and positive feelings, cognitive 
problems, pain, sexual problems, fatigue, social 
avoidance, perceived benefits and recurrence 
distress. 
Non-obese had significantly better outcomes in 
some QoL domains compared to obese.
McCarroll et al.
2015
(26)
Single-arm feasibility 
trial
19 endometrial cancer survivors, 
26 breast cancer survivors, 5 
endometrial + breast cancer 
survivors, stage I-II
BMI ≥25
4-week exercise and 
nutritional intervention  
through interactive mobile 
application, home-based
Weight change, feasibility outcomes, QoL (FACT-G), 
self-efficacy (WEL), physical activity, daily food 
intake, anthropometrics (waist circumference)
At baseline and 4 wks
Improvement of weight, BMI, waist circumference 
and self-efficacy.
No difference in QoL. 
Ovarian cancer
Hwang et al.  
2014
(24)
Controlled trial 40 ovarian cancer survivors, 
stage I-III
Insufficient physical activity
8-week group education  
and self-help (weekly) 
and home-based exercise 
intervention
Cardiopulmonary function (12-min walk test), 
muscle strength, immune response, QoL (FACT-G)
At baseline and 8 wks
Improvement of cardiopulmonary fitness, muscle 
strength and QoL including, physical, social, 
emotional and functional wellbeing in IG compared 
to CG. 
Moonsammy et al. 
2013
(27)
Single-arm pilot study 19 ovarian cancer patients, 7 
undergoing adjuvant treatment, 
12 survivors, stage I-III
6-month exercise and 
cognitive behavioural 
intervention, home-based
QoL (FACT-O), fatigue (FACIT-Fatigue), effects of 
endocrine treatment (FACT-ES), vigour and mood 
(POMS-SF-V), peripheral neuropathy (FACT-GOG/
NTX), depression (CES-D), anxiety (STAI-Y), post-
traumatic stress symptomology (PCL-C), self-
efficacy (CBI-B), physical activity (GLTI), aerobic 
capacity, body fat percentage, waist circumference
At baseline, 12 and 24 wks
Significant improvements in aerobic capacity and 
waist circumference.
No difference in QoL. 
Paxton et al.
2012
(23)
Randomised non-
controlled parallel 
intervention trial 
51 ovarian cancer survivors, 
stage II-IV
6-month dietary 
intervention (LFHF diet or 
FVJC diet), home-based,  
8 weekly, 4 biweekly,  
2 monthly
Serum carotenoid and alpha-tocopherol levels, 
dietary intake, QoL (SF-36), weight, waist-to-hip 
ratio, QoL, albumin, CA125, feasibility outcomes
At baseline and 6 mo 
Significant improvements in carotenoid and alpha-
tocopherol levels in both groups. 
Improvement in dietary intake in LFHF group.
No difference in QoL or weight. 
CG: control group; FVJC: fruit and vegetable juice concentrate; IG: intervention group; 
LFHF: low fat high fibre; mo: months; wks: weeks
Processed on: 12-7-2016
504323-L-bw-Smits
190
CHAPTER 9
Discussion
Quality of life impairment is a significant issue among cancer survivors, but may be 
reversible through modifiable factors such as physical activity levels and weight. 
Within gynaecological oncology, lifestyle interventions are not widely adopted, despite 
this group being known for their unhealthy lifestyle (10). With this review, we aimed to give 
a detailed overview of the current literature evaluating the effectiveness of lifestyle 
interventions in improving the QoL of endometrial and ovarian cancer survivors.  
 We found that within endometrial cancer survivors, lifestyle interventions may 
improve physical functioning and significantly reduce fatigue, as well as have a 
positive effect on self-efficacy and sleep dysfunction. Furthermore, lifestyle interventions 
incorporating physical activity and nutrition resulted in significant weight loss and 
improved physical activity levels. The largest single-arm intervention study showed 
significant improvements in multiple QoL domains over time. However, we did not 
find an improvement in global QoL or other QoL outcomes in the RCTs.  
 Among ovarian cancer survivors, lifestyle interventions have not yet been 
evaluated in a randomised controlled setting. However, preliminary non-randomised 
studies have shown promising results, supporting the feasibility of both exercise 
interventions and dietary interventions. Weight loss and improved physical fitness are 
also achievable, and may result in QoL improvements. 
 When looking at results from other cancer sites, Mishra et al. evaluated the effect 
of exercise on QoL of various cancer survivors who completed active treatment in a 
Cochrane review (12). They found that exercise has a positive impact on global QoL 
and QoL domains including emotional, social and sexual functioning. Furthermore, 
exercise interventions resulted in decreased fatigue, pain and anxiety. However, no 
conclusion could be drawn regarding the effect of exercise on physical, cognitive and 
role functioning (12). Another review also supports the beneficial effects of exercise 
on general health and QoL outcomes in cancer survivors, and stated that dietary 
interventions improve body weight and diet quality (28). 
 Although these findings generally concur with the findings of our review regarding 
the beneficial effects of lifestyle interventions and their feasibility in the endometrial 
and ovarian cancer survivor population, there are still some discrepancies in terms of 
effect on QoL outcomes. We believe that this may be an effect of the limited number 
of studies and the small study populations of the included trials in this review. Despite 
the optimistic results, future studies are needed to establish which QoL outcomes 
and to what extent these outcomes can be modified within this population. 
 In addition, the majority of the studies assessed unsupervised, home-based 
interventions. Although this mode of delivery is convenient and economically 
attractive, it is unclear whether this will result in optimal lifestyle improvements. A 
recent Cochrane review concluded that interventions promoting exercise in cancer 
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survivors should involve setting programme goals, prompting practise and self-mon-
itoring, and encouraging participants to attempt to generalise behaviours learned in 
supervised exercise environments to achieve optimal effectiveness (29). Therefore, 
possible alternatives such as supervised individual and group sessions need to be 
explored, and should also include settings other than home-based. Group sessions 
may be an especially attractive alternative, as they may also function as a means of 
social and psychological support. Furthermore, some studies had variable 
components of interventions and included multimodal programmes or single mode 
programmes of exercise or nutrition alone. As both programmes resulted in significant 
changes in quality of life outcomes, future studies should further evaluate which 
components are essential for optimal quality of life improvements. 
 Currently, there is also a lack of evidence regarding the sustainability of lifestyle 
changes induced by these short-term interventions. It is imperative to understand 
which interventions are most efficacious in supporting long-term healthy lifestyle 
behaviour, especially as there is emerging evidence that physical activity and weight 
influence cancer survival (29-32).  
Overall completeness and applicability of the evidence
This review analysed eight studies, including three RCTs. The studies included both 
endometrial and ovarian cancer patients of which almost all had completed primary 
treatment. The majority of endometrial cancer survivors included were diagnosed 
with early stage disease, consistent with reported rates, and for the ovarian cancer 
studies all stages were included (33). Socio-demographic characteristics were 
described in most studies and comprised a predominantly white population, which 
may limit the applicability to a broader population. In addition, there was significant 
variation in lifestyle interventions in terms of components, mode, duration and 
frequency, and considerable selection bias of overweight and inactive survivors. 
Furthermore, the long-term sustainability and effects have not been addressed. The 
majority of outcomes could not be compared in the meta-analysis because of 
insufficient data on individual QoL domains or symptom distress. We contacted the 
corresponding authors of two papers for additional data, but received no response. 
Quality of evidence 
The results of our review are preliminary following the limited available evidence and 
should therefore be interpreted with caution. The majority of studies were susceptible 
to a high risk of bias, mainly because of their non-randomised or single-arm design, 
and most studies did not adjust for possible confounding factors. All studies used 
internationally validated QoL questionnaires and outcomes were comparable across 
studies. Well-designed future studies are therefore recommended to further assess 
lifestyle interventions as a means to improve health behaviour and QoL.
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Potential biases in review process
We performed a comprehensive search of the literature, which was performed by two 
reviewers (AS and KG), and included a search of the grey literature. A language 
resection was applied to the search to only include English papers. Both reviewers 
assessed potentially eligible articles independently, and differences were resolved by 
appeal to a third reviewer (AL).
Future studies
There is a need for further lifestyle intervention studies in the gynaecological cancer 
population to determine its exact effect on QoL outcomes. Ideally, these will be 
performed in a randomised controlled setting, and should include women regardless 
of their BMI and physical activity levels. Essential attributes of the interventions in 
terms of components, delivery mode, frequency and duration need to be further 
explored to establish optimal effectiveness. Future studies should consider assessing 
supervised interventions in settings other than home-based. Furthermore, the 
sustainability of lifestyle changes and QoL improvements need to be evaluated on a 
long-term basis, and whether they will translate in a survival benefit.
Conclusion
Lifestyle interventions have the potential to improve the QoL, and significantly reduce 
symptom distress such as fatigue in endometrial cancer and ovarian cancer survivors. 
However, the current evidence is limited, and there is a need for future studies further 
evaluating lifestyle intervention and their effect on QoL outcomes. Essential attributes 
of lifestyle interventions still remain unclear and need to be explored to establish 
optimal effectiveness and long-term sustainability.
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Appendix 1 – Search strategy
 1. ENDOMETRIUM CANCER 
 2. endometr* cancer 
 3. uter* cancer 
 4. endometr* neoplasm 
 5. uter* neoplasm 
 6. endometr* carcinoma 
 7. uter* carcinoma 
 8. OVARY CANCER 
 9. ovar* cancer 
 10. ovar* neoplasm 
 11. ovar* tumour 
 12. ovar* tumor 
 13. GYNECOLOGIC CANCER OR FEMALE GENITAL TRACT CANCER OR GYNECOLOGIC 
CARCINOMA 
 14. gynecolog* cancer 
 15. gynaecolog* cancer 
 16. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 
 17. EXERCISE 
 18. exercise 
 19. PHYSICAL ACTIVITY 
 20. physical activity 
 21. FITNESS 
 22. fitness 
 23. YOGA 
 24. yoga  
 25. WALKING 
 26. walking 
 27. DIET 
 28. diet 
 29. NUTRITION 
 30. nutrition 
 31. diet* AND intervention 
 32. nutri* AND intervention 
 33. lifestyle intervention 
 34. lifestyle AND intervention 
 35. QUALITY OF LIFE 
 36. quality of life 
 37. life quality* 
 38. well being OR wellbeing 
 39. 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 
30 OR 31 OR 32 OR 33 OR 34
 40. 35 OR 35 OR 36 OR 38 
 41. 16 AND 39 AND 40
Processed on: 12-7-2016
504323-L-bw-Smits
Processed on: 12-7-2016
504323-L-bw-Smits
EXERCISE PROGRAMME IN  
ENDOMETRIAL CANCER: PROTOCOL OF 
THE FEASIBILITY AND ACCEPTABILITY 
SURVIVORSHIP TRIAL (EPEC-FAST)
A Smits, A Lopes, N Das, R Bekkers, L Massuger, K Galaal
British Medical Journal Open 2015;5:e009291
10
Processed on: 12-7-2016
504323-L-bw-Smits
198
CHAPTER 10
Abstract
Introduction
Obesity has been associated with impaired quality of life and poorer outcomes in 
endometrial cancer survivors. Lifestyle interventions promoting exercise and weight 
reduction have been proposed for survivorship care. However, studies evaluating 
exercise programmes for endometrial cancer survivors are lacking. 
Purpose
The objective of this study is to evaluate the feasibility of an individualised exercise 
intervention for endometrial cancer survivors to improve quality of life. 
Methods and analysis
This is a feasibility study in which women will undergo a 10-week exercise programme 
with a personal trainer. The study population comprises women with confirmed 
diagnosis of endometrial cancer, who have completed surgical treatment with 
curative intent and are aged 18 year or older. The study will take place at the Royal 
Cornwall Hospital Trust, in the UK. Feasibility will be evaluated in terms of recruitment, 
adherence and compliance to the programme. Secondary outcomes are quality of 
life, psychological distress, fatigue, pain and complication rates. In addition, the 
acceptability of the programme will be assessed.
Ethics and dissemination
Ethical approval was obtained through the Exeter NRES Committee. The study results 
will be used to optimise the intervention content, and may serve as the foundation for 
a larger definitive trial. Results will be disseminated through peer-review journals, 
congresses, relevant clinical groups and presented on the Trust website. 
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Background
Endometrial cancer is the most common gynaecological cancer in the United 
Kingdom, with 8,475 new cases being diagnosed in 2011 alone (1). Endometrial 
cancer has a relatively good prognosis, with a ten-year survival of 78%, resulting in a 
large group of long-term survivors (1). Subsequently, health related quality of life is 
now recognised as an important outcome for endometrial cancer survivors. 
 The majority of women diagnosed with endometrial cancer are obese, as excess 
weight is an important risk factor for endometrial cancer (2, 3). In addition, few 
endometrial cancer survivors meet health recommendations for physical activity (4). 
Obesity and inactivity have been identified as significant factors negatively influencing 
the quality of life of endometrial cancer survivors, surpassing the physical and 
psychological stress that comes with cancer diagnosis and treatment alone (5, 6). In 
addition, obese endometrial cancer survivors are at risk of numerous obesity-related 
comorbidities and possibly poorer survival (7, 8).
 It has been suggested that exercise and weight reduction may be viable means 
to improve the quality of life and other health-related outcomes of cancer survivors (9, 
10). In addition, the American College of Sports Medicine (ACSM) has recommended 
exercise training for cancer patients, stating it is safe and benefits functioning and 
quality of life (11). However, previous research has shown that endometrial cancer 
survivors struggle to achieve this on their own, as they do not engage in a healthy 
lifestyle and find it difficult to implement lifestyle changes (4, 12). 
 The feasibility of some lifestyle interventions including multidisciplinary counselling, 
behavioural change interventions and a home-based exercise programme has been 
demonstrated in endometrial cancer survivors (13-16). Thus far, relatively few studies 
have been performed to test the potential usefulness of an exercise intervention to 
improve the quality of life and other health outcomes of endometrial cancer survivors. 
In addition, the essential components and attributes of an intervention, including 
mode, intensity, frequency and duration of an exercise programme, have not yet 
been established (10, 11). To the best of our knowledge, an individualised exercise 
intervention has not yet been evaluated. 
 We, therefore, want to evaluate the feasibility of introducing an individualised 
exercise programme in the care for endometrial cancer survivors to improve quality 
of life and other health outcomes.
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Methods
Design
This is a single-arm prospective feasibility study to evaluate the introduction of an 
individualised exercise intervention for endometrial cancer survivors. In addition, a 
qualitative evaluation will be performed to assess the acceptability of the intervention. 
The study will take place at the Royal Cornwall Hospital Trust, and has received 
national ethical approval through the Exeter NRES Committee.
Study population
The eligibility criteria are women older than 18 years with a diagnosis of primary 
endometrial cancer, undergoing surgical treatment with curative intent. Exclusion 
criteria are; women, presenting with recurrent endometrial cancer, those with a 
concurrent cancer, patients unable to give informed consent and those women 
undergoing palliative treatment. Women with recurrent cancer or receiving treatment 
in the palliative setting will not be asked to participate because of the burden of the 
study and as surgical treatment is usually not a standard component of palliative 
patient care in endometrial cancer. 
Recruitment
A member of the care team will identify potentially eligible women after confirmation 
of diagnosis and multidisciplinary team (MDT) review (Figure 1). Study posters will be 
displayed in gynaecological outpatient clinic and an information leaflet will be 
provided during admission for surgery. Women will be contacted one week after they 
have been discharged to discuss the study in detail. Women who express an interest 
will be seen during their post-operative check-up and consented for the study. 
Women will be recruited over a 12-month period; we aim to recruit a minimum of 15 
patients.
Intervention
The exercise programme consists of 60-min individualised (one-to-one) training 
sessions with a personal trainer, once a week, for ten consecutive weeks (Table 1). 
The training sessions will be delivered by one personal trainer to provide consistency. 
The programme begins after the patient has had her six-week post-operative 
check-up, and will take place at a local gym facility. The programme will be tailored 
to the individual patient through a pre-exercise health assessment, taking into 
consideration their current health status, physical activity level, comorbidities and 
medical history. Each session consists of a 10-min warm-up, a 40-min work out, 
consisting of aerobic (cardiovascular) exercise, pillar strength exercise (including hip 
and core stability), and resistance training (muscular strength and endurance 
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Figure 1  Flow diagram of the clinical and research pathway of the study
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training), and a 10-min cool down including flexibility training. The exercise phase will 
be performed at a level of 40-60% maximum heart rate (MHR), measured using a 
Polar Heart Rate monitor, using the Karvonen method for calculating the target heart 
rate interval. The resistance training will be performed at an intensity of 40-60% of 
one repetition maximum (1 RM). In the case of potential adverse effects such as a 
strain, injury or exacerbation of other symptoms, the session will be discontinued and 
the participant will be referred for medical attention, if needed. Participants will 
receive general physical activity recommendations of moderate-intensity exercise for 
150 minutes per week as part of standard practise (11, 17).
Outcomes
Outcomes are assessed at baseline, at completion of the intervention, and three 
months after completion of the intervention. Figure 1 demonstrates the pathways of 
the study including data collection.
Primary outcome 
The primary outcome of this study will be its feasibility aspects including; willingness 
of clinicians to recruit patients, number of eligible patients and recruitment rates. 
These will be obtained from hospital medical files, as the clinical care team will 
document eligibility and recruitment. Willingness of clinicians to recruit will be 
assessed through interviews with the clinical care team. Adherence and compliance 
rates to the programme will be collected from registration forms used during the 
exercise programme. Reasons for non-adherence or non-compliance will be 
identified and further addressed in the qualitative evaluation. 
Secondary outcomes
Several measures evaluating possible outcomes for a definitive trial will be assessed 
at baseline, post-intervention (three months) and at six months to provide character-
istics and standard deviations. Quality of life is evaluated through the internationally 
established EORTC QLQ-C30 and the QLQ-EN24 questionnaires (18, 19). The 
QLQ-C30 is a cancer-specific questionnaire covering several areas of quality of life; 
physical, role, emotional, cognitive and social functioning, as well as symptom 
distress and global quality of life (18). The QLQ-EN24 is a specific module for 
endometrial cancer patients, covering specifically relevant issues such as body 
image, sexuality and treatment symptoms (19). The Hospital Anxiety and Depression 
Scale (HADS) is used to assess psychological distress, and fatigue and pain are 
measured through the Brief Fatigue Inventory (BFI) and the Brief Pain Inventory (BPI) 
(20-22). Permissions are obtained for all measures used during the study. 
 Participants will receive a physical fitness assessment at baseline and at three 
months, which includes their current health and measuring weight and height, body 
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mass index (BMI), waist circumference, body fat percentage, lean muscle tissue, 
resting metabolism and the 6-minute walk test. The six-minute walk test will be 
performed on a treadmill, using an adaptation of the American Thoracic guidelines 
(23). Weight and BMI will also be collected at six months. Other outcomes such as 
adverse outcomes will be collected throughout the trial. 
Qualitative evaluation
A qualitative evaluation will be undertaken after completion of the exercise programme. 
This will be through one-on-one telephone interviews using a moderator guide with 
a selected subgroup of the study population. Open-ended questions will be used to 
encourage reflection and elaboration on different aspects of the exercise programme. 
The interviews will be recorded and transcribed, and data-analysis of the interviews 
will occur through content analysis using simple descriptive thematic analyses, which 
will be performed by a researcher independent of the research delivery team (24). 
All data will be prospectively collected in an electronic database.
Data-collection
The quantitative measures will be collected by a member of the clinical care team at 
three time points; baseline, after completion of the exercise programme (three months), 
and three months after completion (six months). Questionnaires will be completed 
during standard clinical visits, which follow the same time points. The qualitative 
element of the study will be undertaken after completion of the exercise programme. 
We aim to evaluate approximately eight to ten participants through individual 
semi-structured interviews. This will be a purposively selected population with 
maximum variation in terms of age, BMI, adherence and adverse events. 
Statistical analysis 
Data will be presented detailing the numbers of patients that were approached, the 
number that were eligible and the number providing consent. As this is a feasibility 
study, no power calculation has been performed. Compliance rates at all stages will 
be presented; the number of exercise sessions undertaken (mean, median and full 
distribution), the numbers of questionnaires completed at each stage, and more 
generally the completeness of data on all outcomes at each time point. Participating 
patients’ characteristics (demographics, comorbidities, clinical details) will be 
summarised and, where possible, compared with the overall population of relevant 
patients to explore possible factors associated with participation. Where possible, 
the reasons will be ascertained for potentially eligible patients not being approached 
to consider participation.
 The questionnaire outcomes (EORTC QLQ-C30 + QLQ-EN24, HADS, BPI and 
BFI) will be analysed according to scoring procedures and will be linearly transformed 
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Table 1   The EPEC-FAST Exercise programme ©
Exercise 
phase*
Details
Warm-up
10 
minutes
Low intensity warm-up using an exercise bike or a treadmill.
Exercise phase
40 
minutes
Aerobic exercise  (20 minutes)
Walking on a treadmill or cycling on an exercise bike. The exercise phase will be 
performed at a level of 40-60% of maximum heart rate.
Pillar strength training (10 minutes)
Consists of 4 exercises to improve stability and strength of the hip, and 3 
exercises to improve core stability and strength. Patients are recommended to 
perform 8 repetitions of each of the hip stability movements per leg, and a set of 
10-15 repetitions of each core muscle exercise. A stability ball may be used to 
facilitate some of the exercises. 
Hip movements: Core movements:
- Hip flexion -  Crunch
- Hip extension -  Back extension
- Hip adduction -  Opposite arm/leg raise
- Hip abduction 
Resistance training (10 minutes)
Consists of one set of 8 to 12 repetitions of 8 exercises that include all the major 
muscle groups. After initial phase repetitions, this can be increased up to 20-25 
repetitions (40-60% of 1 RM) during one session. A dumbbell, stability ball or 
bench may be used to facilitate the exercises.  
Exercises: 
- Basic squat
- Lateral raise
- Dumbbell deadlift 
- Shoulder press 
- Hamstring curl 
- Dumbbell biceps curl 
- Overhead triceps extension
- Calf raise
Cool down
10 
minutes
Set of 6 stretching and flexibility exercises. Four repetitions of each of the 
following muscle groups will be performed for 10 – 30 seconds: 
- Lower back 
- Tensor fascia lata
- Hip flexor
- Quadriceps 
- Hamstring 
- Calf
*:  The content of the programme will subject to individual variability and will be adjusted to the individual 
patient.
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into scales. The analysis for the outcome of quality of life, measured with the EORTC 
QLQ-C30 and QLQ-EN24 questionnaire is based on standard scoring procedures 
(25). Data will be presented on means (or medians as appropriate) and standard 
deviations at each time point, plus correlations and changes between baseline and 
follow-up scores (to inform future sample size calculations for a potential randomised 
trial).
Ethics and dissemination
The study results will be used to optimise the intervention content and may serve as 
the foundation for a larger definitive trial. We aim to disseminate the results through 
peer-review journals, presentation at international conferences, relevant clinical 
groups and results will be presented on the Trust website. Ethical approval was 
obtained through the Exeter NRES Committee.
Discussion
The aim of this article was to describe the protocol of a feasibility study evaluating an 
individualised exercise intervention in the management of endometrial cancer 
survivors to improve quality of life and other health related outcomes. 
 Research has shown that the majority of endometrial cancer survivors do not 
meet recommendations for physical activity, have poorer fitness and are usually 
overweight or obese (2, 4, 26, 27). BMI and physical activity levels have been 
extensively linked to the quality of life of endometrial cancer patients identifying BMI 
and physical activity as independent factors impacting quality of life (5, 6, 27, 28). 
Furthermore, it has been hypothesised that physical activity may protect from the 
negative impact of a higher BMI on quality of life outcomes (27).
 The intervention consists of ten individualised (one-to-one) training sessions with 
a personal trainer at a local gym. The content of the intervention was based on 
national and cancer-specific recommendations of the American College of Sports 
Medicine, evidence from the literature and feedback from relevant patient groups (11, 
17, 29, 30). The ACSM has concluded that exercise during and after cancer treatment 
is safe and should be encouraged, although prescriptions should be individualised 
according to the patient. Therefore, the EPEC-FAST programme will be tailored to the 
individual patient, taking into consideration their current health status, physical 
activity level, comorbidities and medical history though a pre-exercise medical 
assessment following the ACSM recommendations (11). 
 Unfortunately, the ACSM was unable to make recommendations for exercise 
interventions in gynaecological cancer patients specifically due to limited data. 
Therefore, general recommendations for cancer patients were followed when 
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developing the EPEC-FAST programme to include aerobic fitness, strength exercises 
(pillar strength and resistance training) and flexibility training (11). The frequency 
(once a week) and duration (ten weeks) of the programme were largely based on 
input from patient groups, as we could not find concrete guidance on essential 
components and attributes of an exercise programme for endometrial cancer patients 
in the literature (10, 11). 
 Important strengths of the intervention include the individualised programme 
and the one-to-one sessions in a private gym, which have not yet been evaluated in 
endometrial cancer patients. Attainable goals and individual guidance are known to 
improve adherence and compliance to a programme (30). We believe this is 
specifically applicable for endometrial cancer patients with high BMI, as they 
experience poorer body image and self-esteem after diagnosis and treatment (31, 
32). Third, we consider the timing of the intervention to be advantageous as women 
are in a teachable moment, and are interested in modifying their lifestyle in hopes of 
achieving improved health (33, 34). In addition, the intervention fits within the current 
care pathway, being less burdensome for patients as they do not have to undertake 
additional clinical visits.
 A limitation of the protocol is that the effect of the programme on overall physical 
activity behaviour is not assessed. We recommend this to be included as an outcome 
in a definitive trial, possibly through self-reported measures or objective measures 
such accelerometers. 
Conclusion
In this article, we described the protocol of an intervention aimed at improving 
physical fitness, quality of life and other health outcomes in endometrial cancer 
survivors. In addition, we presented the study design to investigate its feasibility of 
delivering the intervention within the current health care model. The results of the 
feasibility study may be used for optimisation of the intervention and may serve as a 
basis for implementation of the intervention in a randomised controlled trial.
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This thesis described the effect of body mass index on treatment and quality of life 
outcomes of endometrial and ovarian cancer patients. It has also evaluated the current 
evidence on the effect of lifestyle interventions as a means to improve quality of life in 
gynaecological cancer patients. In addition, it presents a protocol assessing the feasibility 
and acceptability of an exercise programme in endometrial cancer as part of a post- 
treatment survivorship programme. The relevance and clinical implications of the thesis 
will be discussed in this chapter, along with recommendations for future research. 
Endometrial cancer
Surgery is the mainstay of curative endometrial cancer treatment, followed by 
adjuvant therapies such as radiotherapy and/or chemotherapy in intermediate to high 
risk cases (1). In Chapter 2 we have shown that obese and especially morbidly obese 
endometrial cancer patients require longer operating times at open surgery, and that 
laparoscopic surgery is associated with increased conversion rates to open surgery. 
Furthermore, the number of post-operative complications increased with BMI, with 
more wound complications and antibiotics use in women with BMI ≥ 30 kg/m². These 
associations were more pronounced at open surgery, with morbidly obese patients 
being at highest risk.
 Giugale et al. have further explored the effect of obesity in relation to surgery and 
reported a higher incidence of post-operative complications and higher conversion 
rates among the morbidly obese and super obese (BMI ≥ 50 kg/m²) compared to the 
mild and moderate obese (BMI 30-39.9 kg/m²) (2). Minimal invasive surgery was 
performed significantly less often in morbidly obese and super obese women. Other 
adverse outcomes such as blood transfusion, bowel injury, pneumonia and increased 
blood loss were initially associated with higher obesity classifications, but these 
effects were mitigated when minimal invasive procedures were performed (2). 
 We therefore conclude that obese women, and especially women at the extreme 
end of raised BMI, benefit from a minimal invasive approach in terms of post-operative 
outcomes. Moreover, minimal invasive surgery is associated with improved QoL 
outcomes compared to open surgery in endometrial cancer irrespective of BMI (3). 
Laparoscopic surgery should therefore be the favoured approach specifically in 
obese endometrial cancer patients. 
 Obesity is a well-known factor complicating radiation therapy in terms of positioning 
of the patient, set-up errors and margin requirements (4-8). However, in a relatively 
small study of retrospective design, we did not find any evidence to suggest that BMI is 
associated with increased radiation toxicities from EBRT of brachytherapy (Chapter 3). 
Several studies collaborate our findings, but others have reported that a higher BMI 
was associated with increased gynaecological and cutaneous toxicities but with less 
gastro-intestinal toxicities (6, 9-11). Further well designed studies would help to 
provide a more definitive conclusion on this association. 
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Ovarian cancer 
We have shown that obesity does not compromise the feasibility of obtaining 
complete surgical cytoreduction, although obese patients may still pose significant 
surgical challenges (Chapter 6). Postoperatively we found that obese ovarian cancer 
patients had an increased risk of wound complications and a significantly prolonged 
hospital stay. In some cases, these complications may negatively impact recovery 
and delay commencement of adjuvant treatment. Therefore, specific care needs to 
be incorporated in the operative pathway of obese gynaecological cancer patients. 
This may include enhanced wound care programmes and prehabilitation programmes 
comprising the optimisation of patients prior to surgery.
 Definitive conclusions for women with BMI ≥ 40 kg/m² are yet to be established, 
although a large study by Kumar et al. suggests that morbidly obese women with 
ovarian cancer have a significantly higher risk of severe operative complications (12). 
The morbidly and super obese have been identified as an important group at risk of 
adverse surgical outcomes in endometrial cancer, and future studies are needed to 
confirm whether these specific groups face the same challenges in ovarian cancer 
surgery.
Quality of life
Obesity negatively impacts QoL outcomes of endometrial and ovarian cancer survivors 
(Chapter 4, 7 and 8). In endometrial cancer there is ample evidence identifying 
increasing BMI as a negative impact, while in ovarian cancer the association between 
BMI and quality has received less attention. Other important outcomes such as 
sexual dysfunction and psychological distress and their association with BMI remain 
underreported in gynaecological cancer survivors, despite being well established 
in the general population (13-15).
 It has been hypothesised that obesity negatively impacts QoL through several 
mechanisms. Unhealthy lifestyle behaviours including low physical activity, a poor diet 
and smoking, are frequently found in obese cancer patients, and have been independently 
linked to poorer QoL and general health outcomes (16-19). Obesity-related comorbidities 
such as cardiovascular disease, diabetes and osteoarthritis may further impact QoL, 
as do discrimination and stigmatization in personal relationships, employment and 
health care settings (20-24). In addition, the adverse treatment-related effects 
associated with increasing BMI such as surgical complications and decreased rates 
of minimal invasive surgery may also negatively impact the QoL of this population (3).
 Although the majority of studies have assessed the effect of BMI on QoL of 
survivors, Doll et al. recently identified that obese gynaecological cancer patients 
experience poorer QoL prior to treatment compared to their non-obese counterparts 
(25). Interestingly, pre-treatment QoL has been associated with treatment outcomes 
and survival of gynaecological cancer patients (26-29). Results from the LACE trial 
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showed that a lower preoperative QoL was associated with severe adverse events, 
which persisted after correction for other known prognostic variables. Interestingly, 
poor QoL scores also predicted poor surgical outcomes, even in patients receiving 
minimal invasive surgery (26). A lower baseline QoL was also associated with 
increased mortality rates in ovarian patients undergoing adjuvant chemotherapy or 
interval secondary cytoreduction (28, 29). 
Lifestyle interventions
There is considerable evidence that the QoL of cancer patients and survivors may be 
improved through modifiable factors such as weight and physical fitness (30, 31). 
Within endometrial and ovarian cancer, the current evidence reviewing lifestyle 
interventions is limited. In Chapter 9 we have shown that lifestyle interventions have 
the potential to improve several aspects of QoL and significantly reduce fatigue (32). 
In addition, interventions incorporating both exercise and nutrition resulted in 
significant weight loss and physical activity levels. In ovarian cancer, the feasibility of 
lifestyle interventions as a means to improve QoL has only been demonstrated by 
preliminary non-randomised studies.
 We have shown that there is a clear need for further large prospective studies to 
assess the effect of lifestyle interventions on QoL outcomes of endometrial and 
ovarian cancer survivors. It remains unclear to what extent these outcomes can be 
modified, and which interventions will result in optimal improvements. The majority of 
studies have assessed unsupervised home-based interventions, and alternatives 
such as supervised individual or group sessions need to be explored (32). Moreover, 
there is a paucity of evidence regarding the long-term sustainability of lifestyle 
changes induced by these interventions, which needs to be addressed in future 
studies. Determining which interventions will result in a long-term healthy lifestyle is 
imperative for sustainable QoL improvements.
Future directions
The importance and prognostic significance of waist-hip-ratio (WHR) has recently 
been shown in a study based on the large NHANES III survey. The authors concluded 
that normal-weight central obesity defined by WHR was associated with higher total 
and cardiovascular mortality than BMI-defined obesity (33). The value of WHR in 
gynaecological cancer has mainly been assessed as a risk factor, linking an elevated 
WHR to an increased risk of endometrial cancer and ovarian cancer (34, 35). It would 
be interesting to evaluate its relation to treatment outcomes and QoL, and whether 
incorporating this anthropometric measure increases the prognostic significance of 
BMI. However, both BMI and WHR may be disputed as an appropriate measure to 
evaluate obesity at time of diagnosis in specifically ovarian cancer patients because 
of the presence of ascites or cachexia (36). 
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 The role of physical activity has not been extensively assessed in this thesis, 
even though it is inextricably associated with BMI. In Chapter 8 we have shown that 
sedentary behaviour is an independent factor negatively influencing the QoL of 
ovarian cancer survivors, and has an additional detrimental effect to BMI. Other 
studies among ovarian and endometrial cancer patients support these findings, 
suggesting that improving physical activity levels is an important target for future 
interventions (16, 37-39). Furthermore, physical activity has been associated with an 
improvement in overall survival in breast and colon cancer (40, 41). The effect of 
lifestyle interventions on survival of women with gynaecological cancer has not yet 
been assessed, mainly because lifestyle behaviours have only recently emerged as 
important modifiable risk factors in prevention, treatment and outcomes of 
gynaecological cancer. Therefore, an important question that remains is whether 
post-diagnosis lifestyle changes such as weight loss and improved physical activity 
can mitigate the adverse association between obesity and poorer survival. 
 Chronic inflammation is known to play a role in the process of carcinogenesis 
and has been linked to obesity. In Chapter 5 we found that obesity is associated with 
higher levels of a range of inflammatory markers, and that CRP is an independent 
prognostic factor for overall survival of endometrial cancer patients. In addition, other 
studies support the prognostic value of several inflammatory markers (42-44). It would 
be interesting to assess whether strategies, modifying these markers would result 
in improved outcomes for endometrial cancer patients. It is well established that 
both exercise and caloric restrictions have an anti-inflammatory effect, and that 
they may reduce the risk, and possibly increase the survival, of several cancers 
(41, 45-48). Furthermore, anti-inflammatory drugs such as non-steroidal anti-inflam-
matory drugs (NSAIDS) have been suggested to be protective for obesity-associated 
carcinogenesis, although data remains tentative (49). 
 Besides exploring new interventions, opportunities to improve general lifestyle 
behaviours according to national health recommendations in this population should 
also be explored. Following the demonstrated unhealthy lifestyle behaviours of the 
majority of gynaecological cancer patients, the need for education is evident and 
should be part of routine care (50, 51). Current counselling practices have been 
shown to be inadequate and incongruent with patients’ needs. Only 50% of patients 
report receiving any lifestyle counselling, with specific recommendations rarely being 
offered (52). Moreover, referrals to nutritionists, weight loss programmes or bariatric 
specialists are rare, despite clinicians acknowledging the importance and 
effectiveness of such interventions (52-54). Lifestyle counselling, and especially 
weight loss counselling, is perceived as harmful to the doctor-patient relationship by 
clinicians, even though the majority of patients prefer their doctors to address weight 
using direct, face-to-face counselling with specific recommendations and referrals to 
the appropriate specialties (52, 53). After a cancer diagnosis, patients are in a 
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teachable moment; willing to make lifestyle modifications in hopes of achieving 
improved health (55, 56). Clinicians should therefore incorporate general health 
education and recommendation into their survivorship care, encouraging their 
patients to make health lifestyle changes. 
 The majority of studies in this thesis were of retrospective or cross-sectional 
design performed at one site, with one study being a two-centre cross-sectional 
study. To strengthen the results of our studies, we performed several systematic 
reviews of the literature to enhance the level of evidence. However, recognising the 
limitations of these studies inherent to their design, we have commenced a 
prospective cohort study at the Royal Cornwall Hospital Trust to further evaluate 
the effect of BMI on treatment modality, outcomes and QoL. Furthermore, studies 
assessing exercise as a possible means to improve QoL outcomes of gynaecological 
cancer patients are still in their infancy. We have therefore designed a feasibility trial, 
currently running at the Royal Cornwall Hospital Trust, which is assessing a 
personalised exercise intervention for endometrial cancer patients, which may serve 
as the foundation for a larger definitive trial (Chapter 10). 
Conclusion
Obesity has a negative impact on surgical treatment in endometrial cancer, with 
increased rates of complications, conversion rates to open surgery, longer operating 
times and a prolonged hospital stay. These negative effects are more pronounced 
with an open surgical approach, suggesting that minimal invasive surgery may 
mitigate these adverse outcomes. BMI is known to impede the application of 
radiotherapy in endometrial cancer, but we did not find evidence that it influences 
radiation toxicities. New radiotherapy techniques aimed at reducing radiation 
exposure should be further explored, as treatment toxicities are still highly prevalent 
irrespective of BMI.
 In ovarian cancer, obese patients have an increased risk of wound complications 
and a prolonged hospital stay, although obesity does not compromise the ability 
of obtaining complete cytoreduction nor does it negatively affect other operative 
outcomes.
Following treatment, BMI significantly impacts on several aspects of the QoL of 
survivors, with poorer global QoL, physical, social, cognitive and role functioning in 
obese endometrial and ovarian cancer survivors. Lifestyle intervention trials have 
shown promising results with regards to improving QoL through modifiable factors 
such as weight, diet and physical activity. However, as these interventions are still in 
their infancy, future research should aim to elucidate the role of lifestyle interventions 
on the outcomes of endometrial and ovarian cancer patients, including the long-term 
sustainability and effect on survival.
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Summary 
Endometrial cancer and ovarian cancer are the most common gynaecological 
cancers in the developed world and are known to be associated with obesity. The 
escalating obesity epidemic in countries such as the United Kingdom has resulted 
in the majority of endometrial and ovarian cancer patients being overweight or obese. 
It is crucial to determine the influence of excess weight on the outcomes of endometrial 
and ovarian cancer patients. Therefore, this thesis evaluated the effect of body mass 
index (BMI) on treatment and quality of life (QoL) outcomes of endometrial and 
ovarian cancer patients, and has assessed the effect of lifestyle interventions as a 
means to improve QoL.
Endometrial cancer
Surgery is the mainstay of curative endometrial cancer treatment. In Chapter 2 we 
have assessed the effect of BMI on the surgical outcomes of endometrial cancer 
patients. We showed that obese and especially morbidly obese endometrial cancer 
patients require longer operating times with open surgery, and that laparoscopic 
surgery is associated with increased conversion rates to open surgery. Furthermore, 
the number of post-operative complications increased with a higher BMI, with more 
wound complications and antibiotics use in women with BMI ≥ 30 kg/m². These 
associations were more pronounced at open surgery, with morbidly obese patients 
being at highest risk. Other peri-operative outcomes and 30-day mortality were not 
associated with BMI. We therefore conclude that the laparoscopic approach should 
be favoured over laparotomy, especially in obese endometrial cancer patients, 
to improve operative and postoperative outcomes.
 Radiotherapy is one of the cornerstones of adjuvant therapy in intermediate and 
high risk endometrial cancer. Radiation-related toxicities remain prevalent and are of 
particular concern for endometrial cancer patients. It is therefore important to identify 
possible contributing factors. In Chapter 3 we have evaluated whether BMI has an 
impact on the occurrence of radiation toxicities and complications. In this relatively 
small retrospective study, we did not find any evidence to suggest that BMI is 
associated with increased radiation toxicities. However, as the current evidence is 
limited, larger well designed studies are needed to provide a definitive conclusion 
regarding the impact of BMI on radiation complications.
 Quality of life issues are important outcomes for cancer patients, as cancer 
diagnosis and treatment have a significant impact on the quality of life. In Chapter 4 
we show that an increasing BMI has a negative impact on the quality of life outcomes 
of endometrial cancer patients at our institution. Furthermore, we have performed a 
systematic review and meta-analysis of the literature on this association, demonstrating 
that obese women experience significantly poorer physical functioning, social functioning, 
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and role functioning compared to non-obese survivors. Physical, social and role function 
further deteriorated significantly in the morbidly obese patients (BMI ≥ 40 kg/m²). 
 Chronic inflammation is known to play a role in the process of carcinogenesis. 
Although, obesity causes chronic inflammation through an inflammatory response in 
the adipose tissue, its role in carcinogenesis remains unclear.  In Chapter 5 we have 
evaluated the association between inflammatory markers and obesity, and their 
prognostic value in endometrial cancer. In this study, obesity was associated with 
higher levels of a range of inflammatory markers, and specifically CRP was found to 
be an independent prognostic factor for overall survival in endometrial cancer 
patients. Further studies are needed to explore the association between BMI and 
inflammatory markers, and determine its exact role in the pathogenesis and prognosis 
of endometrial cancer.
Ovarian cancer
Surgery plays an important role in ovarian cancer management and is usually 
extensive, as complete cytoreduction (removal of all visible disease) is an important 
prognostic factor for survival. The impact of BMI on the surgical treatment and 
outcomes of ovarian cancer surgery has been described in Chapter 6. We found that 
obesity does not compromise the feasibility of obtaining complete cytoreduction, 
although obese patients may still pose significant surgical challenges. Obese ovarian 
cancer patients did have an increased risk of wound complications and a significantly 
prolonged hospital stay. Definitive conclusions for women with BMI ≥ 40 kg/m² are 
yet to be established, but our results suggest that morbidly obese women have a 
significantly higher risk of severe operative complications such as organ failure. Other 
surgical complications and 30-day mortality were not affected by BMI. 
 Thus far, the relation between BMI and QoL has received limited attention in ovarian 
cancer, despite the majority of patients being overweight or obese. In Chapter 7 and 8 
we have described the detrimental effect of excess weight on the QoL outcomes of 
ovarian cancer survivors. Obese survivors experience significantly poorer global 
QoL, physical, cognitive and social functioning and they report more fatigue and a 
poorer body image. No conclusions could be provided regarding the morbidly 
obese, as only a minority of women studied had a BMI ≥ 40 kg/m². 
 BMI and physical activity are inextricably associated and the majority of ovarian 
cancer patients do not meet the national health recommendations for physical 
activity. In Chapter 8 we assessed the effect of physical activity on the QoL of ovarian 
cancer survivors, showing that sedentary behaviour is an independent factor 
negatively influencing QoL, and has an additional detrimental effect to BMI. 
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Lifestyle interventions
Within endometrial and ovarian cancer, the current evidence reviewing lifestyle 
interventions is limited. In Chapter 9 we have shown that lifestyle interventions 
have the potential to improve several aspects of QoL and significantly reduce fatigue. 
The interventions assessed in our review included single-mode exercise programmes or 
a combination of both exercise and nutrition. In endometrial cancer patients, lifestyle 
interventions may improve physical functioning, fatigue, self-efficacy and sleep 
dysfunction. In addition, interventions incorporating both exercise and nutrition 
resulted in significant weight loss and physical activity levels. In ovarian cancer, 
the feasibility of lifestyle interventions as a means to improve QoL has only been 
demonstrated by preliminary non-randomised studies, suggesting that these 
interventions may result in QoL improvements. However, the effect of lifestyle 
interventions on QoL outcomes of endometrial and ovarian cancer patients, needs 
to be further assessed. In addition, the majority of studies assessed unsupervised 
home-based interventions, and alternatives such as supervised individual or group 
sessions need to be explored. 
 This has led us to the development of a feasibility intervention study assessing a 
personalised exercise intervention for endometrial cancer patients, which is outlined 
in Chapter 10. The study is currently running at the Royal Cornwall Hospital Trust, 
and may serve as the foundation for a larger definitive trial.
 Finally, we have outlined the results of this thesis and placed our outcomes into 
context using the literature (Chapter 11). In addition, we have provided clinical 
 recommendations and discussed possible directions for future research.
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Samenvatting
De obesitas-epidemie heeft ertoe geleid dat meer dan de helft van de mensen in het 
Verenigd Koninkrijk overgewicht heeft, van wie 25% kampt met obesitas. Verwacht 
wordt dat ook andere Europese landen te maken krijgen met een duidelijke stijging 
van het aantal mensen met obesitas. Baarmoeder(endometrium)kanker en eierstok-
(ovarium)kanker zijn beide geassocieerd met obesitas, met als gevolg dat de 
incidentie van deze ziekten toeneemt. Tegelijkertijd kampt een groot deel van deze 
patiëntenpopulatie met overgewicht of obesitas. Endometrium- en ovariumkanker 
zijn momenteel de meest voorkomende soorten gynaecologische kanker in Europa 
en ze treffen jaarlijks meer dan 15.500 vrouwen in het Verenigd Koninkrijk. Het is 
daarom cruciaal om inzicht te krijgen in het effect van obesitas op de behandeling 
en uitkomsten van deze groeiende patiëntengroep. In dit proefschrift is de invloed 
van Body Mass Index (BMI) op de behandeling en kwaliteit van leven van patiënten 
met endometrium- en ovariumkanker onderzocht. 
Endometriumkanker
Chirurgie is een belangrijke pijler van de behandeling van endometriumkanker. In 
hoofdstuk 2 hebben wij de invloed van een verhoogde BMI op de chirurgische 
behandeling en uitkomsten van endometriumkanker onderzocht. Hieruit bleek dat de 
operatieduur bij open buikoperaties gemiddeld langer is bij vrouwen met een BMI 
≥ 30 kg/m² dan vrouwen met BMI < 30 kg/m². Bovendien wordt bij de eerstgenoemde 
groep vaker een minimaal invasieve benadering (kijkoperatie) omgezet naar een 
open buik operatie. Dit is nadelig voor de patiënt omdat langere operaties gepaard 
gaan met toenemende stress en een verhoogd risico op complicaties. Daarbij 
betekent een open buikoperatie vaak een langer en moeizamer herstel, waarbij het 
risico op postoperatieve complicaties hoger is dan bij een kijkoperatie. Een andere 
belangrijke uitkomst van de studie is dat vrouwen met een BMI ≥ 30 kg/m² een hoger 
risico hebben op postoperatieve complicaties in vergelijking met vrouwen met 
een normaal gewicht of overgewicht (BMI < 30 kg/m²). Dit verschil is met name 
uitgesproken onder vrouwen die een open buikoperatie ondergaan, waarbij obesitas 
geassocieerd is met meer wondcomplicaties en antibioticagebruik. Vrouwen met 
extreme obesitas (BMI ≥ 40 kg/m²) lopen hierbij het grootste risico. Hieruit hebben wij 
geconcludeerd dat een minimaal invasieve benadering (kijkoperatie) moet worden 
nagestreefd bij obese vrouwen om het verhoogde risico op postoperatieve complicaties 
te reduceren.
 Radiotherapie is een belangrijk onderdeel van de adjuvante behandeling van 
endometriumkanker. Deze wordt in de vorm van uitwendige therapie, inwendige/
vaginale therapie of een combinatie hiervan gegeven. Radiotherapie heeft als doel 
het risico op locoregionale recidieven te reduceren, maar heeft geen effect op de 
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overlevingskans en staat daarom nog steeds ter discussie. Omdat radiotherapie 
vaak gepaard gaat met complicaties, is het essentieel om factoren die van invloed 
zijn te identificeren. In hoofdstuk 3 hebben wij onderzocht of obesitas geassocieerd 
is met complicaties bij verschillende vormen van radiotherapie. Uit onze retrospectieve 
studie bleek dat obesitas niet van invloed is op de incidentie van complicaties ten 
gevolge van radiotherapie, in tegenstelling tot de resultaten van sommige andere 
studies. Nieuwe studies zijn daarom noodzakelijk om het effect van obesitas verder 
te evalueren. 
 Kwaliteit van leven is een belangrijke uitkomst voor kankerpatiënten. Het is 
welbekend dat overgewicht in de gezonde populatie de kwaliteit van leven negatief 
beïnvloedt maar het effect hiervan op endometriumkankerpatiënten is minder 
evident. In hoofdstuk 4 tonen wij aan dat een hoger BMI een nadelig effect heeft 
op de kwaliteit van leven van patiënten van het Royal Cornwall Hospital Trust. Onze 
resultaten worden ondersteund door verscheidene studies die zijn gebundeld in een 
meta- analyse. Vrouwen met een BMI ≥ 30 kg/m² ervaren een slechtere kwaliteit van 
leven in de vorm van een verminderd fysiek functioneren, sociaal functioneren en 
 rol functioneren (dagelijkse bezigheden). Deze domeinen verslechteren significant 
naarmate het BMI verder stijgt (BMI ≥ 40 kg/m²). 
 Obesitas veroorzaakt een chronische ontsteking door een inflammatoire reactie 
in adipeus weefsel. Dit wordt gekenmerkt door een infiltratie van ontstekingscellen 
zoals lymfocyten en myeloide cellen. Chronische inflammatie speelt een rol in de 
carcinogenese van endometriumkanker, maar de rol van obesitas hierin is nog 
onduidelijk. Obesitas is geassocieerd met een toename van verschillende ont-
stekingscellen in het bloed van patiënten met endometriumkanker (hoofdstuk 5). 
Vooral het C-reactief proteïne (CRP) was duidelijk verhoogd bij obese patiënten 
en bleek van prognostische waarde waarbij een preoperatief CRP ≥ 5.0 (mg/L) 
geassocieerd was met een slechtere overleving. De rol en voorspellende waarde van 
preoperatieve biomarkers dient daarom verder onderzocht te worden. 
Ovariumkanker
Chirurgie neemt ook een centrale plaats in bij de behandeling van ovariumkanker. 
Dit zijn vaak uitgebreide operaties omdat bij de meerderheid de kanker in een 
vergevorderd stadium wordt gediagnosticeerd. Het primaire doel is het behalen van 
complete debulking (verwijdering van al het zichtbare tumorweefsel), aangezien dit 
de overlevingskans van de patiënt vergroot. De impact van obesitas op de uitkomsten 
en complicaties van chirurgische behandeling van patiënten met ovariumkanker is 
onderzocht in hoofdstuk 6. Obesitas heeft geen nadelige invloed op het behalen van 
complete debulking, al kan het de moeilijkheidsgraad van de operatie verhogen. 
Obese patiënten hebben wel een verhoogd risico op wondcomplicaties en een 
langere opnameduur in vergelijking tot patiënten met een BMI ≤ 30 kg/m². Vrouwen 
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met morbide obesitas (BMI ≥ 40 kg/m²) hebben een verhoogd risico op ernstige 
complicaties waaronder orgaanfalen, al is deze specifieke patiëntengroep slechts in 
twee studies is onderzocht. Andere belangrijke uitkomsten zoals de 30-dagen-
mortaliteit worden niet negatief beïnvloed door obesitas. 
 Het effect van overgewicht op de kwaliteit van leven van patiënten met 
ovariumkanker heeft tot dusver weinig aandacht gekregen. Doormiddel van twee 
institutionele studies hebben wij geconcludeerd dat een hogere BMI geassocieerd is 
met een verminderde kwaliteit van leven (hoofdstuk 7 en 8). Obese patiënten met 
ovariumkanker ervaren een slechtere kwaliteit van leven, met onder andere een 
verminderd fysiek, cognitief en sociaal functioneren, en geven blijk van meer 
vermoeidheid en een slechter lichaamsbeeld. We konden geen conclusies trekken 
bij patiënten met een BMI ≥ 40 kg/m², aangezien dit slechts een kleine subgroep van 
de populatie betrof. Verder onderzoek is nodig om het effect van extreme obesitas op 
de kwaliteit van leven van patiënten met ovariumkanker te evalueren. 
 Obesitas en verminderde lichaamsbeweging zijn onlosmakelijk met elkaar 
verbonden. De meerderheid van patiënten met ovariumkanker voldoet niet aan de 
bewegingsvoorschriften van nationale richtlijnen. In hoofdstuk 8 is daarom de rol 
van lichaamsbeweging op de kwaliteit van leven onderzocht, waaruit naar voren 
kwam dat sedentair gedrag een onafhankelijke risicofactor is naast BMI. 
Leefstijlinterventies
Verschillende onderzoeken suggereren dat BMI en lichaamsbeweging modificeerbare 
factoren zijn om de kwaliteit van leven van kankerpatiënten te verbeteren. In hoofdstuk 9 
presenteren we een literatuuronderzoek over het effect van leefstijlinterventies ter 
verbetering van de kwaliteit van leven van patiënten met endometrium- en ovarium-
kanker, nadat zij hun behandeling hebben voltooid. Hieruit bleek dat leefstijlinterventies 
de potentie hebben om verschillende aspecten van kwaliteit van leven te verbeteren. 
De geïncludeerde studies onderzochten een verscheidenheid aan interventies 
variërend van beweging tot voeding, of een combinatie hiervan. Patiënten met endo-
metriumkanker rapporteerden een verbetering in fysiek functioneren, zelfeffectiviteit 
en slaapstoornissen. Daarbij leiden interventies bestaande uit een combinatie van 
beweging en dieet tot significant gewichtsverlies en toegenomen lichaamsbeweging. 
Ten aanzien van ovariumkanker is er een beperkt aantal preliminaire niet-gerandomi-
seerde studies die suggereren dat leefstijlinterventies verschillende aspecten van 
kwaliteit van leven bevorderen. Verdere bewijsvoering voor het effect van leefstijlinter-
venties in de patiënten met endometrium- en ovariumkanker is echter noodzakelijk. 
De meerderheid van de onderzoeken evalueerde ongesuperviseerde interventies in 
de thuisomgeving. Alternatieven waaronder gesuperviseerde interventies in de vorm 
van individuele sessies of groepssessies moeten nog nader worden onderzocht. 
Dit heeft ertoe geleid dat wij een studieprotocol hebben ontwikkeld voor een 
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 geïndividualiseerd bewegingsprogramma onder directe supervisie van een personal 
trainer (hoofdstuk 10). De pilotstudie loopt momenteel in het Royal Cornwall Hospital 
Trust in het Verenigd Koninkrijk, en zal mogelijk als basis fungeren voor een groter 
gerandomiseerd onderzoek. 
 In hoofdstuk 11 worden de resultaten van de verschillende studies in dit proefschrift 
bediscussieerd en onze bevindingen vergeleken met de literatuur. Hierbij hebben we 
enkele aanbevelingen voor de klinische praktijk en toekomstig onderzoek geformuleerd. 
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